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Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with a dismal 
prognosis.  Few patients present with disease amenable to resection and 
chemotherapy is not curative.  The incidence of ICC is rising worldwide and new 
therapeutic approaches are urgently required.  Notch signalling is critical for the 
embryological development and regeneration of the biliary tree in the mammalian 
liver.  Dysregulation of Notch is known to drive tumorigenesis in a range of solid 
and haematological malignancies and the aim of this work was to define its 
contribution to the pathogenesis of ICC. 
Transgenic overexpression of Notch1 has been described to result in the formation 
of biliary lineage tumours in the liver.  I have used resected human tissue, a 
chemically-induced model of ICC in rat and a novel transgenic murine model in 
which the tumour suppressor p53 is conditionally deleted from biliary epithelia, to 
demonstrate that endogenous Notch signalling is acting via the Notch3 receptor to 
drive tumorigenesis.  I use multiple independent methods of Notch3 blockade to 
establish that Notch3 promotes epithelial cell survival and self-renewal in ICC and 
demonstrate that Notch3 inhibition significantly attenuates tumour growth in vivo.   
My data suggest that Notch3 promotes activity through the PI3K/AKT cell survival 
cascade via a mechanism independent of the effector of canonical Notch, RBPJκ.  
Given the significant toxicity associated with gamma-secretase inhibitors these 
findings offer a novel and specific target for further investigation and future 






This dissertation has been written by me and represents my own work.  All 
experiments described herein were performed by me, but where I have collaborated 
with other researchers this is stated within the text.  These data have not been 
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Chapter 1:  Introduction 
Biliary Tract Cancer 
Classification 
Biliary tract cancer (BTC) can be defined as a malignant lesion arising from the 
biliary epithelium lining the gallbladder or extra or intrahepatic biliary tree.  
Historically these tumours have been divided into three clinical phenotypes 
according to anatomical location: those arising from the intrahepatic ductular 
network within the liver (Intrahepatic Cholangiocarcinoma (ICC)); those arising 
from the large distal ducts outwith the liver (Extrahepatic Cholangiocarcinoma 
(ECC)) and gallbladder cancers.  This has been a clinically useful classification due 
to differences in presentation and clinical behaviour.  Intrahepatic tumours present 
as mass lesions within the liver parenchyma in contrast to extrahepatic tumours 
which typically cause biliary obstruction.  Furthermore these cancers demonstrate 
differing responses to therapy and therefore management and outcomes differ (1).  
The most frequently involved site is the confluence of the right and left hepatic 
ducts (2).  The boundary between intra and extrahepatic ducts at this site is often 
unclear and surgical management of these tumours is similar so consequently the 
two types have been grouped together (hilar cholangiocarcinoma).  An eponymous 
classification of these tumours by Gerald Klatskin in 1965 (3) has led to 
inconsistencies in the diagnostic classification of the two tumour phenotypes and a 
misrepresentation of outcome data for these cancers (4).  This has been compounded 
by inconsistencies between the second and third editions of the International 
Classification of Diseases for Oncology (ICD-O), which recommended hilar tumours 
be cross-referenced as intrahepatic (ICD-O-2) and later either intrahepatic or 
extrahepatic (ICD-O-3) (4). 





In light of low prevalence rates, individual epidemiological data for ECC, ICC and 
gallbladder cancers are frequently grouped together.    Where this has occurred or 
no distinction has been made in the literature, I have used the encompassing 
nomenclature biliary tract cancer (BTC) in this text.    This introduction attempts to 
present an overview of the current understanding and statistics for all these tumour 
subgroups; however the scientific focus of the primary data presented in this 
dissertation is on ICC.  There is evidence that gallbladder cancer and cancers of the 
distal extrahepatic ducts as a group have a distinct tumour biology and differing 
responses to treatment to intrahepatic tumours (1).  Such distinctions between 
intrahepatic and hilar tumours are as yet unclear, and in fact immunoreactivity 
between these two subsets is similar (5).  Where human specimens have been used 
in this research, in the interests of including statistically relevant cohorts, I have 
included both intrahepatic and hilar tumours, which are herein referred to as ICC.  
Where this is not the case, this is specifically referred to in the text.   
 
 
The global health burden  
In the USA and Western Europe biliary tract cancers are uncommon, with a 
reported incidence of 1-2 per 100,000, accounting for 3% of all gastrointestinal 
tumours (6, 7).  In contrast in regions of South East Asia where infestation with the 
liver fluke parasites Opisthorchis viverrini and Clonorchis sinensis is endemic, age-
standardised incidence rates of BTC can reach as high as 94.8 and 39.4 per 100,000 
males and females respectively (8).  Incidence and mortality rates of intrahepatic 
cholangiocarcinoma (ICC) in industrialised nations however have been substantially 
increasing over the last 20 years, (9-11).  In the UK following 1993 ICC became the 
most commonly recorded cause of malignant liver tumour-related death in females 
in England and Wales (12, 13).  This prompted examination as to whether 
misclassification of ‘Klatskin’ or perihilar tumours as intrahepatic rather than 




extrahepatic cholangiocarcinoma by the International Classification of Diseases for 
Oncology, 2nd Edition (ICD-O-2) had skewed such trends.  However when 
diagnoses were re-classified to an extrahepatic code, the observed increases in 
incidence rates were upheld (4) and have been subsequently corroborated by other 
independently collected datasets and World Health Organisation data (7, 14, 15).  
Biliary tract cancers confer a dismal prognosis:  less than 5% overall survival at 5 
years (16), equating to a median overall survival of 9 to 10 months (17).  This is 
attributable to their late presentation, complexity of diagnosis as well as lack of 
response to conventional chemotherapy. 
 
The aetiology of biliary tract cancer 
Although the majority of biliary tract cancer (BTC) arises spontaneously, a number 
of pathological conditions increase the risk of developing this malignancy. 
Established risk factors Probable risk factors 
Primary sclerosing cholangitis (PSC) (18, 19) Smoking 
Hepatolithiasis (20)  
Clonorchis sinensis infection (21)  
Opisthorchis viverrini infection (21)  
Choledochal cyst (congenital biliary cystic 
disease)(22, 23) 
 
Cirrhosis (24)  
Hepatitis C virus infection (24, 25) 
Hepatitis B virus infection (24) 
 
Obesity (24)  
Type II diabetes mellitus (24)  
Alcohol (24)  
Table 1.1  Risk factors for the development of biliary tract cancer 
The natural history of primary sclerosing cholangitis is heterogeneous and a 
variable incidence of cholangiocarcinoma reported (18, 19).  The overall lifetime risk 
of developing cholangiocarcinoma is 10-15% (26).  This represents a particularly 
dismal prognosis for these patients as they will rarely be candidates for resection 
due to multifocal disease or inadequate residual hepatic function.   




The propensity for patients with congenital biliary cystic abnormalities to develop 
malignancy is thought to be due at least in a proportion of patients to chronic reflux 
at an abnormal choledochopancreatic junction and similarly patients who have 
undergone sphincteroplasty or sphincterotomy for benign conditions are at an 
increased risk of developing malignancy compared to the general population (22, 
23).   
Infection with the trematode Opisthorchis viverrini is endemic in south east Asia 
particularly Thailand, Vietnam, Loas and Cambodia.  Clonorchis sinensis is prevalent 
in Korea and China.  Both species are now classified as a type I carcinogen by the 
International Agency for Research in Cancer of the World Health Organisation and 
chronic infection is associated with a 27 fold increased risk of developing 
cholangiocarcinoma (21).  Similarly chronic inflammation secondary to intrahepatic 
pigmented hepatolithiasis, especially common in Japan, is a contributing factor to 
high incidence rates in these regions (20).   
Due to the relatively low incidence of BTC in regions of the world where liver 
parasite infection is uncommon, meta-analysis of smaller epidemiological studies 
has been required to determine the true odds ratios for potential aetiological factors 
previously implicated in this disease (27).  These studies have concluded that 
Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) infection, cirrhosis, alcohol, 
type II diabetes mellitus and obesity are all major risk factors for the development of 
cholangiocarcinoma (24).     
  




Existing treatment strategies  
Surgery is the sole cure for biliary tract cancer, however less than 7% of patients 
present with disease that is amenable to curative resection (28).  This procedure 
usually involves excision of the involved hepatic lobe (partial hepatectomy) and 
extrahepatic biliary system, regional lymphadenectomy and Roux-en-Y 
hepaticojejunostomy.  For tumours involving the distal ducts, a 
pancreaticoduodenectomy may be required.  Contraindications to surgery include 
contralateral or bilateral vascular encasement, or tumour extension bilaterally to the 
level of the secondary biliary branches.  Until recently the Bismuth-Corlette 
classification system has been used to assess suitability for surgical resection (29).  
This system stratifies patients solely on the extent of ductular involvement of the 
tumour and therefore has had little predictive value in terms of either resectability 
or survival.   The American Joint Committee on Cancer (AJCC) 6th edition classified 
tumours based on histopathological criteria and so similarly was not useful for 
preoperative staging (30).  Consequently a modified score, the Blumgart clinical 
staging system (31) is now used, which takes into account the extent of bile duct and 
portal vein involvement as well as the presence of hepatic lobar atrophy and is 
incorporated into the 7th edition of the AJCC staging system.   The most important 
predictor of post-resectional recurrence is a positive resection margin (32).  Well-
differentiated histology and a papillary phenotype are independent predictors of 
long-term survival (33).  Given the incidence of BTC and the proportion of patients 
suitable for resectional surgery, the efficacy of adjuvant chemoradiation has been 
difficult to assess through clinical trials and no data currently support its use (34).   
A single centre in the USA has pioneered liver transplantation as a curative option 
for patients with perihilar cholangiocarcinoma (35).  Patients with unresectable 
disease including patients with PSC who meet a rigorous selection criteria undergo 
a treatment protocol of neoadjuvant external beam radiotherapy followed by 
intracavitary brachytherapy with iridium-192 and oral capecitabine up until 
transplantation.  Once prioritised, patients undergo staging laparotomy to exclude 




extrahepatic or nodal metastasis previously missed by endoscopic ultrasound-
guided biopsy before going on to transplantation.  Initial results from this highly-
selected cohort appear encouraging.  Recurrence-free survival is reported to be 68% 
at 3 years, plateauing at 60% at 10 years.  Predictors of recurrence are a high CA19-9 
level, portal vein encasement and residual tumour on explant.  Pre-transplantation 
drop out from the waiting list is predicted by a high CA19-9, mass >3cm in radial 
diameter or a MELD score of >20 (36).  These results have recently been supported 
by initial results reported by the Irish National Liver Transplantation Programme, 
who report a similar survival rate of 61% at 4 years (37).  In both these uncontrolled 
studies, patients are stringently selected and indeed, not all patients undergoing 
neoadjuvant treatment progress to liver transplantation.  Indeed it could be argued 
that patients not progressing to surgery are subjected to a worse end of life 
experience than those undergoing conventional therapy.  In this context it is difficult 
to directly compare outcome data from those receiving a graft with published 
survival rates following resection, and therefore transplantation remains an 
experimental treatment in a limited number of centres.   
The majority of patients with BTC are not suitable candidates for any surgical 
option and for them the goals of treatment are supportive care and maximisation of 
quality of life.   Multiple studies have been performed using chemotherapeutic 
agents either alone or combination (fluropyrimidines, platinum agents, gemcitabine, 
taxanes and irinotecan) and demonstrate partial disease response rates of the order 
of 10-30% but with only modest benefits in overall survival (38-41).  One recent 
phase III randomised clinical trial however has demonstrated a significant 
improvement in short term survival in response to combined treatment with 
cisplatin and gemcitabine compared with gemcitabine alone, and this has now been 
adopted as an accepted standard of care (17).  Clinical trials are ongoing to assess 
the use of neoadjuvant or adjuvant chemotherapy in patients undergoing curative 
resection for BTC.   




Other agents currently undergoing clinical trials for BTC include monoclonal 
antibodies targeted to receptor tyrosine kinases, particularly against the Epidermal 
Growth Factor (EGF) and Fibroblast Growth Factor (FGF) pathways. Encouraging 
initial results have demonstrated an improvement in disease progression-free 
survival and in a subgroup of patients, complete response or response sufficient to 
permit surgical resection (42-44).  Combination with a VEGFR inhibitor similarly 
appears to induce partial disease response (45).   
The use of palliative radiation or photodynamic therapy have not been widely 
adopted even for locally advanced disease without distant metastasis due to a lack 
of survival benefit compared to other palliative measures such as stenting, 
percutaneous biliary drainage or biliary-enteric bypass (46).  These measures form 
the basis of supportive care and symptomatic relief to improve quality of life for the 
majority of patients with this disease.     
  




The genomic mutations of biliary tract cancer  
Compared to other solid tumours types little is known of the genetic, epigenetic and 
chromosomal aberrations occurring during the pathogenesis of cholangiocarcinoma.  
Few studies have used genomic sequencing to analyse somatic changes and hitherto 
this has not been performed in a large cohort of human specimens.  Exome 
sequencing of eight fluke-associated tumours has been used to validate recurrently 
mutated genes observed in a larger cohort of 46 cases (47).  This study identified 
abnormalities in a number of known tumour suppressor and oncogenes including 
TP53 (44.4%), KRAS (16.7%) and SMAD4 (16.7%) as well as other genes not 
previously implicated including MLL3, ROBO2, RNF43, PEG3 and GNAS.  The same 
group went on to compare fluke-associated with non-fluke associated tumours 
using a larger number of cases, identifying a difference in mutational signature.  A 
higher frequency of mutations was observed in BAP1, IDH1 and IDH2 in sporadic 
ICC compared with infection-related tumours where TP53 was more commonly 
mutated (48).  These findings corroborate a pattern independently identified in 
which two biological classes of ICC appear to exist; those associated with 
inflammation, up-regulation of cytokines and inflammatory signalling pathways 
including STAT3 activation, and those termed ‘proliferative’, characterised by 
activation of oncogenic signalling including MAPK and MET, frequent DNA 
amplifications, copy number alterations and mutations in KRAS and BRAF.  This 
second group appears to be associated with poorer clinical outcomes (49).  Similarly 
other laboratories have highlighted KRAS mutation and HER2/EGFR signalling as 
poor prognostic indicators, characterised by transcriptional enrichment of genes 
regulating proteosomal activity (50, 51).  In general terms the mutational signature 
of ICC does appear to be heterogeneous compared with other tumour types (52).  
Interestingly mutations in IDH1 and its mitochondrial counterpart IDH2 are 
repeatedly identified in ICC (48, 53-55).  IDH1/2 aberrations have been previously 
identified in a limited but stereotypical group of tumours; gliomas, acute myeloid 
leukaemia and chondrosarcomas, all of which demonstrate a hypermethylated 
phenotype and intense research is focussing on these targets for future therapeutic 




development.  Few studies have assessed the global methylation changes in ICC.  
Initial reports suggest however that, like most cancers, ICC has non-randomly 
distributed patterns of promoter methylation that are enriched for in cancer-related 
pathways including Wnt, TGFβ and PI3K signalling (56).   
  




The tumour-stroma microenvironment 
ICC is characterised by an intense desmoplastic reaction in which multiple cell types 
including myofibroblasts, inflammatory and vascular cells interact with neoplastic 
epithelia invested by a supporting 3-dimensional extracellular matrix to actively 
support tumour growth.  The extent of desmoplasia and expression of the activated 
myofibroblast marker α-smooth muscle actin (α-SMA) inversely correlate with 
patient survival (57, 58) and there is a multitude of evidence in favour of the concept 
that cancer-associated fibroblasts (CAFs) actively drive tumour cell growth (59, 60).  
This population of CAFs appears to be phenotypically heterogeneous, for example 
tumours with a distinct subpopulation expressing the glycoprotein podoplanin have 
reduced survival and greater lymphatic metastasis (61).   Furthermore CAFs secrete 
growth factors that enhance tumour cell migration and invasiveness including HGF, 
SDF-1, periostin and tenascin-C (62-64).  In particular, secretion of matrix 
metalloproteases, especially MMP1, 2 and 9 serves to remodel matrix and promote 
cancer progression and invasiveness (65).  The dominant result of CAF growth 
factor secretion however is a fibrogenic response, whereby myofibroblasts produce 
a dense stromal scaffold rich in an extensive array of modified extracellular matrix 
proteins, including fibrillar collagens (I, III, V and XI), laminin and the basement 
membrane proteins fibronectin and collagen IV (66).  In comparison to 
hepatocellular carcinoma, this microenvironment is relatively hypovascular.  
Hypoxia and associated hypoxia-inducible factors (HIFs) are likely to play a role in 
tumour behaviour but again, this is an understudied area of research in ICC.  
Neoangiogenesis however is intrinsically linked to metastasis and a number of pro 
and anti-angiogenic factors have been identified to be up-regulated in ICC, 
including VEGF, the endothelins and thrombospondin-1 (67, 68).  
The stromal microenvironment of ICC has an abundant inflammatory infiltrate 
including neutrophils, monocytes and T cells, although the precise role of these cells 
in tumour progression has yet to be fully characterised.  As in other cancer types, a 
major subset of these cells is tumour-associated macrophages.  Little work has been 




done in ICC to assess their contribution to tumour progression, however it is known 
that they stain positively for CD68 and the ‘alternatively’ activated or ‘M2’ marker 
CD163 and that although macrophage density does not correlate with overall 
survival, infiltration of CD163+ macrophages does inversely correlate with disease-
free survival (69).  Furthermore patients with ICC have higher levels of CD14+ 
CD16+ dual positive circulating monocytes (the precursors of the tissue 
macrophage), compared with healthy patients or patients with benign disease, and 
that this is associated with poor clinical outcome and rapid tumour progression (70).    
This malignant niche is rich in soluble cytokines and growth factors released by 
both neoplastic epithelia as well supporting and inflammatory cells.  Transforming 
growth factor beta (TGFβ) secreted by multiple cell types but particularly cancerous 
epithelia and CAFs, has a dominant role in driving both fibrosis through matrix 
deposition and in cholangiocarcinoma progression via direct stimulation of cancer 
cell proliferation.  Direct inhibition of tumour development and regression of 
established fibrosis can be achieved in vivo using a neutralising monoclonal 
antibody targeted against TGFβ or genetic deletion of its receptor TGFbr2 (71, 72).  
In addition a  strong association has been established between the inflammatory 
cytokine interleukin-6 (IL-6) and ICC progression (73).  This is thought to be 
mediated through the effects of IL-6 on aberrant promoter methylation including 
that on the EGFR gene. (74) 
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Figure 1.1 The tumour microenvironment of cholangiocarcinoma.  Malignant biliary 
ductules are invested by αSMA positive myofibroblasts which secrete soluble 
factors and extracellular matrix proteins, contributing to the surrounding dense 
desmoplasia.  Inflammatory cells including neutrophils, T cells and tumour-
associated macrophages infiltrate tumours, phagocytosing tumour cells and 
secreting cytokines.  Neoangiogenesis promotes tumour growth and endothelia 
secrete growth factors including VEGF.    




Rodent models of ICC 
Until recently the number of rodent models of ICC that faithfully recapitulate the 
inflammatory stromal histology and clinical features of the human cancer have been 
few.  Several rat models using chemical carcinogens have been developed to mimic 
the stepwise progression of biliary carcinogenesis with good tumour penetrance, the 
most widely used of which is oral administration of thioacetamide (TAA) (75).  
Cytochrome P450 (2B and 2E1) and flavin monooxygenase enzymes in zone 3 of the 
liver metabolise TAA to potently hepatotoxic products which disrupt ribosomal 
function, alter protein assembly and stimulate DNA synthesis (76, 77).  Prolonged 
administration reproducibly results in bile duct proliferation, dysplasia and 
ultimately carcinoma, with a 50% penetrance at 16 weeks and 100% at 22 weeks.  
Histological features closely mimic human disease, with metaplasia foci, a dense 
desmoplastic stroma and neoplastic ducts displaying CK19, c-Met and c-erb-B2 
positivity.      Alternative chemical agents inducing biliary carcinogenesis in rat 
include furan (78) and 3'-methyl 4-dimethylazobenzene (79, 80). 
Alternative but less practicable approaches have used orthotopic transplantation of 
transformed cholangiocytes (81, 82) or have combined administration of 
dimethylnitrosamine (DEN) with liver fluke Opisthorchis viverrini metacercariae in 
hamster (83).   
Transgenic murine models of ICC are now emerging.  Currently the only murine 
model of gallbladder adenocarcinoma employs overexpression of wild type rat 
ErbB-2 under control of the cytokeratin 5 (CK5) promoter with all homozygous 
animals developing de novo tumours between 3 and 8 months of age (84).  ICC 
develops with high penetrance (100%) following liver-specific deletion of the 
tumour suppressors Smad4 and Pten using an embryonic albumin-driven Cre 
recombinase system (85).  Neoplastic foci emerge at 2 months of age in all animals 
carrying both gene deletions, compared to no tumour formation in Smad4-only 
deleted mice and only a third of Pten-only deleted animals at one year, suggesting a 
synergistic relationship between these tumour suppressors.  This albumin-specific 




Cre recombines loxP sites in both cholangiocytes and hepatocytes, but interestingly 
hepatocellular tumours only developed in mice carrying Pten deletion.   
An constitutive albumin-linked Cre system has also been used to combine tissue-
specific p53 deletion with an activating mutation of KrasG12D (86) .  Albumin is 
expressed in all hepatoblasts during embryogenesis and thereby in the adult liver 
recombination of floxed alleles has occurs in hepatocytes, cholangiocytes and 
hepatic progenitor cells (HPCs) in this model.  Animals carrying activated KrasG12D 
mutation and homozygous loss of p53 developed tumours by 9 weeks of age 
(median survival 19 weeks); those heterozygous for p53 deletion developed 
tumours at 32 weeks (median survival 52 weeks).  Animals without Kras mutation 
but homozygous for p53 deletion were followed to one year of age without 
abnormality.   
The use of an alternative promoter Cyp2A1 (referred to as AhCre) expressed in 
mature hepatocytes but also in gallbladder epithelium, has similarly been used to 
conditionally induce Pten deletion and kRas activation in the adult liver (87).  
Findings from this study mirrored those seen by O’Dell et al. in that mice with Pten 
deletion or Pten deletion combined with kRas activation displayed reduced survival 
and histological biliary neoplasia, whereas animals with kRas activation alone were 
histologically normal.   
An alternative strategy of disease modelling is to combine transgenic tumour 
suppressor deletion or oncogene activation with chronic biliary injury.  
Administration of the hepatotoxin and pro-fibrotic agent carbon tetrachloride (CCl4) 
to p53 null mice over a 16 week period precipitates multifocal ICC in p53-/- and 
p53+/- mice with an allelic dose dependant reduction in survival.  A number of 
other tumour types also develop in these animals however, including HCC, 
lymphoma and sarcoma, and the high reported mortality precludes its widespread 
adoption as useful model of ICC.   




In summary, compared to other cancer types, rodent models of ICC are flawed, and 
consequently one of the principal aims of this study was to develop a more specific 
murine model in which genetic alterations within the biliary compartment of the 
liver are permissable, to allow interrogation of epithelial signalling during ICC 
tumorigenesis.   
  




The cell of origin of ICC 
Historically it has been assumed that ICC arises from the oncogenic transformation 
of mature biliary epithelia in light of its glandular histological morphology, location 
within and adjacent to the biliary network and expression of cholangiocyte specific 
proteins including mucin and biliary cytokeratins 7 and 19 (88).  Moreover the 
propensity for patients with chronic biliary inflammation to develop ICC, in 
particular those with primary sclerosing cholangitis or liver fluke infection, has 
added further weight to this theory (21, 89).  Bipotential hepatic progenitor cells 
have also been considered a cellular source, especially in tumours classified as 
combined hepatocellular cholangiocarcinoma (CHC); which display features of both 
cholangiocarcinoma and hepatocellular carcinoma, as well as cholangiolocellular 
carcinoma (CLC), where tumours display prominent ductular reaction and cords 
resembling the canals of Hering (90, 91).   
Interestingly however the incidence of ICC is also increased in chronic 
hepatocellular injury such as HCV and HBV infection indicating a more complex 
cellular origin of these cancers (24) and indeed recent work has demonstrated 
mature hepatocytes possess potential for transdifferentiation into ICC (92, 93).  In 
these fate-tracing experiments tumours were established in transgenic mice carrying 
an inducible heritable label for either hepatocyte (Alb-CreERT2) or biliary (CK19-
CreERT2) lineages using the chemical carcinogen thioacetamide (TAA).  Labelled 
neoplastic nodules positive for Epithelial Cell Adhesion Molecule (EpCAM) were 
observed in tumours arising in Alb-CreERT2 but not CK19-CreERT2 animals, 
suggesting that ICC arises from hepatocytes rather than cholangiocytes in this 
model (93).  This transdifferentiation of hepatocytes to a biliary program is shown to 
be dependent on intracellular Notch signalling through gain and loss of function 
experiments.  Overexpression of the Notch1 intracellular domain in Albumin-
expressing cells (Alb-CreERT2;R26RNotch/+) or conversely deletion of its downstream 
effector Hes1 (Alb-CreERT2;Hes1fl/fl) resulted in a respective increase and decrease in 
the number of primitive CK19-positive ductules formed.  Similarly, an independent 




group have demonstrated injection of a N1-ICD transposase-mediated plasmid to 
result in the formation of biliary cystadenomas, which in combination with a 
myristolated AKT1 plasmid precipitate the formation of ICC displaying biliary 
lineage markers 1.5 weeks following injection (92).  Interestingly these tumours 
developed around the central lobule of the liver.  Tumours were subsequently 
lineage-traced using an adeno-associated virus to deliver a hepatocyte-specific Cre 
recombinase (driven by a transthyretin promoter) in R26R-EYFP transgenic mice.  
N1-ICD/AKT Plasmid injection resulted in eYFP positive tumours staining positive 
for biliary (Sox9, Ck8) indicating that similarly in this system the cell of origin was 
the hepatocyte.    




The Canonical Notch signalling pathway 
Notch signalling is one of the most highly conserved pathways in metazoan 
evolution.  It is one of a tightly restricted number of pathways including Hedgehog, 
Wingless(Wnt), Transforming growth factor beta, Receptor tyrosine kinase and 
JAK/STAT that act individually and in combination during development to co-
ordinate cellular transcriptional responses and thereby regulate cellular 
proliferation or death, binary cell fate decisions, specification, tissue patterning and 
morphogenesis (94).  This orchestration allows complex multicellular tissues organs 
and organisms to develop with fidelity but also means that perturbation in these 
signals through mutation or dysregulation results in a wide range of developmental 
syndromes.  Moreover these pathways continue to regulate the homeostasis of adult 
tissues and regeneration following injury, and therefore aberration of these signals 
also promotes the onset of adult disorders of tissue repair including cancer.   
The core canonical Notch pathway is activated through cell to cell communication 
involving ligand and receptor tethered to the membrane of their respective cells.  
Notch signal transduction is unusual in that this interaction triggers a series of 
proteolytic cleavage events which release an active, truncated form of the receptor 
which translocates to the nucleus to effect transcription of Notch target genes 
(Figure 1.2).   
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Figure 1.2 The core pathway of Notch signalling in mammals.   
 
Figure 1.2 The core pathway of Notch signalling in mammals.  Notch ligand is provided 
by a neighbouring cell to interact with one of four receptors (Notch 1, 2, 3 or 4).  This 
triggers enzymatic cleavage of receptor into an activated, truncated form (N-ICD) 
which travels to the nucleus.  In the absence of N-ICD, Notch target genes are 
maintained in an actively repressed state, however when N-ICD forms a complex 
with the DNA binding protein RBPJκ, co-repressors are displaced by co-activators 
including MAML and SKIP and transcription of downstream Notch target genes 
(Hes/Hey) occurs.   




The Notch Receptors 
The Notch gene of Drosophila melanogaster codes for a single 300kD type I 
transmembrane glycoprotein receptor.  Two paralogs are found in Caenorhabditis 
elegans (cLIN-12 and c-GLP-1) and four in human: NOTCH 1, 2, 3 and 4. Although in 
C.elegans the two Notch paralogs can fully substitute for each other, in mammals the 
four receptors each have both overlapping and distinct tissue distributions as well 
as redundant and distinct functions (95).  All receptors are constituted by three 
principal domains: an extracellular region, a transmembrane portion and an 
intracellular domain (N-ICD) (Figure 1.3).   
The extracellular domain comprises at its N terminals between 29 and 36 tandem 
epidermal growth factor (EGF)-like repeats which mediate ligand interaction and 
determine ligand selectivity according to context (96, 97).  Functionally productive 
interactions between neighbouring cells known as trans interactions are mediated by 
repeats 11 to 12, whereas repeats 24 to 29 have been implicated in cis interactions, 
i.e. between receptors and ligands expressed on the same cell where no signal is 
transmitted.  These EGF repeats contain motifs for fucosylation (by O-Fut1) and 
glucosylation (by Rumi) and the ligand-binding regions of the four paralogs differ 
in these modification patterns.  Proximal to the EGF repeats, a negative regulatory 
region (NRR) is found, composed of three cysteine-rich Lin12-Notch repeats (LNR) 
and a heterodimerisation domain, which act to prevent signal transduction in the 
absence of ligand binding (i.e. this region maintains the autoinhibitory resting state 
of the receptor). 
The transmembrane portion of the receptor contains a single domain characterised 
by a C-terminal sequence of 3 to 4 arginine-lysine residues that acts as a “stop 
translocation” signal.   
Inside the cell an RBPJκ-association molecule (RAM) domain links the single-pass 
transmembrane region with seven ankyrin repeats, followed by a nuclear 
localisation sequence and a transactivation domain.  At the C-terminal, a degron*-




containing PEST (proline/glutamic acid/serine/threonine-rich motif) sequence 
regulates the stability of the NICD. 
In Caenorhabditis elegans the two Notch paralogs can fully substitute for each other in 
cell fate decisions (98).  Of the four mammalian receptors, Notch1 and 2 exhibit the 
highest structural similarity.  Only these two paralogs contain a full transactivation 
domain (TAD), located C-terminal to the ANK repeats (99).  Notch3 displays a 
particularly short TAD-containing region and this is thought to account for a 
weaker transcriptional activity of the N3-ICD compared to that of Notch1 and 2.  
Comparison of amino acid identity between Notch1 and 3 has revealed high 
similarity in the ankyrin repeat region (72%) compared to the RAM (42%) and C-
terminal (21%).  Such differences have been proposed to account for the differential 
ability of Notch paralogs recruit co-activators and repressors as well as a differential 
capacity to undergo conformational changes (99).  Furthermore the extracellular 










* Degron  A specific sequence of amino acids in a protein that drives the starting 
place of degradation. 
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Figure 1.3 The structural organisation of mammalian Notch receptors.   
 
 
Figure 1.3 The structural organisation of mammalian Notch receptors.  Notch receptors 
are membrane-spanning (type I) proteins, each comprising an extracellular domain 
(ECD), transmembrane domain (TMD) and intracellular domain (ICD).  The 
extracellular region is composed of a sequence of EGF-like repeats, of which some 
mediate ligand interactions.  Furthermore the EGF-like repeats contain motifs for 
fucosylation (by O-fut) and glycosylation (by Rumi) during translation, and the 
distribution of these differs between paralogs.  Proximal to this, the negative 
regulatory region (NRR) abuts the transmembrane domain (TMD).  The intracellular 
domain (ICD) contains an RBPJκ-association molecule (RAM) for partner binding, a 
nuclear localisation sequence (NLS), seven ankyrin repeats, a transactivation 
domain (TAD) and a conserved PEST motif.   





Activation of Notch signalling in mammals is initiated through a short-range 
‘juxtacellular’ interaction between receptor and one of five ligands tethered within 
the membrane of a neighbouring cell.  Although it is believed that in mammals any 
one of the five ligands (Delta-like1,2,3 or Jagged1,2) are able to interact and 
stimulate any of the four Notch receptors (Notch1,2,3,4), genetic screens in drosophila 
have revealed that it is the EGF-8 repeat in the receptor’s extracellular domain 
which discriminates between Delta or Serrate binding and this has been 
evolutionarily conserved to the mammalian homologs Delta-like and Jagged (97).  
Screening of drosophila mutants has also elucidated that missense mutations in the 
ligand Delta that cause defective ubiquitylation of the ligand’s intracellular portion 
or those causing dysfunction of endocytosis and intracellular receptor trafficking 
result in disruption of functional signalling following receptor-ligand interaction 
(101).  It is important to note there is no signal amplification in the Notch pathway – 
one ligand binds to one receptor, whose intracellular domain translocates to the 
nucleus to drive target gene transcription.  As a consequence, ligand and receptor 
availability at the cell surface is the sole determinant of signal strength and effector 
transcription.  Therefore spatial and temporal expression of Notch ligand is tightly 
regulated during development and injury to ensure the effects of Notch are co-
ordinated in a context-dependent manner.  Post-translational ligand modifications 
such as ubiquitylation by the E3 ubiquitin ligases Mindbomb and Neuralized are 
consequently important regulators of ligand presentation and thereby pathway 
activity (102).  A novel gene complex known as Bearded in drosophila code for a 
family of proteins that are able to negatively regulate Neuralized activity and 
therefore reduce efficiency of Notch activation, but are themselves Notch target 
genes, thereby providing a negative feedback loop to control signal strength (103). 
Much still remains to be ascertained about the functional consequences of different 
combinations of receptor-ligand interaction, although there is consensus that 




binding with Dll3 ligand in xenopus and mammals is actually suppressive to Notch 
signalling (104).   
 
Intra-membrane Proteolysis 
The Notch pathway is set apart from other conserved signalling cascades by a series 
of proteolytic cleavage events that occur within the membrane of the signal-
receiving-cell following ligand binding.  The initial interaction triggers cleavage of 
Notch at its negative regulatory region (NNR) by ADAM, a disintegrin and 
metalloproteases, an event known as S2 cleavage (Figure 1.4).  This releases an 
‘ectodomain’, leaving behind an intermediate fragment known as Notch 
extracellular truncation (NEXT), which becomes the substrate for the gamma-
secretase complex.  This multi-protease complex cleaves the receptor sequentially, 
starting at the inner plasma membrane (S3) and ending within the transmembrane 
domain (S4), causing release of the intracellular domain of the receptor (N-ICD) 
which is then free to translocate to the nucleus.  Γ-secretase cleavage can occur both 
at the membrane and in the endosome, however cleavage in the membrane 
produces a more stable N-ICD. 
Point mutations or viral integration in the S2 cleavage site in the negative regulatory 
region (NRR) result in Notch signalling in the absence of ligand, such as is seen in 
acute T lymphoblastic leukaemia in humans or lymphoma in mice (105, 106).  It is 
the steric structure of this NRR which defines the Notch receptor to be ‘OFF’ in its 
resting state.    Gamma-secretase itself is made up of four membrane proteins:  the 
catalytic unit presenilin and three co-factors: Nicastrin (NCT), Pen2 and Aph1.  Two 
different isoforms of both presenilin and Aph1 exist in mammals, meaning that at 
least four gamma-secretase complexes can exist, each resulting in differing protein 
interactions, although the precise functions of the various complexes is as yet 
unknown.   
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Figure 1.4 Regulated proteolysis mediates Notch receptor maturation and activation.   
 
 
Figure 1.4 Regulated proteolysis mediates Notch receptor maturation and activation.  
Following translation the Notch receptor undergoes a maturation process involving 
fucosylation and glycosylation by the enzymes O-fut and Rumi before its first 
proteolytic cleavage event in the golgi at site 1 (S1) by furin.  The receptor can then 
be targeted to the membrane as a heterodimer.  Following ligand-receptor 
interaction ligand endocytosis begins to occur exerting a mechanical force upon the 
receptor and inducing a conformational change which exposes the S2 site for 
cleavage by ADAM metalloproteases. This generates the Notch extracellular 
fragment (NEXT), a γ-secretase substrate.  Progressive cleavage by γ-secretase at S3 
and S4 releases the N-ICD for nuclear translocation.   





The Canonical pathway:  ICD translocation and target transcription 
It remains unknown how the translocation of the intracellular domain (N-ICD) is 
regulated.  DNA binding requires the presence of CSL (RBPJκ in mammals) which, 
in the absence of N-ICD acts to repress transcription of Notch target genes through 
recruitment of co-repressor proteins including SKIP, hairless, CtBP or Groucho 
(TLE).  Such repression however is complex and thought to be of variable 
significance in different tissue contexts.  In skin for example, RBPJκ mutants do not 
display as severe a phenotype seen in animals that have lost either multiple Notch 
receptors or gamma-secretase, indicating that there may be de-repression of Notch 
targets in these animals, however in contrast, loss of RBPJκ in Notch mutants does 
not alleviate their phenotype (107).  Adding further to the complexity, occupancy of 
RBPJκ on Notch target gene promoters can also be transient, and further work is 
required to better understand the mechanisms of this crucial step in the pathway. 
N-ICD contains a RAM domain (RBPJκ Associated Molecule) which mediates 
binding to RBPJκ and induces dissociation of transcriptional repressors.  The co-
activator Mastermind-like (MAML) as well as other co-activators including SKIP are 
then recruited and this complex can recruit histone acetylases (including p300) and 
chromatin remodelling factors to assemble a transcriptional activator complex on 
target promoters.  Notch target genes are numerous; however in mammals the 
archetypal family is the Hairy/Enhancer of Split genes (Hes) which encode a series 
of basic Helix Loop Helix (bHLH) proteins which are often functionally redundant 
and which certainly exert different actions in different cell types.  The determination 
of such differing responses is thought to be a result of crosstalk from other 
pathways but might also be a result of the action of Notch-responsive enhancer 
elements.  Much has yet to be learnt about the factors governing transcription of 
target promoters, which are not stereotypical; for example even Hes1 is not always 
activated by Notch1 (108).   
 




Termination of Notch signalling 
The cellular processes regulated by Notch activity require that its effectors have a 
short nuclear half-life.  In this way, assembly of the transcriptional activating 
complex RBPJκ-NICD-MAML also results in N-ICD dissociation. This is achieved in 
part, by recruitment of factors including Cyclin dependent kinase 8 (CDK8) which 
phosphorylates N-ICD, thereby converting it into a substrate for the ubiquitin E3 
ligase SEL10 and targeting it for degradation by the proteosome (109).  In the 
absence of N-ICD, RBPJκ will again recruit its co-repressors (in drosophila, Hairless 
and Groucho.  No mammalian homolog for Hairless has been identified, but SMRT 
and SHARP are proteins which can recruit the co-repressor CtBP.  SKIP may also 
form part of this repressor complex).  It is likely that other kinases and other E3 
ligases are also involved and that these vary according to context.    




Notch signalling and cell fate 
The Notch pathway functions at many different stages of development and adult 
tissue homeostasis to regulate cell number and determine cell fate.  The unusual 
property of Notch is the transmembrane nature of both ligand and receptor, 
meaning that signalling is restricted to only occurring between neighbouring cells.  
The consequence is that Notch functions via three general modes of action: 
Lateral Inhibition 
During development there is frequently a requirement for amplification of small 
(and often random) differences between equivalent cells in order to generate 
different cell types from a seemingly homogenous population.  For example in the 
developing hermaphrodite gonad of C.elegans, Notch signals between two 
neighbouring cells so that one specifies to become an anchor cell and one a uterine 
precursor cell.  Initially both the receptor lin-12 and the ligand lag-2 are expressed 
equally in both cells, however autoregulation of lin-12 transcription amplifies 
stochastic fluctuations in expression so that lin-12 gets restricted to the presumptive 
uterine precursor cell and lag-2 to the anchor cell (110).   
Lineage Commitment 
Asymmetric cell division is a faithful and efficient way of producing cell fate 
diversity during development.  In the developing peripheral nervous system of 
drosophila melanogaster, asymmetric inheritance of the Notch antagonist Numb 
results in the specification of sensory organ precursor (SOP) cells into either a 
neuronal or supporting cell type (111). Asymmetric distribution of other Notch 
regulators including Neuralized mediates cell fate commitment in multiple 
developmental and adult regenerative contexts (112-114). 
Inductive signalling & formation of boundaries 
Despite being a juxtacellular signal, Notch can in fact co-ordinate the generation of 
developmental signalling boundaries through restriction of expression of Notch 




components including ligands, target genes and the Notch modulator Fringe (114, 
115).  For example restriction of Esl target genes across the dorso-ventral boundary 
of the wing imaginal disc in drosophila forms a boundary across which sensory organ 
cells and trichomes (hair cells) are specified in a distinctive pattern (116). 
  




Notch signalling in liver development  
Notch activity is critical for the faithful embryological development of multiple 
tissues in diverse organisms through regulation of cell fate decisions.  The extent of 
this influence is evident following mutation or transgenesis resulting in loss of 
Notch function as in the inherited disorder Alagille syndrome (117-119).  This 
autosomal dominant congenital syndrome is a heterogeneous disorder characterised 
by cholestasis and jaundice as a result of failure of development of the intrahepatic 
bile ducts.  This disorder occurs in approximately 1 in 70,000 births and is the 
second most common cause of intrahepatic cholestasis in infancy.  Despite its 
autosomal dominant inheritance, expressivity is variable and the phenotype can 
range from an apparently normal phenotype through to severe liver failure 
requiring transplantation.   Life expectancy is dependent on the degree of liver 
failure present.   
Hepatobiliary anomalies are typically accompanied by congenital heart defects 
particularly pulmonary valve hypoplasia and peripheral pulmonary artery stenosis.  
Musculoskeletal abnormalities are also present, including ‘butterfly’ vertebrae, 
where there is a reduced interpedunculate distance in the lumbar spine, and 
stereotypical craniofacial malformations including a broad forehead, deep set eyes, 
a pointed mandible and bulbous tip of the nose (119, 120).  Less frequently renal and 
vascular abnormalities occur.  Most patients are of normal intelligence, although 
learning disabilities and mental retardation have been reported (117).   
In 94% of individuals with a clinically confirmed diagnosis Alagille syndrome is the 
result of mutation of the JAG1 gene (121).  A minority of patients carry mutations in 
the NOTCH2 receptor (117, 122).  JAG1 mutations are a result of premature 
termination codons in 72%, splice site mutations in 15% and missense mutations in 
13% of cases.  Between 3 and 7% have deletions encompassing the entire gene (123).  
Furthermore the resulting phenotypes are indistinguishable between patients with 
full gene deletions and those with intragenic mutations; indicating JAG1 
haploinsufficiency is sufficient for Alagille syndrome (123).  In addition non-genetic 




gene modifications are likely to also be important in accounting for the variable 
expressivity of the disease.  For example it is known that monozygotic twins can 
exhibit differing phenotypes.  One case report describes one twin with severe 
pulmonary atresia and mild liver disease; the other with Tetralogy of Fallot and 
severe liver failure requiring transplantation (124).   
The molecular result of such mutations in Notch is that hepatoblasts in the 
embryonic liver fail to express hepatic nuclear factor (HNF) 1 beta; a key biliary 
specific transcription factor, and hence embryonic biliary precursors are unable to 
differentiate down the biliary fate route (125).   
Congenital intrahepatic dilatation of the bile ducts (Caroli disease and syndrome) is 
a rare developmental malformation corresponding to type V in the Todani 
classification of congenital bile duct cysts (126).  It is commonly associated with 
congenital hepatic fibrosis which is thought to arise as a result of remodelling of the 
ductal plate in response to cystic dilatation of the intrahepatic bile ducts (127).  
Patients with Caroli disease are at 100 times greater risk of developing BTC than the 
general population (128).  Immunohistochemical studies have demonstrated that in 
a rat model of Caroli disease, myofibroblasts were abundantly present in the portal 
tracts of embryonic (E20), one day old and one week old animals, and that these 
mesenchymal cells express Jagged1.  Furthermore Notch2 appears to be up-
regulated by cholangiocytes in this model (129).  More studies are required to assess 
the full contribution of Notch to the pathogenesis of this developmental anomaly. 
It is surprising and unexplained why mice with the genotype of Alagille syndrome 
do not recapitulate the clinical phenotype seen in man.  Gene targeting has 
permitted detailed characterisation of Notch pathway mutations in the mouse 
embryo.  Heterozygous mutation of Jag1 alone results in defects in the anterior 
chamber of the eye but not the full suite of phenotypic characteristics.  Jag1 null 
mutants die before birth due to vascular defects in the yolk sack (130).  The human 
phenotype is observed in mice heterozygous for Jag1 in addition to mutation in 




either Notch2 or any one of the Fringe glycosyltransferase genes which modify 
receptor-ligand affinity: Lunatic (Lfng), Radical (Rfng) or Manic (Mfng) Fringe (131, 
132).  These mice exhibit growth retardation, jaundice and bile duct paucity in 
addition to cardiac, ocular and renal abnormalities as seen in Alagille patients.  
Gene targeting of the Hes/Hey family of Notch effectors results in a spectrum of 
phenotypic characteristics.  Hey2 mutants demonstrate similar cardiac abnormalities 
seen in human patients (133, 134). 
 
Table 1.2  Phenotypes associated with mutations in murine Notch 
Mutation (mouse) Phenotype 
Jag1 Embryonically lethal (hom); eye defects (het) (130) 
Jag1; Notch2 Alagille syndrome (132) 
Jag1; Lfng/Rfng/Mfng Alagille syndrome (131) 
Notch1 (AlbCre;Notch1flox/flox)* No abnormality in bile duct architecture (135) 
Notch2 (Alb1Cre;Notch2flox/flox)* Alagille syndrome (136) 
Notch1;Notch2 (AlbCre;Notch1flox/floxNotch2flox/flox)** Disorganised biliary architecture with multiple 
immature, dilated ducts extending into the hepatic 
lobe (135) 
Hes1 Normal ductal plate; No tubular morphogenesis at 
birth (die perinatally due to CNS defects) (137, 138) 
 
* (N.B: Constitutive knockout mice for Notch1 or Notch2 display embryonic lethality 
before day 11.5) 
** (N.B: Phenotype rescued by addition of a single copy of Notch2 (but not Notch1)) 
 
 
Conditional ablation of Notch2 in hepatoblasts (AlbCre-Notch2flox/flox) decreases the 
density of intrahepatic bile ducts in a dose-dependent fashion, whilst activation of 
Notch (AlbCre-ROSANotch1) has the opposite effect.  It is also clear that there is 
redundancy between Notch receptors as Cre-mediated deletion of RBPJκ results in a 
more severe phenotype with associated parenchymal injury, and that this process 
may act independently of the downstream Notch effector Hes1 (139).  Interestingly 
such regulation of the 3-dimensional ductal architecture is not mediated through a 




change in proliferation of bile duct progenitor cells, suggesting that Notch is playing 
a permissive role for other signalling networks to drive cholangiocyte specification 
(140).  Indeed, combining deletion of Notch (Rbpjκ) with deletion of the biliary 
transcription factor HNF-6 results in a more severe phenotype than Notch deletion 
alone (141).  Furthermore the source of Jagged1 ligand driving Notch activity during 
this phase of duct formation has been identified as the portal vein mesenchyme 
(SM-22Cre) rather than the endothelia of the portal vein (V-CadherinCre) (142).  
This role for Notch in the development of the intrahepatic bile ducts is 
evolutionarily conserved across species; deletions of Notch and Jagged in zebrafish 
cause an Alagille’s phenocopy and staged administration of pharmacological Notch 
inhibitors during development causes retardation of growth and expansion of the 
ductal network  (143, 144). 
Such mutant phenotypes provide evidence that Notch is required for tubular 
morphogenesis and arborisation of the intrahepatic bile ducts in the developing 
liver.  The transgenic systems used here fail however to define its role in the earlier 
developmental stage of specification and differentiation of bipotential hepatoblasts 
into biliary progenitors and later biliary epithelial cells.  Albumin transcription 
begins at approximately embryonic day 9.5, concomitant with the commencement 
of ductal plate specification and is likely a consequence of hepatoblast fate 
commitment itself, making these conditional knockout mice a flawed model in 
which to study the mechanisms of fate determination in the developing liver bud.  
Consequently mouse transgenics have been engineered in which Cre recombinase 
could be driven by one of the transcriptional activators of the liver-specific 
programme, Foxa3 (HNF-3G), in order to interrogate the requirement of Notch 
during these earlier events of hepatoblast specification (145).  Hepatic Nuclear 
Factors (HNFs) are members of the Forkhead class of DNA binding proteins and 
drive transcription of liver-specific transcripts including albumin and transthyretin 
(146).  This Cre-based construct was used to induce deletion of Rbpjκ , the 
downstream nuclear binding partner of all four Notch paralogs to bypass potential 




redundancy between receptors.  This resulted in a reduced number of ductal plate 
cells at E16.5 and bile ducts later at P0, indicating a requirement for Notch in both 
the generation of the ductal plate as well as duct formation.  In contrast over-
expression of N1-ICD using Foxa3-Cre resulted in the ectopic appearance of biliary 
cells which displayed features of mature epithelia as early as E16.5, suggesting 
Notch drives biliary differentiation of hepatoblasts (145).  In support of this, 
transfection of cultured fetal hepatoblasts with a N1-ICD plasmid significantly 
reduces the expression of hepatocyte (and hepatoblast) markers including albumin, 
whilst inhibition of Notch2 with siRNA or gamma-secretase inhibitors promoted 
hepatocyte differentiation (147).    
Finally, Notch also plays a role in the ontogeny of the extrahepatic biliary system.  
Hes1 is expressed in the extrahepatic bile ducts throughout development and acts to 
repress differentiation of these cells to a pancreatic programme by directly 
inhibiting transcription of the proendocrine gene Neurogen3.  Hes1 deficient mice 
fail to develop a gallbladder and exhibit hypoplasia of the extrahepatic bile ducts 
(148).   
  




Notch signalling during adult tissue homeostasis 
In line with its prevailing role for maintaining ‘stemness’ and inhibiting 
differentiation, Notch acts to sustain normal homeostasis in a variety of adult tissues 
through regulation of stem cell pools and control of cell fate.  This has been best 
characterised in the most actively self-renewing of endodermal organs, the intestinal 
epithelium.  The crypt-villus axis is maintained by canonical Wnt signalling.  When 
Apc, a key negative regulator of Wnt is deleted transgenically, or mutated in 
colorectal cancer, intestinal cells remain highly proliferative and fail to differentiate 
into enterocytes or migrate up the villus (149).  It is now known however that Notch 
ligand (Dll1, Dll4) supplied by Paneth cells within the crypt acts to maintain the 
Lgr5 stem cell population; an example of how stem cells can receive niche support 
from their own specialised differentiated progeny (150).  Genetic deletion or 
pharmacological inhibition of this Notch activity induces transdifferentiation of 
proliferating progenitor cells into a post-mitotic secretory, goblet cell phenotype 
(151, 152). 
The role of Notch in liver homeostasis is less defined.  Very few studies have been 
performed to genetically delete Notch components in the adult liver in the absence 
of injury.  One study has used a Cre-loxP system under the control of an Mx1 
promoter to delete Notch1 (Mx1Cre-Notch1flox/flox) (153).  Mx1 protein is an 
interferon-induced binding protein that forms part of the innate immune response 
against viral infection (154).  In response to interferon (IFN), expression of this 
protein is induced in the liver (hepatocytes and biliary epithelial cells) and bone 
marrow.  Without additional injury, the resultant phenotype following IFN 
administration and Notch1 deletion was nodular regenerative hyperplasia (NRH) of 
the liver; an increase in liver weight and parenchymal nodulation without 
associated inflammation, fibrosis or venous congestion.  Notch1 knockout animals 
displayed a dramatic increase however in the number of BrdU positive hepatocytes 
and the authors suggest that mutual inhibitory signalling between Jagged1 and 
Notch1 positive hepatocytes might account for the majority of hepatocytes 




remaining in an extended period of G0 quiescence.  It should be noted however that 
the observation of Jagged1 expression on hepatocytes has not been widely 
replicated (155).   
Although embryonic deletion of Notch2 is known to result in ongoing dysfunction 
of intrahepatic bile duct organisation long into the post-natal period, adult biliary 
deletions of Notch once normal ductal development has been completed have not 
been performed. Consequently true assessment of the ongoing requirement for 
Notch activity in biliary maintenance cannot as yet be made. 
In spite of this, descriptive studies have been performed to define the expression of 
Notch pathway components in human adult and fetal liver.  Flynn and colleagues 
for example have detected mRNA transcript for all four Notch receptors in fetal, 
paediatric normal and diseased liver.  In the developing liver they found Notch3 
detectable on mesenchymal cells adjacent to ductal plate cells expressing Jagged1 
ligand (156).   This is consistent with the findings of Zong et al. who found Jag1 to 
be expressed in portal vein endothelium from E12.5 onwards and on the portal side 
of ductal structures by E16.5 where it co-localised with CK19 and Sox9.  No Jag1 
was detectable on the parenchymal side of the ductal plate at any stage of 
development.  Similarly, they observed Hes1 on peri-portal and endothelial cells at 
the early stage of ductal plate development (E12.5), and by E18.5 this was also on 
mature ductal structures, co-localising with HNF4α (145).   
Further than this, the results of immunohistochemical analyses of Notch proteins in 
healthy liver have frequently produced inconsistent results.  In healthy paediatric 
liver Flynn et al found Notch1 and Notch2 detectable on bile ducts but also reported 
expression on hepatic arteries and hepatocytes.  In contrast they observe Notch3 on 
hepatocytes, portal veins and hepatic arteries, with Notch4 only detectable on 
arteries (156).  Nijjar et al. report expression of Notch1 and 2 on the sinusoidal 
endothelium as well as the bile ducts, and Notch2 in hepatocytes.  Notch3 is 
reported to be found on bile ducts, hepatocytes and the vasculature (157).  Both 




studies find very little Notch4 expression.  All studies concur that the Notch ligand 
Jagged1 appears to be the dominant ligand in healthy liver and is up-regulated 
during disease, however there still remains some debate as to which cell types 
represent its source (155, 158).  




Notch signalling in adult liver disease & regeneration 
The adult liver has a remarkable capacity for regeneration following injury.  After 
2/3 partial hepatectomy in the rat, the residual liver lobes enlarge to restore liver 
mass within 5 to 7 days, and up to 90% of the parenchyma can be removed whilst 
still achieving eventual restoration of original size (159).  In the healthy liver this 
process is achieved through hepatocyte division; the potential for which appears 
almost unlimited.  As many as 12 sequential hepatectomies have been performed in 
rat without apparent impairment of regenerative capacity (160).  In chronically 
diseased liver for example cirrhosis however, proliferation of hepatocytes can fail 
and the liver becomes reliant on activation of a population of bipotential hepatic 
progenitor cells (HPCs) with the ability to differentiate into either hepatocytes or 
biliary epithelia (161, 162).  These activated cells thought to arise from the terminal 
ductules of ‘Canals of Hering’ and their accompanying inflammatory reaction have 
been described as ‘Ductular Reactions’ (163) and are found in all forms of chronic 
and severe acute liver diseases in man both biliary and hepatocellular, with 
numbers correlating with disease severity (164-166).   
Biliary atresia is a paradigm cholangiopathy in which ductular reaction, 
inflammation and portal fibrosis occur in response to destruction or failure of 
development of the major extrahepatic bile ducts.  This contrasts with Alagille 
syndrome, where there is a lack of ductular reaction and progenitor cells with 
accompanying loss of the biliary transcription factor HNF1β, implying that Notch 
signalling may indeed play a role in progenitor-mediated parenchymal repair (125).  
A deficiency of Notch signal in the embryo resulting in biliary malformation implies 
that Notch is required for faithful development and maintenance of the biliary 
system.  Notch pathway components are up-regulated in response to chronic biliary 
diseases in man including primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC).  This contrasts to hepatocellular insults such as Hepatitis C Virus 
(HCV) infection and is evident both in terms of gene transcription and protein 
expression (155, 157, 158, 167, 168).  Importantly such up-regulation includes the 




downstream target effectors of Notch, in particular Hes1 and Hey1 (158).  For 
instance isolated CK7 positive ductular reactions laser microdissected from human 
PSC and PBC livers exhibited high expression of NOTCH1 and NOTCH2 compared 
to those from livers infected with Hepatitis C Virus (169).  Jagged1 and Dll4 are the 
only Notch ligands expressed by the human liver.  Jagged1 is strongly up-regulated 
during chronic biliary disease, and has been described on HPCs, hepatocytes and 
hepatic stellate cells (155, 170, 171).  Little is known about Notch activity in liver 
fluke cholangiopathies.   Exome sequencing studies have identified a number of 
genetic alterations that appear to discriminate fluke-associated and sporadic BTC, 
however in these series Notch does not appear to be a target of mutagenesis.  
Further work is required to determine whether wild type Notch plays a role in these 
conditions.   
 
During chronic liver disease the local microenvironment changes in response to 
damage; myofibroblasts and inflammatory cells infiltrate regions of local necrosis 
and produce growth factors and matrix proteins including laminin to form a 
stereotypical niche that will promote expansion of the HPC pool and re-
epithelialisation of the liver parenchyma (172).  In biliary disease this niche is 
characterised by a close spatial relationship between αSMA positive myofibroblasts 
and the emerging HPCs, resemblant of the portal mesenchyme in the embryo, 
forming a potential juxtacellular communication through which mesenchymal 
Jagged1 can activate epithelial Notch activity (158).   
Chronic biliary disease can be modelled in the mouse using 3,5-diethoxycarbonyl-
1,4-dihydrocollidine (DDC) dietary induced injury (173).  Notch inhibition through 
genetic deletion (AlbCre-Rbpjκflox/flox) or gamma-secretase inhibitors results in a 
decreased number of HPCs and ductular reaction in mice fed with DDC, with an 
accompanying reduction transcription of Hes/Hey Notch targets and genes 
involved in biliary differentiation (HNF6; HNF1β; γGT) (158, 174).  In Notch2 




knockout mice (AlbCre-Notch2flox/flox) fed with DDC, clusters of CK19 positive cells 
are unable to form ductular reactions with a normal tubular structure; RBPJκ 
knockouts suffer a more severe injury with an almost absence of ductular reaction 
and accompanying parenchymal necrosis (174). 
The bipotential switch in cell fate of HPCs towards cholangiocyte or hepatocyte is 
mediated by the Notch antagonist Numb.  During hepatocyte injury inflammatory 
macrophages phagocytose hepatocyte and matrix debris, triggering secretion of 
Wnt3a into the niche.  This activates β-catenin-mediated Wnt signalling within 
HPCs, transcription of Wnt downstream targets TCF-LEF, and stimulates expression 
of hepatocyte genes including HNF4α and the ubiquitin ligase and Notch 
antagonist Numb.   Inhibition of Numb with siRNA causes in reactivation of the 
Notch pathway and up-regulation of the biliary gene programme (Hes1; HNF1β; 
HNF6) (158).  Transgenic overexpression of Notch in hepatocytes using adeno-
associated viral delivery of hepatocyte-specific Cre reprograms  hepatocytes to the 
biliary lineage (175).    
Notch therefore appears necessary and sufficient for embryological development of 
the biliary tree in terms of both cholangiocyte specification of hepatoblasts and 
tubular morphogenesis of the branching ductular network.  It would appear likely 
that this role extends to maintenance of this system in the homeostatic adult liver 
and has certainly been shown to be a required signal during progenitor-mediated 
regeneration following biliary injury in disease.  




Notch signalling in cancer 
The implication of Notch in the aetiology of cancer arose from the discovery that a 
proportion of patients with T cell acute lymphoblastic leukaemia (T-ALL) carry a 
(7;9) translocation of the β T cell receptor (TCRβ) gene to a locus within the coding 
region for Notch1.  The result is expression of a truncated and constitutively active 
Notch1 protein (also known as translocation-associated Notch1 (TAN-1)) (176).  
Functional characterisation of Notch1 led to the discovery that the receptor is 
needed for the commitment of pluripotent progenitors to a T cell fate (177) and later 
the assembly of the pre-T cell receptor complex in immature thymocytes (178).  Such 
a role would explain the later discovery that more than 50% of human T-ALLs carry 
activating mutations involving the extracellular heterodimerisation and PEST 
domains of Notch1 (105).  T-ALL can therefore be modelled very effectively in the 
mouse through transplantation of N1-ICD over-expressing bone marrow into 
irradiated mice (100% disease penetrance) (179).  Notch2 and Notch3 have also been 
implicated in the pathogenesis of T cell leukaemia (180-182). 
Mutations of Notch leading to oncogenesis are much rarer in non-haemopoietic 
systems; rather it is dysregulation of wild type Notch activity that appears to 
promote tumorigenesis in solid organs.  In non-small cell lung cancer (NSCLC) 
gain-of-function mutations in Notch1 have been reported in up to 10% of cases 
(183), however more frequently there appears to be loss of the Notch antagonist 
Numb (183) or over-expression of activity through the Notch3 receptor paralog 
(184).  Furthermore it has been demonstrated through genetic deletion experiments 
that the canonical Notch components RBPJκ and the gamma-secretase complex are 
both necessary for the formation of KrasG12D–driven NSCLCs in mouse (185).  In 
human disease expression of Notch1 and its ligand Dll4 are prognostic of poor 
outcome (183, 186).  Tumour progression in many cancer types is thought to be 
driven by self-renewal of a distinct population of tumour propagating cells which 
also are likely to mediate drug resistance (187-190).  In NSCLC it appears that 
Notch, and in particular the Notch3 enriches with the markers CD24 and ITGB4, 




with tumour-propagating ability and that the gene signature of this population is 
predictive of poor prognosis in human disease.  These markers appear to represent a 
stable population following serial transplantation and which enriches after 
treatment with chemotherapy.  ShRNA experiments demonstrate the Notch3 
receptor plays a non-redundant role in driving self-renewal of these cells in vivo 
(191).    
Activation of different Notch receptor paralogs appear to action different effects 
according to context.  Notch1 and Notch2 are expressed in different compartments 
in pancreas; Notch1 is expressed by acinar cells whereas Notch2 appears in the 
ductal epithelium and becomes up-regulated in the PanIN lesions of pre-
malignancy and in invasive tumours (192).  Genetic deletion of Notch2 but not 
Notch1, results in a significant improvement in survival in a kRasG12D-driven model 
of pancreatic ductal adenocarcinoma (PDA) and a reduction in tumour progression 
(193).  As in lung cancer, blockade of Notch using gamma-secretase inhibitors 
inhibited the growth of human PDA cell lines as well as the in vivo formation of 
tumours in a Notch-dependent fashion (192).   
The role of Notch in mammary stem cells has been well characterised and acts to 
commit cells exclusively along a luminal lineage whilst promoting self-renewal.  
Transgenic activation of Notch in differentiated luminal cells promotes 
tumorigenesis, triggering the development of hyperplastic nodules and re-
activating clonogenic capacity (194).  It has been suggested that one mechanism by 
which the stroma may be supporting tumour cell growth is through provision of 
Notch ligand although this evidence is not well developed.  Inflammatory stromal 
cytokines and epigenetic dysregulation of NIK expression leads to over-activation of 
NFκ-B signalling in triple negative breast cancer and up-regulated Jagged1 
expression (195).  Furthermore Jagged2 expression is negatively correlated with 
both overall and metastasis-free survival in breast cancer patients (196).  In breast 
cancer metastases it has been shown that stromal hypoxia leads to up-regulation of 
Jagged2 expression, particularly at the invasive fronts of tumours.  Furthermore up-




regulation of Jagged1 by breast ductal carcinoma cells themselves can activate 
Notch signalling in osteoblasts and promote osteolytic bone metastasis (197).  It is 
thought that Aes (Amino-terminal Enhancer of Split) (a member of the 
Groucho/Transducin-like Enhancer of Split (TLE) family) acts as an endogenous 
inhibitor of metastasis through repression of Notch transcription and indeed hepatic 
metastases of primary colorectal tumours can be suppressed using gamma secretase 
inhibition (198).    In pancreas direct co-culture of  stellate cells with cancer cells 
leads to activation of epithelial Notch and enhancement of proliferation compared 
to indirect co-culture (and stimulation via non-juxtacellular signalling 
pathways)(199).  Furthermore in PDA it is thought that mesenchymal stem cell-
derived myofibroblasts are able to maintain stemness in tumour-initiating epithelial 
cells through Notch provision (200).  Perhaps the strongest data comes from B-
lineage ALL, where clonal expansion of B cells is highly dependent on signals from 
the surrounding microenvironment of the bone marrow.  Bone marrow 
mesenchymal cells express Notch ligands, in particular Jagged1,2 and Dll1 (201).  
Specific neutralising antibodies targeted against Jagged1,2 and Dll1 results in an 
increase in stromal-mediated apoptosis of B-ALL cells via up-regulation of Blc2 and 
down-regulation of Caspase3 (202).   
 
Notch signalling in primary liver malignancies 
In comparison to other tumours types, the role for Notch in primary hepatic 
tumorigenesis is less well defined.  Constitutive expression of N2-ICD in albumin 
expressing cells is sufficient to induce HCC and biliary hyperplasia with associated 
up-regulation of pro-proliferative genes in both hepatocytes and biliary epithelia 
(203).  Furthermore N2-ICD overexpression accelerate DEN-induced hepatic 
tumorigenesis with resulting tumours exhibiting less differentiation than DEN alone 
controls.  In addition to this reduction in HCC latency, Alb-Cre;N2-ICD mice treated 
with DEN concomitantly develop ICC.  Immunohistochemical analysis of Notch1, 
Notch2 and Hes1 has been performed in BTC, and whereas expression of these was 




reported to be absent in homeostatic biliary epithelia, tumours appeared strongly 
positive, in particular for Notch1 (204).  The full role of endogenous, wild-type 
Notch in ICC has yet to be fully characterised.    




The mechanisms by which Notch promotes malignancy 
To fulfil its role in self-renewal and maintenance of stem cell pools, it is likely that 
wild type Notch interacts with molecular pathways controlling proliferation, 
regulation of the cell cycle or apoptosis.  The frequency with which dysregulation of 
the Ras cascade occurs in human tumours has prompted enquiry as to whether 
there is communication between oncogenically activated Ras and Notch signalling, 
however this relationship appears complex (205).  These authors have used two in 
vitro systems to address this question: human foreskin fibroblasts and human 
embryonic kidney epithelial cells (HEK), both expressing the telomerase reverse 
transcriptase subunit (hTERT), SV40 oncoproteins and oncogenic H-RasV12.  They 
demonstrated Ras to be upstream of Notch1, with Ras activation inducing CBF-1 
reporter activity, up-regulation of the active subunit of Notch 1 (N1-ICD), and its 
translocation to the nucleus.  Similarly introduction of a dominant negative form of 
H-Ras led to down-regulation of Notch activity.  Transfection of Ras-transformed 
cells with an antisense Notch construct, but not cells expressing SV40 alone resulted 
in a significant reduction in proliferation.  The same was seen following treatment 
with gamma-secretase inhibitors.  To test this interaction in vivo, transformed 
fibroblasts were injected into NOD/SCID mice and tumour burden assessed.  
Tumour growth was exponential in all animals that received vector-transfected 
cells, whereas no tumours were observed in any animals that received cells 
transfected with antisense Notch until as late as day 35.   
The authors of this study observed that Notch1 transcription was only modestly 
increased by H-RasV12, suggesting that Notch1 protein is modified by Ras at a post-
transcriptional level.  Immunoprecipitation confirmed that Notch1 protein was 
much more dramatically affected by Ras transformation, and in particular Pre-
Senilin1 (PS1), a component of the gamma-secretase complex appeared to be 
significantly induced by H-RasV12 activation and decreased following transfection 
with dominant negative Ras.  Q-rtPCR confirmed these effects to be post-
transcriptional.  To test which level of the Ras cascade was acting to regulate Notch, 




pharmacological inhibitors of the pathway (MEKK, MEK1/2, PI3k, p38 and PKC) 
were tested; only cells treated with a p38 inhibitor demonstrated any reduction in 
Notch1 and PS1 proteins and proliferation.  Furthermore this effect could be 
abolished with introduction of N1-ICD.  These findings together indicate that in 
these contexts Notch1 was acting as a key downstream mediator of oncogenic Ras 
and in fact was necessary to maintain the neoplastic phenotype in Ras transformed 
cells.   
Such an interaction between Notch and Ras has been described in other systems and 
in other species (206-208).  It has been suggested downstream activation of Notch by 
oncogenic Ras represents the pathological aberration of a physiological feedback 
mechanism in which Ras uses Notch to regulate its own signalling.  Thus a 
mechanism is presented by which Notch can exert completely different effects in 
transformed cells from its physiological role in healthy tissues.   
Collaboration between Notch and other oncogenic pathways have also been 
described: c-myc in a mouse model of thymoma driven by truncated Notch (106); 
oncogenic products E6 and E7 of papillomavirus 16 driving downstream activation 
of AKT in invasive cervical tumours (209); TGFα during acinar to ductal metaplasia 
in exocrine pancreas and consequently adenocarcinoma (210).   
It therefore seems clear that the cell survival signals potentiated by Notch vary 
according to both cellular context and the genetic alterations that have occurred 
within the cell.   
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Chapter 2:  HYPOTHESES & AIMS 
Hypotheses 
(i) The tumour-stroma microenvironment in ICC represents an aberrant 
pathological extension of the regenerative hepatic progenitor cell niche of 
chronic liver disease 
(ii) Notch activity within cancerous biliary epithelia is driving tumour 
progression 
(iii) Ablation of Notch signalling will attenuate tumour expansion 
(iv) Pharmacological Notch inhibitors represent a potential therapeutic strategy 
in ICC 
Aims 
(i) To generate a conditional transgenic model of ICC in mouse to enable 
inducible and specific deletion of Notch within the biliary compartment 
(ii) To characterise endogenous Notch pathway expression in human ICC and 
rodent models  
(iii) To elucidate Notch function in disease progression of ICC 
(iv) To assess the potential of targeting Notch as a future therapeutic strategy in 
ICC  
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Human Tissue Collection & Ethical approval 
Freshly frozen human tissue was obtained prospectively from patients undergoing 
hepatic resection of ICC at the Royal Infirmary of Edinburgh with written informed 
consent and local ethical approval from the NHS Lothian Tissue Governance ethics 
committee (10/S1402/33).  In addition archival formalin-fixed paraffin embedded 
human tissue was also obtained from the South East Scotland SAHSC Bioresource 
and MRC Sudden Death Brain and Tissue Bank (10/H0716/3) Healthy liver tissue 
was collected and fixed following a standardised operating procedure, however 
BTC samples were obtained over a 20 year period without standardisation.(211).   
In vivo models of ICC 
All animal experiments were performed according to UK Home Office regulations 
and with local veterinary approval (PIL 60/12907).  All animals were housed in 
rooms with a 12:12 hour light:dark cycle at an ambient temperature of 22 ± 1°C and 
given chow and water ad libitum.  Culling was performed using a Schedule 1 
procedure (either CO2 asphyxiation or cervical dislocation).   
Chemically induced models of ICC 
Eight week old male Sprague-Dawley rats ≥350g were administered 0.06% 
thioacetamide (TAA) in drinking water sweetened with orange squash (5:1) for 26 
weeks.  Rats were monitored with daily weights and observation of clinical 
condition and supplemented with mashed diet made with TAA water.  If rats lost 
≥20% body weight or displayed clinical signs of dehydration, animals were 
temporarily administered normal drinking water without TAA.   This period did 
not exceed 72 hours in any given rat.  Tissue from a timecourse of rats on the TAA 
regimen was also used in this study, kindly donated by Andrew Robson (previous 
MRC Clinical Research Fellow Forbes Lab).  In this case rats were sacrificed at the 




following timepoints: 10, 12, 14, 16, 20, 22, 24 and 26 weeks (n=3 at each timepoint).  
Control animals received 26 weeks of normal drinking water (n=6).   
Xenograft model of ICC 
Six week old male immunocompromised mice (CD1-Nude) received bilateral 
subcutaneous flank injections of the human ICC cell line CC-LP-1 (5 x 105 
cells/injection (100µl))(212).  Tumours were allowed to establish over a 28 day 
period before mice were exposed to treatment regimens.  Tumour burden was 
assessed following harvesting and tumour dissection using a fine balance to 
measure tumour mass and digital calipers to measure maximal tumour length and 
width.  Tumour volume was then calculated using the modified ellipsoid formula: 
½(length x width2).  I found this to be a more accurate assessment than serial 
external measurement of tumours through the skin using digital calipers which did 
not produce reproducible measurements.   
Transgenic models of ICC 
CK19CreERT mice on a mixed genetic background were obtained as a kind gift from 
Guoquaing Gu, Vanderbilt Medical Centre, Tennessee, USA.  R26ReYFPf/f mice on a 
C57/Bl6 background were obtained as a kind gift from Owen Sansom, Beatson 
Institute for Cancer Research, Glasgow, UK.  Trp53tm1Brn (p53f/f) and B6.129S4-
krastm4tyj/J (kRasG12Dlsl) mice were purchased from Jackson Laboratories.  Mice were 
cross-bred to produce the following lines: 
CK19CreERT;R26ReYFP f/f 
CK19CreERT;R26ReYFPf/fp53f/f 
CK19CreERT;R26ReYFP f/f p53f/fkRaslsl 
Cre Induction 
Recombination of loxP sites by Cre was induced using i.p. injection of 30mg/ml 
tamoxifen (TM) (Sigma) in corn oil.   Two regimes were used to assess efficiency of 
Cre:  




 One injection of 80mg/kg TM (n=25) 
 Three injections of 4mg TM on alternate days (n=19) 
The following experimental groups were used in both regimes: 
Cre – YFP+/+ TM + 
Cre + YFP+/+ TM – 
Cre + YFP+/- TM + 
Cre + YFP+/+ TM + 
 
Mice were sacrificed 5 days post-injection.   Cre efficiency was assessed by 
performing immunohistochemistry staining for YFP.  The number of YFP +ve and 
total number of bile duct cells were counted on 50 consecutive fields at a 
magnification of x400 to quantify both the total number of YFP+ve cells as well as 
the proportion of bile ductal cells +ve for YFP.  One section per mouse was used in 
this analysis.   
Genotyping 
A commercial service (Transnetyx©) was used to undertake all genotyping for this 
project.  Ear notches were taken at the time of weaning at 4 weeks of age.   
 
Pilot Model 1:  CKCreERT;R26ReYFPf/fp53f/f + CCl4 
CK19CreERT;R26ReYFPf/fp53f/f mice underwent induction of Cre at 6 weeks of age 
with 3 x 4mg i.p. injections of TM.  At 8 weeks of age mice then underwent 3 x 
weekly i.p. administration of 1µl/g carbon tetrachloride (CCL4) in olive oil or olive 
oil control for 16 weeks.  CK19CreERT;R26ReYFPp53+/+ n=21;  
CK19CreERT;R26ReYFPp53+/- n=21.   Mice were culled at 24 weeks of age.   




Pilot Model 2:  CKCreERT;R26ReYFPf/fp53f/f + TAA 
CK19CreERT;R26ReYFPf/fp53f/f mice underwent induction of Cre at 6 weeks of age 
with 3 x 4mg i.p. injections of TM.  At 6 weeks of age mice were administered 
600mg/l oral TAA for 26 weeks.  CK19CreERT;R26ReYFPp53+/+ n=4;  
CK19CreERT;R26ReYFPp53+/- n=14 CK19CreERT;R26ReYFPp53-/- n=7.   Mice were 
culled at 32 weeks of age.   
Pilot Model 3:  CKCreERT;R26ReYFPf/fp53f/f kRas 
CK19CreERT;R26ReYFPf/fp53f/fkRas mice underwent induction of Cre at 6 weeks of 
age with 3 x 4mg i.p. injections of TM.  Mice were observed daily for clinical signs of 
tumour formation for a period of up to 9 months.   
Quantification of tumour burden in vivo  
Presence or absence of malignancy was confirmed by a specialist liver 
histopathologist in each model (Dr Timothy Kendall).  Rat livers were manually cut 
into 3mm sections before being aligned and paraffin embedded to ensure a maximal 
surface area of liver was available on each 4µm section.  4 to 5 blocks were 
generated per animal.  H&E staining was performed on one section from every 
block for each animal.  A blinded liver histopathologist manually demarcated 
tumour boundaries for each section and assessed tumour area using Image J 
software, as well as counting the total number of tumours.   
 
Inhibition of Notch signalling in vivo 
Gamma-secretase inhibition of ICC in rat 
The gamma-secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester  (DAPT) was administered to male Sprague-Dawley rats 
undergoing the TAA regime of tumour induction as previously described.  10mg/kg 
DAPT or equivalent volume of olive oil control was administered by i.p. injection on 




3 consecutive days followed by 4 rest days for 5 weeks between weeks 21 and 26 of 
TAA administration (DAPT n=8; Control n=12).  Rats were culled at 27 weeks.   
Gamma-secretase inhibition of ICC xenografts 
Xenografted tumours were established as previously described.  After 28 days of 
engraftment, mice were administered 40mg/kg DAPT in olive oil i.p. or equivalent 
volume of olive oil control on 3 consecutive days followed by 4 rest days for 2 
weeks (n=4).   
 
Tissue and Cellular analysis 
Tissue preparation 
At the time of sacrifice murine and rat livers were flushed using 5 or 10mls sterile 
PBS via the IVC and liver, kidney, spleen, intestine and lung harvested.  All tissues 
were fixed overnight in 4% buffered formalin or methacarn (60% methanol; 30% 
chloroform; 10% acetic acid) before being transferred to 70% ethanol.  Following 
fixation tissue was embedded in paraffin and cut into 4µm sections.   
Immunostaining of paraffin embedded sections 
Immunostaining was performed according to protocols previously described by our 
laboratory (172).  De-waxing was performed using 10 minutes of immersion in 
xylene before re-hydration with serially dilute ethanol solutions before transfer to 
PBS.  Sections were mounted in sequenza racks with PBS. 
Blockade of endogenous peroxidase activity was performed as part of all protocols 
using 3% hydrogen peroxide (Sigma) for 10 minutes before washing with PBS 
containing 0.01% Tween20 (Sigma) for permeabilisation.  For peroxidase detection 
endogenous avidin and biotin were blocked at this point using an avidin-biotin 
blocking kit (Dako); 15 minutes incubation with avidin followed by 3 PBS washes 
and 15 minutes incubation with biotin followed by 3 PBS washes.  Antigen retrieval 
was performed using microwave based heat or enzymatic digestion (see Table 2.1 




for antigen-specific protocols).  Sections were washed a further 3 times in PBS before 
incubating for one hour with a universal protein block (Spring Bioscience).  Sections 
were then incubated with the appropriate primary antibody (in antibody diluent 
(Invitrogen)). 
 
Table 2.1  Table of primary antibodies 
Primary Ab Clone/Cat. no. Species Fixation Ag Retrieval Incubation 
Notch1 Abcam  
ab8925 
Goat Formalin 10 mins HP M/W 
Sodium citrate 
1 in 50 
O/N 4°C 
Notch2 Santa Cruz  
sc-7423 
Goat Cells only 10mins 0.01% Triton X 1 in 50 
O/N 4°C 




2 x 5mins HP M/W 
Tris EDTA 
1 in 100 
O/N 4°C 
Notch4 Santa cruz  
sc-32613 
Goat Cells only 10mins 0.01% Triton X 1 in 50 
O/N 4°C 
Jagged1 Santa cruz 
Sc-8303 
Rabbit Methacarn 10mins 0.01% Triton X 1 in 100 
O/N 4°C 
CK19 Troma III Rat Formalin 10 mins HP M/W 
Sodium citrate 




Mouse Methacarn 0.01% Trypsin in 0.1% 
CaCl 8mins 37°C 
1 in 100 
O/N 4°C 
mAChR3 Abd Serotec 
AHP1355 
Rabbit Formalin 2 x 5mins HP M/W 
Tris EDTA 




Rabbit Formalin 2 x 5mins HP M/W 
Sodium citrate 




Rabbit Formalin 2 x 5mins HP M/W 
Sodium citrate 
1 in 500 
1hr RT 
Pan Cytokeratin Dako 
Z0622 
Rabbit Formalin 5mins HP M/W 
Sodium citrate + 5 mins 
Proteinase K 37°C 




Rat Formalin 5mins LP M/W 
Tris EDTA 




Rat Formalin 2 x 5mins HP M/W 
Tris EDTA 




Mouse Formalin 3 x 5mins HP M/W 
Sodium citrate 






Rabbit Formalin 2 x 5mins HP M/W 
Sodium citrate 






Rabbit Formalin 3 x 5mins HP M/W 
Sodium citrate 






Rabbit Formalin 2 x 5mins HP M/W 
Sodium citrate 






Rabbit  Formalin 2 x 5mins HP M/W 
Sodium citrate 
1 in 1000 
O/N 4°C 
c-Met Abcam  
ab5662 
Rabbit Formalin 2 x 5mins HP M/W 
Tris EDTA 
1 in 100 
O/N 4°C 
TGFβRII Santa cruz 
Sc-220 
Rabbit Formalin 2 x 5mins HP M/W 
Tris EDTA 
1 in 100 
O/N 4°C 
CYP2D6 Prof Roland Wolf Sheep Formalin 2 x 5mins HP M/W 1 in 200 




Uni of Dundee Sodium citrate O/N 4°C 
CD31 Abcam 
Ab28364 
Rabbit Formalin 2 x 5mins HP M/W 
Tris EDTA 
1 in 100 
O/N 4°C 
GFP Abcam  
ab13970 
Chicken Formalin 2 x 5mins LP M/W 
Tris EDTA 




Goat Formalin 3 x 10mins HP M/W 
Sodium citrate 




Mouse Formalin 2 x 5mins HP M/W 
Sodium citrate 




Rat Formalin 2 x 5mins HP M/W 
Sodium citrate 
1 in 100 
O/N 4°C 
Nanog  Rat Frozen 10mins 0.01% Triton X 1 in 100 
O/N 4°C 
Oct4 Santa cruz 
Sc-8629 
Goat Frozen 10mins 0.01% Triton X 1 in 100 
O/N 4°C 
 
Table 2.1  Table of primary antibodies 
 
M/W Microwave based heat for antigen retrieval (HP High power; LP Low power).  
Sections were incubated with primary antibody either overnight at 4°C (O/N) or for 
an hour at room temperature (RT). 
 
Following incubation, sections were washed three times in PBS before incubation 
for 30 minutes with the appropriate secondary antibody. 
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Table 2.2  Table of secondary antibodies 
Species Conjugation Source Dilution 
Anti-Goat Alexa 555 Invitrogen 1 in 200 
Anti-Rabbit Alexa 555 Invitrogen 1 in 200 
Anti-Mouse Alexa 555 Invitrogen 1 in 200 
Anti-Sheep Alexa 555 Invitrogen 1 in 200 
Anti-Rabbit 488 Invitrogen 1 in 200 
Anti-Rat 488 Invitrogen 1 in 200 
Anti-Chicken 488 Invitrogen 1 in 200 
Anti-Rabbit Biotinylated Dako 1 in 200 
Anti-Goat Biotinylated Dako 1 in 200 
Anti-Mouse Biotinylated Dako 1 in 200 
Anti-Rabbit HRP Dako 1 in 200 (1 in 500 
Tyramide) 
Anti-Goat HRP Dako 1 in 200 (1 in 500 
Tyramide) 
Anti-Mouse HRP Dako 1 in 200 (1 in 500 
Tyramide) 
Anti-Chicken HRP Dako 1 in 200 (1 in 500 
Tyramide) 
 
Table 2.2  Table of secondary antibodies 
 
After 3 PBS washes, sections for peroxidase detection were incubated for 30 minutes 
with RTU Avidin-Biotin complex kit (Vector).  A further 3 PBS washes were 
performed before application of DAB (3,3’-Diaminodenzidine) chromogen substrate 
(Dako).   Length of incubation was visually judged according to colour before 3 final 
PBS washes.  Sections were counterstained with Harris Haematoxylin for 10 seconds 
and washed in tap water before immersion in Scott’s tap water for 5 seconds 
followed by further washing.  De-hydration was achieved with serially more 
concentrated ethanol solutions and xylene (2 x 5 minutes).  Coverslips were 
mounted with Pertex. 
For fluorescent detection, sections were washed 3 times with PBS following 
secondary antibody incubation.  In most cases antibodies with directly conjugated 
fluorophores were used, in which case at this point coverslips were mounted using 




DAPI-containing fluoromount (Southern Biotech).  In the case of dual 
immunofluorescence where the two primary antibodies were raised in the same 
host species, a tyramide amplification kit was used (PerkinElmer).    Here primary 
antibodies were diluted 50 times their standard concentration and a peroxidase-
conjugated secondary antibody used before application of Tyramide amplification 
reagent (1 in 50 in amplification diluent).  Sections were immersed in hot sodium 
citrate buffer for 2 minutes following application of the first secondary antibody and 
retrieval of the second antigen.  Coverslips were mounted using DAPI-containing 
fluoromount as before.   
Immunocytochemistry 
Cells for immunocytochemistry were cultured on chamber slides before PBS 
washing and fixation with cold 1:1 methanol/acetone at room temperature for 10 
minutes.  Protein blocking was performed as before with for 1 hour before 
application of primary antibody (see table).  3 PBS washes were performed before 
incubation with the appropriate secondary antibody for 30 minutes at room 
temperature.  DAPI-containing fluoromount was used to mount coverslips.   
TUNEL 
For detection of apoptosis by TUNEL, an in situ cell death detection fluorescein kit 
(Roche) was used according to manufacturer’s instructions.  Frozen sections were 
pre-treated with 10µg/ml proteinase K and permeabilisation with 0.1% Triton X.   
Microscopy 
A Nikon Eclipse E600 microscope was used for all bright field and fluorescent 
microscopy in conjunction with Axiovision Elements software v3.0. 
Cell counting and image analysis 
For cell counting and pixel analysis up to 50 photomicrographs were taken under 
standardised conditions at a magnification of at least x200.  In xenograft 
experiments where the total area of tissue was more limited, the entire field was 
photographed and analysed.  Image J software was used for cell counting.  Adobe 




Photoshop was used for pixel analysis.  The ‘fuzziness’ function was used to select 
single colour intensity and standardised to Dapi to control for cell number.  Results 
are expressed as the mean percentage of positive pixels per field. 
Flow cytometry, cell sorting & cell cycle analysis 
CC-LP-1 cells grown in monolayer on plastic were prepared using the following 
method for flow cytometric analysis:  Cells were washed x 3 in PBS and incubated 
for 20 minutes in cell dissociation buffer (Invitrogen).  Cells were spun at 1000rpm 
for 5 minutes; the pellet re-suspended in 100µl 10% human serum in PBS and 
incubated on ice for 15 minutes for blocking.  Cells were washed x 3 with FACS 
buffer (2% human serum in PBS) and spun again at 500g for 5 minutes.  Serial 
dilutions were performed to determine the optimal concentration of antibody for 
analysis.  Cells were incubated in 100µl 1:100 Notch3 PE-conjugated antibody or 
isotype control in FACS buffer for 30 minutes or taken for unstained controls.  Cells 
were then washed with FACS buffer x 3 and spun at 1000rpm for 5 minutes before 
being re-suspended in 400µ FACS buffer.  7-AAD was added at a 1:50 concentration 
before analysis as a live/dead marker.  1µl of Notch3 antibody was added to 1 drop 
of positive IgG beads as a positive control.  Cells were sorted according to forward 
and side scatter to exclude debris before being gated at the top and bottom 5% of 
Notch3 expression.  Cells were sorted directly into culture medium using a BD 
FACS Aria II.  For cell cycle profiling, DNA staining solution (Sony Biotechnology) 
was added to samples immediately before analysis. 
Western Blotting 
Lysates were prepared using the following lysis buffer:  25mM NaHepes, 0.3M 
NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5% Triton X-100, complete protease inhibitor 
(Roche), 0.5mM dithiothreitol, 1mM sodium orthovanadate, pH 7.4.  30mg fresh 
whole liver was homogenised directly into 500µl buffer; 150µl buffer was used to 
lyse one well of cells growing in monolayer on plastic in a 6 well plate.  Lysates 
were sonicated x 3 to minimise nucleotide contamination.   




Protein content of samples was quantified using a BSA standard and BCA reaction 
with Pierce reagent.  Protein quantity was standardised using lysis buffer before 
samples were reduced and denatured by heating to 70°C for 10 minutes in NuPAGE 
sample buffer and 10% β-mercaptoethanol.  4-12% Bis-Tris NuPAGE or 3-8% Tris-
Acetate NuPAGE mini gels were used to run samples, using 1x Tris Acetate or 1x 
MOPS running buffer respectively.  Bis-Tris gels were run at 200V for 35 minutes; 
Tris-Acetate gels at 150V for 60 minutes.  Precision Plus Dual Colour or Precision 
Plus Kaleidoscope ladders (BioRad) were used to asses molecular weight.   
Blotting was performed for 1 hour at 350mA onto nitrocellulose membrane using 
Toubin’s transfer buffer (192mM Glycine, 25mM Tris, 200ml methanol, 800ml dH20).  
Protein transfer was confirmed using Ponceau red solution.  Blots were washed x3 
in TBS-Tween (TBST) (2.42g Tris, 18g NaCl pH 7.4) with 0.1% Tween20 before 
blocking with 5% powdered fat-free milk (Marvel) or Odyssey blocking buffer 
(Licor) for 2 hours.  Blots were washed again x 3 with TBST before incubation with 
primary antibody in 5% milk or blocking buffer for either 3 hours at room 
temperature or overnight at 4°C.  Blots were washed again x 3 with TBST before 
incubation with species-appropriate HRP-conjugated secondary antibodies in TBST 
(1 in 2000) for one hour at room temperature.  Blots were washed x 3 in TBST and 
exposed with chemiluminescent horseradish peroxidase substrate (1:1) (Amersham) 
using x-ray film or the Odyssey digital system (Licor).  To strip blots for re-probing 
the following stripping buffer was used:  15g glycine, 1g SDS, 1% Tween 20 1L dH20, 
pH2.2.  Blots were incubated in stripping buffer for 10 minutes before being washed 
x 3 PBS 10 minutes and x 3 TBST 5 minutes and re-blocking with 5% milk.  Loading 
controls were performed for all blots using antibodies against β-actin or GAPDH 
depending on the molecular weight of the protein of interest.   
The following antibodies were used for western blotting in this study: 
Primary Ab Clone/Cat. no. Species Dilution Incubation 
Notch3 ab23426/Abcam Rabbit 1 in 1000 Overnight 4°C 
RBP 1F1 (RBPJκ) IgG2b/Ascension Rat 1 in 1000 Overnight 4°C 
Beta-actin AC-74/Sigma Mouse 1 in 5000 3 hours RT 




GAPDH ab9483/Abcam Goat 1 in 5000 3 hours RT 
Secondary Ab Clone/Cat. no. Species Dilution Incubation 
HRP Dako Rabbit 1 in 2000 2 hours RT 
HRP Dako Goat 1 in 2000 2 hours RT 
HRP Dako Rat 1 in 2000 2 hours RT 
HRP Dako Mouse 1 in 2000 2 hours RT 
 
Table 2.3  Table of antibodies used in western blotting 
In vitro work 
Culture of immortalised cell lines 
The following immortalised cell lines were used in this study: 
Name Origin Reference 
CC-LP-1 Intrahepatic cholangiocarcinoma (human) Shimizu Int. J. Cancer 2006 
CC-SW-1 Intrahepatic cholangiocarcinoma (human) Shimizu Int. J. Cancer 2006 
SNU-1079 Intrahepatic cholangiocarcinoma (human) Ku Br.J. Cancer 2002 
SNU-1196 Extrahepatic cholangiocarcinoma (human) Ku Br.J. Cancer 2002 
 
Table 2.4 Table of immortalised cell lines 
 
All lines were grown in 4% CO2 at 37°C in Dulbecco’s Modified Eagle Medium 
(Gibco) with 4.5g/l glucose, 2.5% fetal calf serum, 2mM L-glutamine, 10U/ml 
penicillin and 100µg/ml streptomycin.  Cells were allowed to reach an 80% 
confluence level before they were trypsinised for re-plating.  Cell counting was 
performed manually using a haemocytometer. 
Assays of cell viability 
For cell counting trypan blue was used as a live/dead stain.  MTT  (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used for formal 
assessment of cell viability.  Cells were plated at a density of 1 x 105/ml in 96 well 
plates in the presence of appropriate experimental conditions or control in triplicate.  
Cells were cultured for 48 hours before 20µl 5mg/ml MTT was added and incubated 




at 37°C for 4 hours.  Media was then aspirated and 150µl of DMSO added per well.  
Plates were agitated on a shaker for 15 minutes before being read by a 
spectrophotometer at a wavelength of 570nm with a reference wavelength of 
630nm.  All viability experiments were repeated three times.   
Tumour Spheroid culture 
Multicellular sphere culture has been widely adopted as a model to study cancer 
cell behaviour, in particular that of cancer stem cells (CSCs); serial sphere formation 
and serial tumour engraftment are proposed as a functional surrogates of self-
renewal capacity (213).  In neuroblastoma for example, cells with serial sphere 
forming capacity are known to be enriched for the stem cell markers CD133, ABC 
transporter proteins, Wnt and Notch (213).  Furthermore hypoxia arising within the 
centres of tumour sphere is thought to model necrosis occurring within the centres 
of solid tumours (214-216).  The human cholangiocarcinoma lines CC-LP-1, SNU-
1079 and CC-SW-1 were plated at a density of 1 x 105 cells/ml onto low adhesion 
culture plates (Corning).  Aggregations of cells could be observed within 4 hours of 
plating and full tumour spheroids by 24 hours.  This process was captured using a 
Zeiss (Observer) timelapse microscope.   
Assays of clonogenicity 
Cells were plated at clonal density (500cells/cm2) and kept in culture for up to 4 
weeks.  The number of colonies formed per well was then counted.   
Chemotherapy studies 
ICC cells were plated at a density of 1 x 105 cells/ml in 96 well plates using standard 
medium.  Chemotherapeutic agents were added to the culture medium at the 
following concentration ranges: 5-fluorouracil 0 to 100mM; gemcitabine 0 to 200µM; 
cisplatin 0 to 200µM.  Cells were cultured with and without the addition of 50µM of 
the γsecretase inhibitor DAPT.  Cell viability was assessed using MTT assay after 72 
hours of culture and experiments were performed in triplicate.   




Notch inhibition in vitro 
The gamma-secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT) (Tocris) and the HDAC1 inhibitor Trichostatin A 
(Sigma) were used to investigate the effects of Notch inhibition in vitro.  The cancer 
lines CC-LP-1, CC-SW-1, SNU-1079 and SNU-1196 were plated in 96 well plates at a 
density of 1 x 104 cells per well or on low-adherence 6 well plates at a density of a 1.6 
x 106 per well.  Both agents were solubilised in DMSO.  Drug or equivalent volume 
of DMSO was added to the media in increasing concentrations across the following 
range: 0 - 100µM.  Cell viability was assessed using MTT assay.  Cells were cultured 
for 48 hours before 20µl tetrazolium was added to each well, shaken on a rocker for 
15 minutes in the dark and 150µl DMSO added before reading the absorbance on a 
spectrophotometer (BMG Labtech).  A wavelength of 570nm was read with a 
reference wavelength of 630nm.  For assessment of tumour spheroid formation, 
photomicrographs of each well were taken and the diameter of tumour spheres 
measured digitally.  Spheres ≥50µm in maximal diameter were counted.   
Luciferase reporter assays 
To assay activity via the PI3K/AKT pathway in vitro, a Cignal FOXO luciferase assay 
was purchased (SA Biosciences).  This commercial lentiviral reporter construct 
contains a mixture of an inducible FOXO-responsive firefly luciferase and 
constitutively (CMV) expressing Renilla luciferase (40:1) (Figure 2.1).   
Human cholangiocarcinoma cells (CC-LP-1) previously transfected with shRNA 
targeted against NOTCH3 or scrambled sequence control were plated into 96 well 
white-bottomed plates in high glucose DMEM medium without serum and 
antibiotics at a density of 1 x 104 cells/well and left to adhere overnight.  The 
following day cells were transfected with lentiviral particles using a multiplicity of 
infection (MOI) of 50 (total of 2.5 x 105 transducing units (TU) per well).  Negative (a 
mixture of non-inducible firefly and Renilla luciferase (40:1)) and positive 
(constitutively expressing firefly luciferase and Renilla (40:1)) controls (also 
purchased from SABiosciences) were included.  All transfections were performed in 




triplicate.  Viral particles were incubated at room temperature with 0.6µl/well of 
SureENTRY™ transduction reagent (Qiagen) in 25µl/well culture medium for 20 
minutes before being added dropwise onto cells.  The following day, cells were 
washed with PBS and replaced with medium supplemented with antibiotics and 
2.5% FCS.   To quantify the luminescence of the FOXO and Renilla driven luciferase 
activity on day 4, a Dual-Luciferase Reporter Assay (Promega) was used according 
to manufacturer’s instructions.  Luminescence was read using a Promega Glomax 
luminometer.
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Figure 2.1  Lentiviral FOXO luciferase reporter construct (Qiagen Cignal Lenti FOXO Reporter 
Assay).  A FOXO-responsive luciferase vector encoding firefly luciferase under the 
control of a minimal (m)CMV promoter and tandem repeats of the FOXO binding 
site.  
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RNA interference studies 
siRNA in vitro 
Commercial pre-designed short interfering RNA species targeted against the 
NOTCH3 or RBPJκ genes were purchased (SABiosciences).  Four independent 
sequences were obtained for each gene of interest as well as a scrambled sequence 
control (Qiagen negative Allstars siRNA control).  Human ICC cell lines were 
transfected using a lipofectamine ‘fast forward’ transfection protocol using 
HiPerfect reagent (Qiagen) according to manufacturer’s instructions.  Briefly, cells 
were plated in 24 well plates at the following densities: SNU-1079 1.8 x 104/well; CC-
LP-1 5.6 x 104/well; CC-SW-1 7.0 x 104/well and allowed to adhere at 37°C for one 
hour.  siRNA complexes were made up in the following ratio: 5nM siRNA (37.5ng); 
3µl HiPerfect reagent; 96.7µl serum-free media.  Complexes were incubated at room 
temperature for 10 minutes and added drop wise onto cells, swirling the plate for 
even distribution.  Scrambled sequence and untransfected controls were prepared in 
the same way.  The following day, cells were washed in PBS and media replaced.  48 
hours post-transfection three wells were lysed for RNA and protein extraction to 
check gene knockdown efficiency.   
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The following siRNA duplexes were used in this study: 
Gene Name siRNA name Gene 
Accession No. 
Target Sequence 
NOTCH3 Hs_Notch3_1 NM_000435 5’-CAGCGTGACCGAGATAGGTCA-3’ 
NOTCH3 Hs_Notch3_2 NM_000435 5’-ATGCCTAGACCTGGTGGACAA-3’ 
NOTCH3 Hs_Notch3_3 NM_000435 5’-AAGAATAGTTAACACTCAAA-3’ 
NOTCH3 Hs_Notch3_5 NM_000435 5’-CTGCGATTAATGAGGATGA-3’ 
RBPJκ Hs_RBPJ_1 NM_005349 5’-TAGGGAAGCTATGCGAAATTA-3’ 
RBPJκ Hs_RBPJ_2 NM_005349 5’-GTGGCTGGAATACAAGTTGAA-3’ 
RBPJκ Hs_RBPJ_3 NM_005349 5’-TCCAGTAACTTTGGTCCGAAA-3’ 
RBPJκ Hs_RBPJ_SUH_7 NM_005349 5’-CACGCTATTATAGTACACCTT-3’ 
 
Table 2.5  Table of siRNA duplexes 
 
Growth of shRNA plasmids 
For permanent silencing of gene expression, knockdown human cell lines were 
generated using delivery of plasmids containing shRNA sequences targeted against 
NOTCH3.  Four commercial SureSilencing NOTCH3 shRNA plasmids 
(pGeneClip™) were purchased with scrambled sequence controls (SABiosciences).  
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Figure 2.2  NOTCH3 shRNA plasmid  
 
Figure 2.2  NOTCH3 shRNA plasmid  
These vectors were driven by U1 promoters and contained ampicillin and 
puromycin resistance cassettes for selection.  The full sequence of the vector is 
available at:  http://www.sabiosciences.com/RNAiResource.php.   
1µg pDNA was used to transform 50µl DH5α E.coli (Invitrogen).  Bacteria were 
incubated on ice for 30 minutes before being subject to heat shock in the waterbath 
at 42°C for 30 seconds.  250µl lysogeny broth (LB) was added to each culture and 
incubated at 37°C for 60 minutes in a shaker before 20µl was taken for culture on LB 
agar containing ampicillin (1 in 1000) at 37°C overnight.  Two independent colonies 
were picked from each plate and dispensed into 3mls LB containing ampicillin (1 in 
1000).  Cultures were incubated at 37°C in a shaker for 12 hours.  When cloudy, 
200µl of culture was added to 250mls LB (1 in 1000 ampicillin) and again incubated 
at 37°C overnight.  DNA was purified and eluted from cultures using a plasmid 
maxi prep kit (Qiagen) according to manufacturer’s instructions.   




DNA quality and quantity was assessed using Nanodrop spectrophotometry 
(ThermoFisher).  A Pst-1 restriction digest and gel electrophoresis was performed to 
ensure construct insertion had taken place.    
DNA transfection of all four NOTCH3 shRNA sequences and scrambled control 
were performed in the human ICC cell line CC-LP-1.  Cells were plated into 6 well 
plastic culture dishes at a density of 1.6 x 105 cells/well and transfected with 0.5µg 
pDNA the day after seeding using Effectene transfection reagent (a nonliposomal 
lipid reagent) in conjunction with Buffer EC and Enhancer (Qiagen).  After 48hours 
cells were washed with PBS and media replaced with media containing 5µg/ml 
puromycin.  Cells were cultured in puromycin-containing media and observed daily 
for the appearance of colonies.  Once formed, colonies were individually picked 
with a pipette tip and transferred to a new culture plate and expanded.  Three 
colonies per shRNA sequence were cultured in this way.  Rt-qPCR and western 
blotting were performed for Notch3 to assess knockdown efficiency. 
 
DNA and RNA analysis 
RNA extraction, purification and specification 
In preparation for RNA extraction, whole livers were snap frozen on dry ice at the 
time of harvest and stored at -80°C.  50mg of tissue per preparation was defrosted 
and dissociated with an electric homogeniser in 500µl Trizol Reagent (Amersham).  
100µl chloroform was added, vortexed thoroughly and spun at 12000g for 15 
minutes at 4°C.  The aqueous phase was transferred to a clean Eppendorf before 
adding 100µl of molecular grade 70% ethanol.  For cells, 1 x 106 cells were lysed in 
350µl RLT buffer (Qiagen) before the addition of ethanol. 
A Qiagen RNEasy Mini kit was used for RNA purification.  700µl of each sample 
was transferred to the columns provided and spun at 8000g for 15 seconds.  500µl 
RW1 buffer was added to wash the membrane and samples spun again at 8000g 
(15s).  Two washes with RPE buffer (500µl; 700µl) were performed and each time 




spun at 8000g.  Columns were dried by spinning at 16000g for 1 minute before 
elution in 30µl RNase-free water.   
RNA concentration and purity was determined using a Nanodrop 
spectrophotometer (ThermoScientific).  The following parameters were used as an 
acceptable standard. 
RNA concentration >50ng/µl 
RNA purity 260/280 ratio >2 
RNA purity 260/230 ratio >1.8 
 
Table 2.6 Standards of RNA quality and purity 
 
For extraction of RNA from formalin fixed, paraffin embedded archival samples a 
Qiagen RNEasy FFPE extraction kit was used.  20µm sections were cut and placed 
into RNase-free tubes.  160µl of deparaffinisation solution was added to each 
sample and vortexed vigorously.  Samples were incubated at 56°C for 3 minutes 
using a heat block and allowed to cool to room temperature.  150µl of proteinase K 
lysis buffer was added, vortexed and then centrifuged at 11000g for 1 minute.  10µl 
proteinase K was added to the lower, aqueous phase and mixed by pipetting to 
release RNA.  Samples were then incubated at 56°C for 15 minutes and then 80°C 
for 15 minutes to reverse formalin cross-linking.  The lower, uncoloured phase was 
then transferred into a new tube and incubated on ice for 3 minutes before 
centrifuging at 20000g for 15 minutes.  The supernatant was transferred to a new 
tube and 16µl DNase boosting buffer and 10µl DNase added and incubated at room 
temperature for 15 minutes.  320µl RBC buffer was added to each sample and mixed 
followed by 720µl ethanol.  700µl of sample was transferred to an RNeasy MinElute 
column and spun for 15 seconds at 8000g.  This step was repeated until all the 
sample had passed through the column.  RNA was then purified using the same 
steps as described above for freshly extracted RNA, but eluted into 14µl RNase free 
water.   





100ng to 1µg RNA was reverse transcribed using a Qiagen Quantitect Reverse 
Transcription kit.  Samples were standardised to the appropriate concentration by 
dilution in RNase free water.  Elimination of genomic DNA was performed by 
incubating with gDNase at 42°C for 10 minutes.  Template was then incubated with 
1µl reverse transcriptase and random hexamers at 42°C for 30 minutes and the 
reaction quenched by heating to 90°C for 3 minutes.   
rt-qPCR & PCR Arrays 
Real time qPCR was performed using SYBR Fast reagent (Qiagen) in 384 well plates 
with a Roche 480 Lightcycler.  5µl cDNA was used per reaction.  cDNA was diluted 
1 in 200 with RNase free water unless the gene of interest was known to be lowly 
expressed e.g. Notch target genes where cDNA was diluted 1 in 10.  Commercial 
quantitect primers (Qiagen) were used in all cases (see table).  5µl cDNA, 6.25µl 
SYBR and 1.25µl primer were used in each reaction.  18S was used as a standard 
reference gene with Taqman ROX master mix (Applied Biosystems).  Cycling 
conditions were as follows: 
Cycles Temperature (°C) Duration (s) 
Activation 95 20 
40 Cycles:  Denaturation 









Cooling 40 30 
 
Table 2.7   Table of cycling conditions for rt-qPCR (Roche Lightcycler 480) 
 
The standard curve method was used to estimate amplification efficiency for each 
quantitect primer.  cDNA template from each sample was combined and serially 
diluted 1:1 with RNase free water to produce a range of concentrations.  Target gene 
expression was normalised to that of 18S rRNA.  Specificity of PCR products was 




confirmed by melting curve analysis.  The following commercial pre-designed 
primers were used in this study (Qiagen): 
































































































































































Table 2.8  Table of primers 
 
Notch pathway gene expression and proto-oncogene profiling was performed using 
the following RT2 Profiler PCR arrays (SA Biosciences): 
Product No. Target  Species 
PAHS-059Y Notch pathway Human 
PARN-059Z Notch pathway Rat 
PAHS-133Z Liver cancer Human 
 
Table 2.9 Table of PCR arrays used in this study 
 
Plates were prepared according to manufacturer’s instructions and the following 
Lightcycler conditions used: 





45 60 1 min 
 
Table 2.10 Table of cycling conditions for RT2 profiler arrays  (Roche Lightcycler 480) 
 




Data was analysed using online software provided by SA Biosciences at 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php.   
 
Statistical analyses 
Statistical analyses were performed using Prism software (Graphpad Inc).  All data 
were assessed for normal distribution using a D’Agostino and Pearson omnibus 
normality test (p<0.05).  Data are expressed as means ± standard error unless 
otherwise stated.  For comparison between two groups, parametric data were 
analysed using an unpaired two-tailed Student’s t test.  For non-parametric data and 
where n was too small to determine distribution a Mann-Whitney U test was used.  
Comparisons between two or more groups were made using a one-way ANOVA 
(Kruskall-Wallis) and where multiple variables were compared between two or 
more groups a two-way ANOVA was used.  Survival analyses have been performed 
using the Kaplan-Meier method with comparisons between groups determined with 
the Log-rank test.  Levels of significance have been denoted using the following 
notation:  * p≤0.05; ** p≤0.01; ***p≤0.001.   
Non-linear regression analyses were performed using Prism software for dose 
response curves generated from ICC cells treated with chemotherapy with and 
without γ-secretase inhibition.  Log[inhibitor} vs. response curves with three 
parameters were used to generate each fit, constraining the top to 1.0 (data 
normalised to no drug controls).  The mean IC50s of treatment groups were 
compared using the Mann-Whitney U test and significance set at p=≤0.05.   
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Chapter 4:  Establishing a murine model of ICC  
Introduction 
Transgenic murine technology such as the Cre-loxP system allowing temporal and 
cell-specific gene deletion or expression offers an unprecedented opportunity to 
better understand the cellular biology underpinning disease, particularly in 
adulthood.  Few murine models of ICC exist and therefore one of the principal aims 
of this project was the development of a novel conditional transgenic murine model 
of ICC to permit targeted genetic manipulation and characterisation of the 
signalling pathways underpinning its pathogenesis.   In this way, I aimed to 
improve the specificity of previously published models which have generated both 
HCC and ICC in the liver, by using transgenic alterations frequently observed in 
human disease (85, 87, 217).  I hypothesised that by inducing mutations known to 
occur in ICC in man, a model could be generated that would more faithfully 
recapitulate tumour behaviour and response to therapy.  As such, I chose an 
approach that combined targeted genetic deletion of tumour suppressors in biliary 
cells with delivery of chronic injury using toxins.  As chronic inflammation is an 
established risk factor for the development of malignancy, I hypothesised that the 
combination of chemically induced injury and tumour suppressor deletion would 
establish cycles of cholangiocyte death and proliferation and create a pro-
carcinogenic microenvironment to promote cancer development.   
To this end, I used mice carrying a tamoxifen-inducible Cre recombinase (CreERT) 
transgene linked to a cytokeratin 19 promoter (218).  Cytokeratin 19 (CK19) is an 
intermediate filament protein (type I cytokeratin) located in the skin epidermis and 
multiple epithelial beds including oesophagus, intestine, pancreas, thymus and bile 
ducts.  Importantly in the liver CK19 is expressed both in HPCs and mature 
cholangiocytes, but importantly not hepatocytes, so that recombination specifically 




occurs within the biliary compartment.  Furthermore 92% of intrahepatic 
cholangiocarcinomas exhibit positivity for CK19 (219).   
I have used two alternative fluorescent reporter systems in the generation of this 
model.  The first contains a lox-stop-lox eYFP sequence knocked into the Rosa26 
locus (R26eYFP/eYFP), so that in the presence of tamoxifen the stop codon is excised by 
Cre, permitting transcription of eYFP.  This is the original reporting system for the 
CK19CreERT mouse as described by Means et al. (218).  In addition I also utilised a 
second system in which CK19CreERT mice were cross-bred with an Ai14 tdTomato 
reporter mouse purchased from Jackson laboratories.  This mouse carries a Rosa-
CAG-LSL-tdTomato-WPRE::deltaNeo insert; i.e. a CAG promoter driven tdTomato 
reporter inserted into the Rosa locus with a STOP codon flanked by loxP sites.  In 
this way STOP is excised in the presence of Cre, permitting transcription of 
tdTomato and hence tracking of recombined cells.   
Deletions of the tumour suppressor TRP53 are common in human ICC (220).  Both 
CK19CreERTeYFP and CK19CreERTtdTom mice were therefore cross-bred with mice 
carrying loxP sites flanking TRP53 to generate the transgenic lines 
CK19CreERT;R26eYFP;p53flox/flox (herein referred to as CK19CreYFPp53f/f) or 
CK19CreERT;R26tdTom;p53flox/flox (herein referred to as CK19CreTomp53f/f).   
 
Cre recombination efficiency 
I first sought to establish the efficiency with which Cre recombines loxP sites in this 
model.  Two dosing regimens of tamoxifen were tested that had been previously 
published:  a single dose of 80mg/kg i.p. or three doses of 4mg i.p. on alternate days, 
both when mice reached 6 weeks of age (218).   eYFP expression was assessed 7 days 
following the last tamoxifen injection.  eYFP positive cells were manually counted 
from 50 consecutive fields on one section per animal.  The proportion of eYFP 
positive cells as a percentage of the total number of bile duct cells was determined 
(as assessed by morphology on DAB immunohistochemistry).  Only cells that 




formed part of a ductal structure (i.e. those surrounding a lumen) were included.  
For both dosing schedules, no eYFP expression was observed in the absence of Cre 
(n=14) or absence of tamoxifen (n=3).  In the presence of Cre the proportion of 
recombined cholangiocytes in response to 80mg/kg tamoxifen was 15.4% ±1.19 (n=6) 
compared to 13.71% ±2.32 (n=9) in response to three 4mg doses on alternate days 
(Figure 4.1B).   
As recombination efficiency was not statistically different between the two doses, it 
was decided to use the dose published by Means et al. in the original description of 
the CK19CreERT mouse (218).  Three doses of 4mg of tamoxifen were used for all 
subsequent experiments in this study.   
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Figure 4.1  Cre recombination efficiency of the CK19CreERTeYFP mouse.   
 
Figure 4.1  Cre recombination efficiency of the CK19CreERTeYFP mouse.  (A)  
Immunohistochemical staining for eYFP in endodermal tissues 7 days after 3 doses 
of 4mg tamoxifen i.p. (Antibody targeted to GFP).  eYFP positivity was observed in 
enterocytes in intestine and ductular epithelia in pancreas and liver.  In liver eYFP 
positivity was observed only in the presence of Cre and tamoxifen and only in 
ductular cells (white arrows).  No expression was observed in hepatocytes.  
Scalebars represent 100µm.   (B) The number of eYFP positive cholangiocytes as a 
proportion of the total number of ductal cells per mouse is represented in the 
absence of Cre and presence of tamoxifen (Cre-TM+); presence of Cre but absence of 
tamoxifen (Cre+TM-) and presence of Cre and tamoxifen (Cre+TM+).  In response to 




80mg/kg tamoxifen, 15.41% ±1.19 cholangiocytes were eYFP positive compared to 
13.71% ±2.32 following 3 doses of 4mg tamoxifen.   Statistical differences between 
groups represented on the graphs are calculated using the one way analysis of 
variance test (80mg/kg regime p=<0.0001; 3 x 4mg regime p=0.0039).  * p≤0.05; ** 
p≤0.01; ***p≤0.001.   
 
To ensure eYFP positive cells were exclusively labelling cells within the biliary and 
progenitor compartments within the liver and not hepatocytes, I performed co-
immunofluorescent staining for YFP and the biliary markers pan-cytokeratin and 
Sox9, as well as the mature hepatocyte marker Cyp2D6 (Figure 4.2).   
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Figure 4.2 eYFP is expressed by biliary and progenitor cells but not hepatocytes in 
CK19CreYFP mice.   
 
 
Figure 4.2 eYFP is expressed by biliary and progenitor cells but not hepatocytes in 
CK19CreYFP mice.  Representative photomicrographs from CK19YFPp53 mice 
following tamoxifen administration demonstrating eYFP positivity (green) co-
localising with the biliary markers pan-cytokeratin and Sox9 but not the mature 
hepatocyte marker CYP2D6 (red).  Scalebars represent 100µm.   
 




Pilot ICC Model 1: CK19CreYFPp53f/f + CCl4
 
Carbon tetrachloride (CCl4) is a potent hepatotoxin and the most extensively 
characterised inducer of liver fibrosis.  Following a single dose, centrizonal necrosis 
and steatosis occur; however after prolonged administration fibrosis, cirrhosis and 
hepatocellular carcinoma are induced (221, 222).  In light of previous reports of 
concomitant ICC and HCC formation in p53 null mice in response to chronic 
intermittent toxin exposure with CCl4 (217), this experiment was designed to 
determine whether CCl4 induced injury in combination with inducible, targeted 
deletion of p53 in biliary cells could result in a more specific model of ICC.   
Clinical Course:   
CK19CreYFPp53wt/wt and CK19CreYFPp53wt/flox mice were induced with 3 injections 
of 4mg tamoxifen i.p. and allow to recover before undergoing chronic intermittent 
injury with 1ul/g CCl4 or olive oil i.p 3 times a week for 16 weeks.  This model was 
associated with an unacceptably high mortality rate (combined mean survival 84.89 
±13.77 days) and therefore CK19YFPp53flox/flox mice were not commenced on the 
protocol.  Death did not correlate to weight loss and clinical deterioration of mice 
was rapid and unpredictable.  No clinical signs of liver failure such as jaundice were 
evident and no tumour formation was observed on post-mortem examination. 




Figure 4.3  Pilot model 1:  CK19CreYFPp53f/f  + 16 weeks CCl4 
 
 
Figure 4.3 Pilot model 1: CK19CreYFPp53f/f + 16weeks CCl4  (A) Experimental schematic: 
Cre was induced with 3 x 4mg tamoxifen i.p. followed by damage with chronic, 
intermittent 1µl/g CCl4 i.p 3 times a week for 16 weeks.  (B)  Kaplan-Meier survival 
curve for CK19YFPp53wt/wt  (n=19) and CK19YFPp53wt/flox (n=20) mice undergoing 
chronic injury with CCl4 for 16 weeks.  (C)  Daily weights of CK19YFPp53wt/wt and 
CK19YFPp53wt/flox mice undergoing chronic injury with CCl4 for 16 weeks.   




Histological Appearance:   
All mice receiving vehicle displayed normal liver architecture.  Following 16 weeks 
of intermittent CCl4 administration, livers from mice of all genotypes exhibited 
severe centrilobular necrosis, intense inflammatory infiltrates and extensive steatotis 
(Figure 4.4).  As anticipated, picro-sirius staining demonstrated extensive collagen 
deposition with bridging fibrosis in both p53 wild type and p53 heterozygous floxed 
animals, with associated infiltration by αSMA positive myofibroblasts.  H&E and 
pan-cytokeratin staining revealed no biliary hyperplasia or invasive 
adenocarcinoma (and no hepatocellular carcinoma), as assessed by a liver 
histopathologist.  Furthermore no significant ductular reaction or parenchymal 
migration of progenitor cells were observed in this model (Figure 4.4).  




Figure 4.4 Histology Pilot model 1: CK19CreYFPp53f/f + 16weeks CCl4    
 
 
Figure 4.4 Histology Pilot model 1: CK19CreYFPp53f/f + 16weeks CCl4   In comparison to 
mice receiving vehicle, CK19YFPp53wt/wt and CK19YFPp53wt/flox mice undergoing 
chronic injury with CCl4 demonstrated severe centrilobular necrosis with associated 
inflammatory infiltrate on H&E staining (top panel).  Extensive collagen deposition 
with bridging fibrosis was observed in all animals receiving CCl4 and this was 
associated with infiltration of αSMA positive myofibroblasts  (middle panels).  No 
significant ductular reaction or progenitor cell activation was observed in this 
model; PanCK staining showed ductular positivity (black arrows) but no 




hyperplasia or parenchymal migration of progenitor cells (lower panel).  Scalebars 
represent 100µm.     




Pilot ICC Model 2:  CK19CreYFPp53 + TAA 
Thioacetamide (TAA) is an organosulphur which is metabolised to carcinogenic 
products in zone 3 hepatocytes, triggering the development of multifocal invasive 
biliary adenocarcinoma in rats (75).  Following Cre induction with tamoxifen, TAA 
was orally administered to CK19CreYFPp53wt/wt, CK19CreYFPp53wtflox and 
CK19CreYFPp53flox/flox mice for 26 weeks (Figure 4.5A).   
Clinical Course:   
Mortality was unacceptably high in female mice commenced on this protocol (4 out 
of 7 female mice within the first 17 days of the protocol) and accordingly in females 
the experiment was terminated and mice culled via a Schedule 1 method.  A lower 
body weight at the start of the experiment in female mice meant that animals were 
less able to tolerate the initial dehydration and weight loss occurring on 
commencement of TAA (TAA is a sulphurous, unpalatable compound).   
All male mice weighing ≥25g at the time of Cre induction survived irrespective of 
genotype, although weight gain was slower than would be expected in 
transgenically matched mice receiving drinking water alone (Figure 4.5B).  No 
animals died from tumour-related causes before the experimental end-point at 26 
weeks.  No clinical signs of liver failure including jaundice, bleeding or ascites were 
evident even at 26 weeks.  Liver injury as assessed by serum biochemical markers of 
liver function (ALT, AST, ALP, bilirubin and albumin) were equivalent between 
mice carrying one or two floxed alleles for p53 (haemolysis of samples from wild 
type mice left n=1 for analysis) (Figure 4.5C). 




Figure 4.5  Pilot model 2: CK19CreYFPp53f/f + 26weeks TAA   
 
 
Figure 4.5  Pilot model 2: CK19CreYFPp53f/f + 26weeks TAA  (A) Experimental schematic 
of Cre induction with 3 x 4mg tamoxifen i.p. followed by administration of 
600mg/ml TAA in the drinking water for 26 weeks.  (B)  Weights of male 
CK19YFPp53wt/wt, CK19YFPp53wt/flox and CK19YFPp53flox/flox mice undergoing chronic 
injury with TAA for 26 weeks.  (C)  Liver function tests in CK19YFPp53wt/wt, 
CK19YFPp53wt/flox and CK19YFPp53flox/flox mice undergoing chronic injury with TAA 
for 26 weeks (Note n=1 for CK19CreYFPp53wt/wt mice due to haemolysis of samples).  
No significant difference in serum markers of liver function was observed between 




CK19YFPp53wt/flox and CK19YFPp53flox/flox mice (Mann-Whitney U Test).  Data are 
represented as mean ± S.E.M.  (D)  Macroscopic appearance of tumours arising in 
CK19YFPp53flox/flox mice following 26 weeks of TAA.  (E)  Frequency of tumour 
occurrence in CK19CreYFPp53wt/wt, CK19YFPp53wt/flox and CK19YFPp53flox/flox mice 
following 26 weeks of TAA.  5 out of 7 CK19CreYFPp53flox/flox mice exhibited 
tumours.   
Histological appearance:   
All mice receiving vehicle exhibited preserved liver architecture.  No tumours were 
observed in CK19CreYFPp53wt/wt or CK19CreYFPp53wt/flox mice following tamoxifen 
induction and 26 weeks of treatment with TAA.  Both these groups of animals did 
however demonstrate extensive periportal inflammation, centrilobular necrosis and 
pseudo lobule formation, as observed on H&E staining.  Ductular reactions were 
frequent; however there was no evidence of dysplasia or cellular atypia (Figure 4.6).     
Multifocal tumours were observed in 5 out of 7 mice carrying homozygous floxed 
alleles for p53 (Figure 4.5 D-E).  These areas were well to moderately differentiated 
adenocarcinoma with associated mucin production and desmoplasia.  Areas of 
dysplasia not amounting to full adenocarcinoma were also present.  No 
hepatocellular carcinoma was observed in any animals (Figure 4.6).  Staining with 
picrosirius red revealed extensive collagen deposition with bridging fibrosis in all 
genotypes receiving TAA.  Staining was particularly dense around and within 
tumours in CK19CreYFPp53flox/flox mice.  αSMA positivity was limited to blood 
vessels in mice receiving vehicle.  Periportal infiltration of αSMA positive 
myofibroblasts was observed in mice of all genotypes receiving TAA and in mice 
that developed tumours, staining was intense in areas of tumour-associated 
desmoplasia (Figure 4.6). 




Figure 4.6 Histology Pilot model 2: CK19CreYFPp53f/f + 26weeks TAA   
 
Figure 4.6 Histology Pilot model 2: CK19CreYFPp53f/f + 26weeks TAA  H&E staining upper 
panel: Mice receiving treatment with vehicle display normal liver architecture.  
CK19YFPp53wt/wt and CK19YFPp53wt/flox mice exhibit extensive periportal 
inflammation, steatosis and pseudo lobule formation but no biliary dysplasia or 
malignancy.  CK19YFPp53flox/flox mice display multifocal areas of well to moderately 
differentiated adenocarcinoma with mucin production and dense desmoplasia.  
Areas of dysplasia not amounting to adenocarcinoma are also present.  Picrosirius 
red and αSMA staining reveal extensive collagen deposition with bridging fibrosis 
and periportal and peritumoral infiltration of myofibroblasts (centre two panels). 
Pan-cytokeratin staining reveals extensive HPC activation with portal-portal 




bridging in TAA treated CK19YFPp53wt/wt and CK19YFPp53wt/flox, extending between 
foci of invasive adenocarcinoma in CK19YFPp53flox/flox mice (lower panels).  Scalebars 
represent 100µm.   
 
Figure 4.7 Tumours arising in CK19CreYFPp53f/f mice after 26 weeks TAA express 
biliary epithelial markers 
 
Figure 4.7 Tumours arising in CK19CreYFPp53f/f mice after 26 weeks TAA express 
biliary epithelial markers.  Tumours found in CK19CreYFPp53f/f mice express markers 
of cholangiocyte differentiation including pan-cytokeratin (Figure 4.6), mAChR3 
(red) and CD44 (red).  Scalebars represent 100µm.   
  




Pilot ICC Model 3:  CK19CreYFPp53kRas 
The KRAS oncogene is activated in 20 to 50% of biliary tract cancers in man (223-
225).  Non-inducible somatic activation of kRas and deletion of p53 in Albumin-
expressing cells (Alb-Cre;kRasG12D;p53flox/flox) has been previously described in mice 
to induce ICC, HCC and tumours with a mixed morphology that recapitulate the 
histology of human disease (86).  I hypothesised that targeting these mutations to 
the CK19+ population in the adult mouse liver would improve the specificity of this 
mode; inducing the formation of biliary and not hepatocellular tumours.  Six week 
old CK19CreYFPp53f/f;kRasG12D mice underwent induction of Cre with tamoxifen (3 
injections of 4mg i.p on alternate days) and were observed for a period of up to 26 
weeks (Figure 4.7A).   
Clinical Course:   
Following Cre induction, mice were monitored for body weight and signs of illness.   
Animals displaying signs of clinical deterioration were culled and included as 
events for survival analysis.  The most common clinical abnormalities observed 
were abdominal swelling, high respiratory rate and non-specific signs of poor 
condition such as hunched posture, ruffled coat and reduced movement (Table 4.1).  
CK19CreYFPp53flox/floxfkRasG12D mice exhibited significantly shorter survival than 
CK19CreYFPp53flox/wtfkRasG12D mice: 41 ±2.7 days vs. 91.9 ± 11.9 days (Log rank p-
0.019) (Figure 4.7B), suggesting the combination of total loss of p53 and kRas 
activation might be additive in their tumour promoting effects.  In light of this 
unacceptable mortality the experiment was terminated early in the 
CK19CreYFPp53flox/floxfkRasG12D cohort, hence the small n (n=3).   
 




Figure 4.8 Pilot model 3: CK19CreYFPp53f/fkRasG12D.   
 
 
Figure 4.8 Pilot model 3: CK19CreYFPp53f/fkRasG12D.  (A)  Experimental schematic:  
CK19CreYFPp53f/fkRasG12D mice were induced with 3 injections of 4mg tamoxifen 
i.p. and observed for up to 26 weeks.  (B)  Kaplan-Meier survival analysis showing 
of CK19CreYFPp53flox/wtfkRasG12D (n=14) and CK19CreYFPp53flox/floxfkRasG12D mice 
(n=3) following induction of Cre with tamoxifen.  The mean survival of 
CK19CreYFPp53flox/wtfkRasG12D mice was 91.9 ± 11.9 days compared to 41 ± 2.7 days 
in CK19CreYFPp53flox/floxfkRasG12D mice (Log rank p=0.019).   
 
  




Table 4.1  Table of survival, clinical signs and tumour type for CK19CreYFPp53f/fkRasG12D 
mice. 




Clinical signs/Findings at 
necropsy 
Histopathology 
HO5 + het + 58 High respiratory rate, hunched 
posture 
N.A.D 
HO6 + het + 35 Weight loss. No macroscopic 
abnormality at necropsy. 
N.A.D 
HR11 + het + 54 Abdominal swelling; Large 
paracolic mass 
Submucosal GI tract 
spindle cell tumour 
IU3 + het + 149 Quick respiratory rate, abdominal 
swelling, weight loss 
 
KF4 + het + 116 Lip papilloma 








JG3 + het + 79 Weight loss, hunched posture, 
ruffled coat 
N.A.D 
JG4 + het + 181 Lip papilloma Squamous papilloma 
JG6 + het + 116 Weight loss, reduced movement 
No abnormality at necropsy 
No tissue (FD in 
cage) 
JG10 + het + 116 Abdominal swelling, ruffled coat, 
hunched posture 
N.A.D 
JG11 + het + 116 Abdominal swelling, ruffled coat, 
hunched posture 
N.A.D 
JG12 + het + 116 Abdominal swelling, ruffled coat, 
hunched posture 
N.A.D 
JG14 + het + 31 Found dead in cage N.A.D 
JG40 + het + 30 Abdominal swelling No tissue (FD in 
cage) 
JG41 + het + 90 Abdominal swelling; weight loss, 
hunched posture 
No tissue (FD in 
cage) 
LX4 + hom + 41 Weight loss, hunched posture, 
slow movement 
N.A.D 
LX5 + hom + 41 Weight loss, hunched posture, 
slow movement 
N.A.D 




Table 4.1  Table of survival, clinical signs and tumour type for CK19CreYFPp53f/fkRasG12D 
mice. 
 






To maximise the surface area of tissue available for histological examination, tissues 
were manually cut into 3mm portions before embedding and sectioning, three of 
which were stained with H&E for analysis.  At the time of necropsy, no mice 
demonstrated macroscopic tumours of the liver and histological analysis revealed a 
normal liver architecture in all animals.  Tissues from all animals were examined by 
a specialist histopathologist and four out of the fifteen animals exhibited tumours.  
Two displayed benign squamous papillomas of the lip and two malignant spindle 
cell carcinomas. These exhibited pleiomorphism and frequent mitotic activity and 
arose from the spermatic cord and invaded the adjacent skeletal muscle in one case 
and arose from the GI tract submucosa in another (Figure 4.8).   




Figure 4.9 kRas activation and p53 deletion in CK19+ cells does not result in ICC. 
 
Figure 4.9 kRas activation and p53 deletion in CK19+ cells does not result in ICC.  
(A) H&E staining showed liver histology to be normal in all animals.  (B-C) One 
animal (KF4) exhibited a spindle cell tumour arising from the spermatic cord and 
invading adjacent skeletal muscle (filled arrowhead in C indicates skeletal muscle).  
(D) One animal (HR11) exhibited a spindle cell tumour arising from the submucosa 
of the GI tract (filled arrowhead in D indicates adjacent normal crypt architecture).  
Scalebars represent 100µm.   
 
Despite a broad range of epithelial tissues being examined for tumour occurrence 
(lung, intestine, pancreas, oesophagus, thymus), a proportion of animals in this 
protocol exhibited clinical signs warranting Schedule 1 cull, and yet no abnormality 
was detected histologically.  In addition to the solid organs examined, cytokeratin 
19 is expressed in skin, prostate, ovary and mesothelia, making it possible that these 
animals carried tumours that were not detected.  At this point however, in light of 
the absence of biliary tumours, hyperplasia or other liver pathology, and given the 
high mortality associated with this model, I decided to terminate the trial of this 
model and focus attention on the CK19YFPp53flox/flox +TAA model (pilot model 2) for 
further studies.   






Rapidity of breeding and the ability to target genetic mutagenesis to produce 
specific phenotypes have made the mouse (mus musculus) the preferred rodent 
system for modelling human disease (226).   At the onset of this project few mouse 
models of ICC had been described, and none that specifically target genetic 
mutation to the biliary compartment of the liver (85, 86, 217).  Here I aimed to 
generate a novel model that would not only closely mimic human disease but 
enable future interrogation of the influence of other epithelial genes during the 
pathogenesis of ICC.    
Two of the three tested models (Pilot model 1 (CK19CreYFPp53f/f + CCl4) and Pilot 
model 3 (CK19CreYFPp53f/fkRas)) conferred unacceptably high mortality rates and 
neither resulted in the formation of ICC.  Neither of these models has been pursued 
any further for those reasons.  On the other hand, Cre-mediated deletion of p53 in 
CK19 positive cells followed by chronic intermittent injury with TAA (Pilot model 
2) reproducibly induced multifocal invasive biliary adenocarcinoma (tumour 
penetrance of 71% at 26 weeks).  Both loss of p53 and chronic biliary inflammation 
are frequent occurrences in human ICC.  Histologically these tumours exhibited 
many similarities to disease in man, including a dense desmoplastic inflammatory 
stromal reaction, intraneural invasion, atypical ductular proliferation with 
associated progenitor activation, mucin production, and positivity for cholangiocyte 
and biliary markers, including the muscarinic acetyl choline receptor 3 (mAChR3), 
cytokeratins and CD44.  No regions of HCC were observed in any animals; 
distinguishing this model in its specificity from other previously described 
approaches, particularly those relying on Albumin driven Cre systems (86, 217).   
It is important to note however that the pattern of disease observed in this model 
does differ from that typically seen in ICC in man; fewer than 10% of patients with 
biliary tract cancer (including extrahepatic tumours) exhibit multifocal disease or 




diffuse involvement of the biliary tree (227).  Although recombination efficiency of 
this CK19Cre system was only 13.7%, it is likely that diffuse p53 deletion 
throughout the biliary network is permissive to the concomitant development of 
multiple tumours at different sites.  It might be argued that the multifocal nature of 
ICC may make this a problematic model in which to study prognosis or response to 
therapy, as disease is likely to progress much more rapidly or behave differently to 
solitary tumours as is more commonly observed in man.  In terms of studying the 
molecular drivers of tumorigenesis however, this characteristic might be an 
advantage, allowing comparison between multiple tumours arising from a 
syngeneic organ.  This might be particularly useful if wishing to study the clonal 
evolution or heterogeneity of tumours, or for example how chemically-induced 
mutagenesis arises.   
In summary I can conclude that this protocol has produced a novel pre-clinical 
model of ICC with an acceptable tumour latency and penetrance and with excellent 
specificity.  Histologically tumours closely resemble ICC in man and exhibit biliary-
specific proteins, although the pattern of disease is multifocal.  Most importantly 
however, this model will provide a platform from which specific genetic alteration 
of the biliary compartment can be performed in future studies of ICC pathogenesis, 
including the studies of this project.    
  




Chapter 5: Lineage Tracing the Cell of Origin of ICC 
Introduction 
Historically it has been assumed that ICCs arise following oncogenic transformation 
of mature biliary epithelia.  A glandular histological morphology, location within 
and adjacent to the biliary network and expression of cholangiocyte specific 
proteins such as mucin and cytokeratins 7 and 19 have all served to perpetuate this 
theory (88).  Furthermore, patients with chronic biliary inflammation such as 
primary sclerosing cholangitis or liver fluke infection are 161 and 27 times more 
likely to develop biliary tract cancer compared to the general population (89, 228).  
The hepatic progenitor cell has also been put forward as a potential candidate for 
the cell of origin of these tumours, in light of the existence of combined 
hepatocellular cholangiocarcinoma (CHC); tumours containing features of both 
cholangiocarcinoma and hepatocellular carcinoma, and cholangiolocellular 
carcinoma (CLC); tumours characterised by ductular reaction and cords resembling 
the Canals of Hering (91).   
Interestingly however, there is also an increased incidence of ICC in a subgroup of 
patients with chronic hepatocellular injury, in particular those with long-standing 
HBV and HCV infection (24).  In this context ICC can appear to form as mass lesions 
within the hepatocyte parenchyma, suggesting the cell of origin may be more 
complex than originally thought.  Indeed recent published data has confirmed that 
ICC can arise from fully differentiated hepatocytes.  In the first of these reports Fan 
and colleagues used hydrodynamic tail vein injection to deliver a Notch 
intracellular domain plasmid to overexpress Notch in the liver (92).  This 
consistently resulted in biliary tumour formation by 20 weeks and could be 
accelerated to 5 weeks when combined with delivery of an AKT overexpressing 
plasmid.  This model was then performed in R26-EYFP mice concomitantly with 
delivery of an adenoassociated viral vector expressing Cre recombinase from the 
hepatocyte-specific promoter transthyretin (AAV8-Ttr-Cre).  In the presence of Cre, 




a stop codon would be excised to permit eYFP transcription.  The authors 
demonstrate that eYFP positivity within tumours co-localised with the biliary 
markers Sox9 and CK8 but not with the hepatocyte marker Mup, suggesting that 
Notch and AKT drive transdifferentiation and transformation of hepatocytes into 
ICC.     
In the second study Sekiya and colleagues adopted a transgenic labelling approach 
using inducible albumin and cytokeratin 19 driven Cre systems to independently 
label the two cell types in the liver with lacZ or eYFP (93).  Cre was induced with 
tamoxifen and mice administered thioacetamide for 30 weeks, after which time 
tumours demonstrating typical histology of ICC had formed in all animals.  The 
authors found that tumours in all Alb-CreERT2;R26lacZ mice but none from CK19-
CreERT2;R26lacZ mice demonstrated β-gal positivity co-localising with Epcam 
expression.  They conclude that this strongly suggests ICC arises from hepatocytes 
and not cholangiocytes.  They go on to show that tumour formation can be 
accelerated by overexpressing Notch intracellular domain in albumin expressing 
cells (Alb-CreERT2;R26RNotch/+), and conversely impeded through deletion of the 
Notch target gene Hes1 (Alb-CreERT2; R26RHes1f/f).   
CK19+ expressing biliary epithelia can give rise to ICC 
In this study I use a similar cytokeratin 19 driven Cre-loxP system (CK19-CreERT) to 
label cells with an eYFP fluorophore, but in addition I have targeted deletion of the 
tumour suppressor p53 (a common occurrence in ICC in man), to the CK19 
expressing population (CK19-CreERT;R26eYFP;p53f/f).  Mice were administered TAA 
for 26 weeks.  As described in the preceding chapter, tumours developed in 5 out of 
7 mice carrying homozygous floxed p53 alleles.   
Immunostaining for eYFP revealed positivity in all histologically identified 
neoplastic nodules, although interestingly not all cells within tumours staining 
positively for pan-cytokeratin were also YFP positive, suggesting that in this model 




tumours are not necessarily arising from proliferation of a single YFP positive, p53 
null clone (Figure 5.1). 
 
Figure 5.1  Biliary tumours arise from CK19 positive cells in a TAA model of ICC.   
 
Figure 5.1  Biliary tumours arise from CK19 positive cells in a TAA model of ICC.  eYFP 
immunostaining in CK19YFPp53f/f mice following 26 weeks of TAA.  Scalebars 
represent 100µm. 
 
To confirm the identity of eYFP positive cells in this model I performed co-
fluorescent immunohistochemistry for eYFP and the biliary markers CK19 and Sox9 
as well as the mature hepatocyte marker Cyp2D6.  The majority of eYFP positive 
cells co-localised with CK19 and Sox9, whereas no co-localisation of eYFP with 
Cyp2D6 was observed.   




Figure 5.2 Lineage traced eYFP+ cells co-localise with biliary markers in a TAA model of 
ICC.   
 
Figure 5.2 Lineage traced eYFP+ cells co-localise with biliary markers in a TAA model of ICC.  
Representative photomicrographs of ICC arising after 26 weeks of TAA in 
CK19YFPp53flox/flox mice.  eYFP positivity co-localised with the biliary markers 
cytokeratin 19 and sox9, but not the mature hepatocyte marker CYP2D6.  Scalebars 









A principal advantage of the experiments in this study and those published by 
Sekiya et al. is that they do not rely either on viral delivery of a transgene, nor on 
overexpression of an oncogenic driver (Notch/AKT) to induce liver tumorigenesis.  
It can be assumed that chronic injury with the toxin TAA is a more representative 
model of the in vivo situation in ICC in man.  Trp53 deletion at the point of 
tamoxifen administration as described here does not increase labelling efficiency, 
but is likely to cause a preferential expansion of the eYFP labelled population in 
response to TAA induced injury, making it more probable that a transforming event 
will occur in this population compared with labelled cells in a similar fate tracing 
experiment without p53 deletion.  So although this may explain why labelled 
tumours were observed in this model and not the experiments described by Sekiya 
et al. (93), the frequency of p53 loss and chronic biliary inflammation in human ICC 
would suggest this to be a representative model of biliary carcinogenesis in man.  
Furthermore the CK19CreYFP mouse has proved to be a poor tool for lineage 
tracing progenitor-derived hepatocytes during regeneration in the adult mouse 
liver.  The failure to observe eYFP-labelled hepatocytes in dietary models of chronic 
hepatocellular damage has been attributed to a low recombination and hence 
labelling efficiency (unpublished data from Forbes lab, Lemaigre lab et al.).  In light 
of this it would therefore appear unlikely that eYFP labelled tumour cells are arising 
from hepatocytes in this TAA model.   
Interestingly not all CK19 positive cells observed within areas of tumour were eYFP 
positive.  One explanation for this might be that eYFP expression is being 
genetically silenced during the process of ongoing injury and mutagenesis.   eYFP 
negative cells were observed in almost all areas of tumour across different animals 
and indeed, even within the same ductal structure, sitting alongside eYFP positive 
cells.  It seems statistically improbable although possible, that mutation resulting in 
eYFP silencing would be occurring at this frequency.  An alternative explanation is 
that non-recombined cells are contributing to tumour formation.  Such cells may 




either be carrying their own TAA-induced genetic alterations, or be non-
transformed cells that have been ‘recruited’ into the tumour mass e.g. by secreted or 
induced factors.  Whichever of these is the case, it remains interesting that p53 null 
cells do not entirely take over as the dominant clone within tumours and is 
consistent with the school of thought that p53 loss acts as a tumour-permissive 
event rather than a tumour driver.  Fluorescently activated cell sorting or laser-
capture microdissection of individual tumours from the same liver (to control for 
recombination efficiency) could be used to separate eYFP positive from eYFP 
negative cells, followed by sequencing to determine the spectrum of genetic events 
that have occurred.  In vitro assays of clonogenicity could then be used to determine 
the hierarchy of clonal evolution occurring within a single tumour and between 
tumours.  This model would therefore appear to offer an interesting platform from 
which to study tumour evolution and intra-tumour heterogeneity. 
In contrast to the findings of Sekiya et al. and Fan et al., my experiments conclude 
that cholangiocytes have capacity to give rise to ICC.  Currently the limitations of 
transgenic technologies make it difficult to concomitantly label both cholangiocytes 
and hepatocytes in vivo to assess their contribution to tumorigenesis during 
different protocols of cancer induction.  Furthermore different models may target 
different cell types for transformation and experiments using indiscriminate 
delivery of transgenic or viral oncogenic drivers would bias towards a hepatocyte 
origin simply due to their vast outnumbering of cholangiocytes within the liver.  It 
could be postulated that the probable situation in ICC in man is that different cells 
of origin may occur according to disease context and factors supplied by the local 
tumour microenvironment, suggesting that the niche may play a key role in driving 
tumorigenesis in ICC.  What my data have demonstrated however is that the CK19 
expressing cholangiocytes or progenitor cells should not be discounted as a target 
for future therapeutic targeting in ICC.    




Chapter 6:  The Notch pathway in healthy liver and ICC 
Introduction 
Notch signalling is a key determinant of biliary development in the embryo where it 
is activated early on to specify hepatoblasts on the portal side of the ductal plate 
towards a cholangiocyte fate, but also later during liver patterning to regulate 
tubular morphogenesis (the appearance of lumina and duct formation) and 
arborisation (145, 169, 229).  Work from our laboratory and others has demonstrated 
this paradigm extends to the regenerating biliary system following injury in the 
adult liver (169, 174).  Following biliary damage there is a compositional change in 
the regenerative niche, whereby infiltrating myofibroblasts are able to form close 
spatial relationships with HPCs and supply Jagged1 ligand to activate Notch.  In 
this context Notch acts both to control HPC number as well as activating a 
transcriptional programme to specify cells to the biliary lineage (Hes1, Hes5, 
HNF1β) (104, 169).   
Dysregulation of wild type Notch signalling has now been identified as a driver of 
carcinogenesis in a number of solid organs.   Since the commencement of this study, 
work has been published demonstrating that transgenic overexpression of Notch1 
in Albumin expressing cells in the embryo (Alb-Cre;NotchIC) leads to the formation 
of biliary lineage tumours in the adult mouse liver (230).   This transgenic construct 
drives expression of N1-ICD in virtually all hepatocytes and biliary epithelial cells 
during the formation of the ductal plate (145).  As early as 8 months after birth 
morphological changes are observed in the livers of these mice and when liver 
tissue from the Alb-Cre;NotchIC mice is transplanted subcutaneously into the flanks 
of immunocompromised mice, tumours form which stain positively for the biliary 
lineage markers CK7 and CK17 (No tumours form from Alb-Cre controls).   
Exogenous activation of oncogenes through transgenesis can initiate carcinogenesis 
in many different tissues and indeed often in tissues where these oncogenes are not 




overexpressed or mutated in human cancers.  Studies examining KRAS and MYC 
oncogenes for example have shown that the precise levels of overexpression are 
absolutely critical to the biological outcome (231).  Published data on the role of 
Notch in ICC have relied on transgenic over-expression of Notch to induce 
tumorigenesis.  The true role of endogenous wild type Notch in the pathogenesis of 
ICC in man remains unclear.  In this study I therefore aimed to undertake a full 
characterisation of Notch pathway activity in human ICC as well as in rodent 
models in which Notch has not been transgenically altered.  Given the toxicity that 
has impeded the success of γ-secretase inhibitors (GSIs) in clinical trials for other 
solid organ tumours; I hoped this approach might identify Notch pathway 
components that might represent novel targets for therapeutic development.   
  




The Notch pathway is up-regulated in human ICC and rodent models 
Notch pathway transcription is up-regulated in human ICC 
I began by looking broadly at transcription of the entire Notch pathway using a 
commercially available targeted Notch PCR array on 5 resected, treatment-naive 
human ICC cases which were paired with patient-matched non-cancerous liver 
controls.  This RT2 Profiler™ PCR Array (SABiosciences) profiles the expression of 
84 genes implicated in Notch signalling, including components of the core pathway 
as well as those involved in receptor binding and processing and putative targets 
(http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-059A.html).  The 
technical challenge of macroscopically dissecting a pure sample of intrahepatic bile 
duct from these samples meant that it was necessary to use whole liver as a non-
cancerous control to areas of tumour.   
I found components from each stage of the canonical Notch pathway to be up-
regulated including ligands, receptors and target effector genes.  Interestingly 
NOTCH3 is the only receptor to be significantly up-regulated (18.202 fold, 
p=0.000025), NOTCH 1 is transcribed 1.933 fold (p=0.105153), NOTCH2 1.842 fold 
(p=0.136808) and NOTCH4 1.576 fold (p=0.076371) (Table 6.1 and Figure 6.1).  JAG2 
is the most highly up-regulated ligand (12.58 fold p=0.003088), followed by JAG1 
(8.43 fold p=0.000426). Delta like ligands 1, 3 and 4 are not up-regulated.  HEY1 
10.25 fold (p=0.016558) and HEYL 6.02 fold (p=0.000829) are the most highly up-








Table 6.1  Notch pathway PCR Array of human ICC and patient-matched distal non-
cancerous liver.   
Unigene Refseq Symbol Fold Change p Value 
Hs.8546 NM_000435 NOTCH3 18.202 0.000025 
Hs.433445 NM_002226 JAG2 12.5846 0.003088 
Hs.653700 NM_007129 ZIC2 12.2213 0.014216 
Hs.234434 NM_012258 HEY1 10.2518 0.016558 
Hs.244723 NM_001238 CCNE1 9.1662 0.08289 
Hs.728907 NM_000214 JAG1 8.4314 0.000426 
Hs.173859 NM_003507 FZD7 7.5751 0.01193 
Hs.472566 NM_014571 HEYL 6.0241 0.000829 
Hs.525198 NM_003035 STIL 5.9598 0.005442 
Hs.563344 NM_006186 NR4A2 5.0864 0.178302 
Hs.159142 NM_001040167 LFNG 4.5722 0.172785 
Hs.142912 NM_001466 FZD2 4.5159 0.125445 
Hs.502328 NM_000610 CD44 3.3175 0.058305 
Hs.386567 NM_004120 GBP2 3.1529 0.020033 
Hs.492974 NM_003882 WISP1 2.8781 0.669151 
Hs.137510 NM_006312 NCOR2 2.8553 0.078323 
Hs.94234 NM_003505 FZD1 2.5179 0.251392 
Hs.517603 NM_002405 MFNG 2.4929 0.086738 
Hs.591863 NM_003506 FZD6 2.3132 0.155446 
Hs.664706 NM_024015 HOXB4 2.264 0.078899 
Hs.149261 NM_001754 RUNX1 2.1419 0.279567 
Hs.446352 NM_004448 ERBB2 1.9708 0.099765 
Hs.495473 NM_017617 NOTCH1 1.9332 0.105153 
Hs.504096 NM_005188 CBL 1.8568 0.068651 
Hs.487360 NM_024408 NOTCH2 1.8422 0.136808 
Hs.2256 NM_002423 MMP7 1.8389 0.318428 
Hs.728902 NM_203458 NOTCH2NL 1.838 0.076917 
Hs.437922 NM_005376 MYCL1 1.7638 0.372321 
Hs.390736 NM_003879 CFLAR 1.7396 0.122128 
Hs.728776 NM_012423 RPL13A 1.6804 0.123115 
Hs.716382 NM_004210 NEURL 1.6387 0.309506 
Hs.404914 NM_003183 ADAM17 1.6198 0.142189 
Hs.436100 NM_004557 NOTCH4 1.5761 0.076371 
Hs.73090 NM_002502 NFKB2 1.546 0.503839 
Hs.404089 NM_016169 SUFU 1.5366 0.575025 
Hs.349094 NM_002351 SH2D1A 1.4657 0.332305 
Hs.517517 NM_001429 EP300 1.3542 0.953128 
Hs.592082 NM_003502 AXIN1 1.329 0.521975 
Hs.251680 NM_000427 LOR 1.2918 0.284098 
 
Table 6.1  Notch pathway PCR Array of human ICC and patient-matched  non-cancerous 
liver.  Table of top 40 differentially up-regulated genes in human ICC vs. patient-




matched non-cancerous  liver (n=5).  See appendix table 1 for full table of 84 genes 
profiled.   




Figure 6.1  Heat map and volcano plot from Notch pathway PCR Array of human ICC and 
patient-matched  liver.   
 
Figure 6.1  Heat map and volcano plot from Notch pathway PCR Array of human ICC and 
patient-matched distal liver.  (A) Heat map and (B) Volcano plot comparing Notch 
transcription in human ICC vs. patient-matched non-cancerous liver (n=5).  
Horizontal Grey line represents a p value of 0.05.  Vertical grey lines represent 




boundary of ≥3 fold down-regulation and ≥3 fold up-regulation respectively.  Up-
regulated genes are represented in red; down-regulated genes are represented in 
green.   
 
To corroborate these results with an independent technique, I performed rt-qPCR 
on the same cohort of tumours and non-cancerous liver controls that had been 
prospectively collected from patients undergoing resectional surgery at the Royal 
Infirmary of Edinburgh (Tumours n= 5; Non-cancerous liver n=6) (Figure 6.2).  
Again I observed the same profile of transcriptional up-regulation; with NOTCH1 
up-regulated 3.08 fold ±0.89 (p=0.052); NOTCH2 6.23 fold ±2.85 (p=0.126); NOTCH3 
96.85 fold ±59.53 (p=0.043) and NOTCH4 3.03 fold ±1.37 (p=0.082).  The Hes/Hey 
target effectors that were significantly up-regulated on qPCR were Hes4 (9.09 fold 
±3.34 p=0.065) and HeyL (4.53 fold ±1.38 p=0.0427). 




Figure 6.2 Transcription of the Notch pathway is up-regulated in a prospectively collected cohort of human ICC.   
 
 
Figure 6.2 Transcription of the Notch pathway is up-regulated in a prospectively collected cohort of human ICC.  rt-qPCR data of the Notch pathway 
from a prospectively collected cohort of resected ICC at the Royal Infirmary of Edinburgh (Tumour n=5; Non-cancerous liver n=6).  
NOTCH1 was up-regulated 3.08 fold (p=0.052); NOTCH2 6.23 fold (p=0.126); NOTCH3 96.85 fold ±59.53 (p=0.043) and NOTCH4 3.03 fold 
(p=0.082).  The Hes/Hey target effectors that were significantly up-regulated on qPCR were Hes4 (9.09 fold p=0.065) and HeyL (4.53 fold 
p=0.0427).  Data are represented as means ±S.E.M. and differences calculated using the Mann-Whitney U test.  * p≤0.05; ** p≤0.01; 
***p≤0.001.   




In addition I used rt-qPCR to analyse Notch activity in a retrospective cohort of 
archival samples of formalin fixed, paraffin embedded biliary tumours (n=31) and 
healthy control livers (n=30) collected by the NHS Lothian SAHSC BioResource and 
Edinburgh MRC Sudden Death Brain and Tissue Bank.  RNA was extracted using 
an FFPE RNEasy kit (Qiagen) and subject to the same quality control as freshly 
frozen tissue.  I observed the same pattern of transcriptional up-regulation as had 
been seen in the prospectively collected cohort:  NOTCH1 was actually down-
regulated 0.56 fold ±0.14 (p=<0.0001), NOTCH2 up-regulated 9.38 fold ±3.42 
(p=<0.0001), NOTCH3 38.30 fold ±11.46 (p=<0.0001) and NOTCH4 2.26 fold ±0.67 
(p=<0.0001).  The Notch ligand JAG1 was up-regulated 608.99 fold ±466.51 (p 
p=<0.0001), JAG2 1578.25 ±662.25 (p=<0.0001) and DLL1 133.14 ±123.90 (p=<0.0001).  
The target gene Hes1 was up-regulated 861.45 fold ±700.20 (p=<0.0001), Hes4 537.87 
±39.75 (p=<0.0001), Hey1 79.85 39.75 (p=<0.0001), Hey2 685.63 fold ±604.10 
(p=<0.0001) and HeyL 289.33 fold 114.37 ±114.37 (p=<0.0001). 




Figure 6.3 Transcription of the Notch pathway is up-regulated in a retrospective cohort of paraffin-embedded, formalin-fixed human ICC.    
 
 
Figure 6.3 Transcription of the Notch pathway is up-regulated in a retrospective cohort of paraffin-embedded, formalin-fixed human ICC.   rt-qPCR 
data of the Notch pathway from a retrospective cohort of archival ICC from the NHS Lothian Tissue Bioresource (n=31) and healthy liver 
controls (n=30).  As observed in the prospectively collected samples, NOTCH3 was the most highly up-regulated receptor (38.30fold 
p=<0.0001).  Data are represented as means ±S.E.M. * p≤0.05; ** p≤0.01; ***p≤0.001.   




Finally to validate these results from an independently collected and analysed 
cohort, a collaborator, Dr Mina Komuta, a post-doctoral fellow at Professor Tania 
Roskams’ laboratory, KU Leuven, Belgium analysed a cohort of tumours (n=11) and 
non-cancerous liver controls (n=6) using the same primers and methods as had been 
performed on the previous two cohorts.  In this group NOTCH3 was again the most 
highly up-regulated receptor 11.62 fold ±1.34 (p=0.0011) compared to NOTCH1 1.90 
fold ±0.40 (p=0.29), NOTCH2 4.13 fold ±0.62 (p=0.0011) and NOTCH4 1.03 fold ±0.18 
(p=0.58).  Both ligands were up-regulated: JAG1 11.93 fold ±2.67 (p=0.0011) and 
JAG2 8.12 ±1.60 (p=0.0011).  Target genes were transcribed as follows:  HES1 1.61 
fold ±0.34 (p=0.25), HES4 9.17 ±1.51 fold (p=0.0011), HEY1 3.28 fold ±0.85(p=0.138), 
HEY2 0.79 fold ±0.22 (p=0.145) and HEYL 4.47 fold ±1.19 (p=0.003). 




Figure 6.4 Transcription of the Notch pathway is up-regulated in an independently collected and analysed cohort of human ICC (Roskams Lab, KU 
Leuven, Belgium).    
 
 
Figure 6.4 Transcription of the Notch pathway is up-regulated in an independently collected and analysed cohort of human ICC (Roskams Lab, KU 
Leuven, Belgium).   rt-qPCR analysis of the Notch pathway from a cohort of ICC (n=11) and patient-matched controls (n=6) collected and 
analysed by Nina Komuta at KU Leuven, Belgium.  NOTCH3 was the most highly up-regulated receptor (11.62 fold ±1.34 p=0.0011), JAG1 
the most highly expressed ligand (11.93 ±2.67  p=0.0011) and HES4 the most highly up-regulated target gene (9.17 fold ±1.51 p=0.0011).  
Data are represented as means ±S.E.M.  * p≤0.05; ** p≤0.01; ***p≤0.001.   




In all the above datasets only intrahepatic and perihilar tumours were analysed; no 
extrahepatic tumours were included.  The same primers and methods were used in 
the analyses of each cohort, including cDNA dilutions, and therefore I have 
combined the results to give an overall picture of Notch transcriptional activity in 
ICC vs. healthy liver.  Overall when normalised to non-tumour, NOTCH1 was 
down-regulated 1.13 fold ±0.20 (p=0.0001), NOTCH2 up-regulated 7.49 fold ±1.88 
(p=0.0001), NOTCH3 38.28 fold ±10.30 (p=0.0001) and NOTCH4 2.01 fold ±0.40 
(p=0.0001).  The Notch ligand JAG1 was up-regulated 363.33 fold ±251.61 (p=0.0001) 
and JAG2 938.55 fold ±369.51 (p=0.0001).  Transcription of target genes was as 
follows:  HES1 483.69 ±368.22 (p=0.0001), HES4 304.19 ±119.83 (p=0.0001), HEY2 
384.84 ±317.02 (p=0.0005) and HEYL 160.56 fold ±60.06 (p=0.0001). 




Figure 6.5  Transcription of the Notch pathway is up-regulated in ICC.   
 
 
Figure 6.5  Transcription of the Notch pathway is up-regulated in ICC.  Combined rt-qPCR data of Notch pathway transcription from the above 
three datasets (Tumour n= 47; Non-cancerous liver=42).  NOTCH1 was down-regulated 1.13 fold ±0.20 (p=0.0001), NOTCH2 7.49 fold 
±1.88 (p=0.0001), NOTCH3 38.28 fold ±10.30 (p=0.0001) and NOTCH4 2.01 fold ±0.40 (p=0.0001).  The Notch ligand JAG1 was up-regulated 
363.33 fold ±251.61 (p=0.0001) and JAG2 938.55 fold ±369.51 (p=0.0001).  Transcription of target genes was as follows:  HES1 483.69 ±368.22 
(p=0.0001), HES4 304.19 ±119.83 (p=0.0001), HEY2 384.84 ±21.59 (p=0.0005) and HEYL 160.56 fold ±317.02 (p=0.0001).Data are represented 
as means ±S.E.M.  * p≤0.05; ** p≤0.01; ***p≤0.001.   




These data demonstrate across independently collected and analysed cohorts of 
tumours, that transcription of the receptors Notch2 bit more significantly Notch3 is 
up-regulated in human ICC.  This compares to that of Notch1 and Notch4 which are 
modestly down-regulated.  Ligands Jagged 1 and 2 are over-expressed in ICC, as are 
all the Hes/Hey target effectors measured, indicating functional activity through the 
pathway.  The differences in quantitation of Jagged ligand expression observed 
between the cohorts here may be a result of sample size, however it would be 
interesting to perform a subgroup analysis to control for any background of chronic 
liver disease that might be present to assess whether different aetiologies of hepatic 
pathology can differentially activate Notch ligands as a precursor to cancer.   
 
Expression of Notch proteins is up-regulated in human ICC 
To compare the expression of Notch proteins in human ICC compared to distal non-
cancerous liver, I performed immunohistochemistry in formalin fixed tissue on 
samples collected locally as well as a tissue microarray containing 42 ICC cores and 
42 patient-matched liver controls (Figure 6.7).  I found that expression of Notch3 
appeared to be much greater within regions of ICC compared to healthy liver, 
where expression was strongest on the smooth muscle of the hepatic vasculature 
(Figure 6.6). Positivity was greatest on malignant epithelia, where it was frequently 
widespread (Figure 6.7), however I also observed regions of ICC exhibiting clusters 
of Notch3 positive epithelial cells with clear nuclear positivity, suggesting 
functional pathway activity in these cells (Figure 6.6).  Unexpectedly the cancerous 
stroma was also frequently positive for Notch3 although this was quite variable 
between patients (Figure 6.6 and 6.8).  Furthermore epithelial Notch3 
immunopositivity appeared much stronger than that of Notch1 which was only 
modestly up-regulated compared to healthy ductules. (Figure 6.7).   
In contrast Jagged 1 immunoreactivity was principally restricted to the stromal 
compartment of tumours (Figure 6.6) and co-localised with αSMA (Figure 6.8) 






Figure 6.6  Notch3 protein is observed on the hepatic vasculature in healthy liver but 
appears on malignant ductules and stroma in ICC 
 
 
Figure 6.6  Notch3 protein is observed on the hepatic vasculature in healthy liver but 
appears on malignant ductules and stroma in ICC 
In the healthy human liver Notch3 immunoreactivity is confined to the smooth 
muscle surrounding the hepatic vasculature.  In ICC however Notch3 is also 
expression on malignant ductules and the fibroblastic stroma (upper panel and 
Figure 6.7).  Clusters of positive epithelia can be observed exhibiting nuclear 
positivity for Notch3-ICD (upper panel, far right).  Jagged 1 in contrast is absent in 
the homeostatic adult liver, but becomes up-regulated in ICC, principally by the 
cancerous stroma (lower panel).   
 




Figure 6.7  Notch3 protein is up-regulated in human ICC compared to distal non-cancerous 
liver.   
 
Figure 6.7  Notch3 protein is up-regulated in human ICC compared to distal non-cancerous 
liver.  Representative photomicrographs of DAB immunostaining for Notch1 (top 
panels), Notch3 (middle panels) and rabbit isotype control (lower panels) in tissue 
microarrays of human ICC and distal non-cancerous liver.  Tissue microarrays were 




stained with equivalent concentrations of antibody and photomicrographs taken at 
the same exposure.  Scalebars represent 100µm.   
 
Given the apparent up-regulation of the Notch3 receptor in particular, I next co-
stained Notch3 with a range of markers of different liver cell types to confirm which 
cells were expressing Notch3 in tumour and healthy liver (Figure 6.8) .  I found 
some overlap of expression with the Notch ligand Jagged1, which was observed 
primarily on stromal fibroblasts (upper panel).  However I found that Notch3 was 
expressed by both CK19+ epithelial cells as well as αSMA+ myofibroblasts in the 
surrounding stroma (2nd and 3rd panels), and that within the epithelial compartment, 
nuclear Notch3 positivity could be observed; indicating nuclear localisation of N3-
ICD and pathway activity (filled arrowheads in upper panel).  Notch3 was not 
expressed by CD68+ inflammatory cells or CD31+ endothelial cells (lower two 
panels).   




Figure 6.8  Notch3 is expressed by malignant ductules and stromal myofibroblasts in 
human ICC but not other stromal cell types 
   
Figure 6.8 Notch3 is expressed by malignant ductules and stromal myofibroblasts in human 
ICC but not other stromal cell types  Representative photomicrographs from human 
ICC showing co-immunofluorescent staining of Notch3 with Jagged1, CK19, αSMA, 
CD68+ or CD31+.  Notch3 is expressed by both CK19+ epithelia which exhibit nuclear 




positivity, as well as stromal αSMA+ myofibroblasts.  Notch3 is not expressed by 
endothelia or inflammatory cells in the tumour stroma.  Scalebars represent 100µm. 
        
Immunostaining for the Hes/Hey target effectors was unsuccessful in paraffin-
embedded, formalin-fixed tissue despite testing a number of antibodies.  Therefore 
in order to determine whether activity through the Notch pathway was functional 
in human ICC, I performed a western blot for the Notch3 receptor using an 
antibody able to detect the intracellular domain of the protein (95kDa) (Figure 6.9).   
 
Figure 6.9  N3-ICD is up-regulated in human ICC compared to distal non-cancerous liver.   
     
Figure 6.9  N3-ICD is up-regulated in human ICC compared to distal non-cancerous liver.  On 
densitometric analysis of the 4 human ICC specimens and matched non-cancerous 
liver controls assayed with western blot, the intracellular domain of Notch3 is up-
regulated 94.99 fold (p=0.0286).   




Notch is progressively up-regulated during the natural history of disease 
progression in ICC 
Recommended criteria for genetically engineered models of cancer include the use 
of the same mutations that occur in human tumours, preferably with silencing of 
mutations in embryogenesis and early postnatal development (except for paediatric 
tumours) (232).  Even when transgenes are induced in adulthood however, these 
models will only truly represent that subset of patients with tumours carrying that 
defined genetic alteration and are often hindered by variability in tumour latency 
and penetrance (233).  Chemically induced models of cancer, and in particular the 
thioacetamide (TAA) model of cholangiocarcinoma in rat have several advantages.  
Histologically tumours closely resemble those of human disease and exhibit a 
progression from chronic inflammation and fibrosis through to invasive 
adenocarcinoma accompanied by an intense desmoplastic stromal reaction.  Given 
the similarities in this sequence, it is tempting to consider a similar mutagenic 
process may be occurring to that in human ICC; however despite this to date the 
mutational profile of this model has not been characterised.  It is known however 
that these tumours in rat exhibit many of the phenotypic markers typical of human 
ICC including EGFR, MUC1, c-Met, erbB2, MMP2 and MMP9 (75, 234) and as such 
represents a suitable model to study ICC behaviour in vivo. 
A timecourse of this rat model has been previously performed by a clinical research 
fellow in our laboratory Andrew Robson, whereby rats were administered 0.06% 
thioacetamide and harvested at the following time points: 8, 10, 12, 14, 16, 18, 20, 22, 
24 and 26 weeks.  Uninjured controls were also used however these were not time 
matched; all control animals were harvested at 26 weeks (n=3 at each time point; n=3 
uninjured controls).  I have  stained this tissue with H&E and sought independent 
verification of the histological appearance from a specialist liver histopathologist:  
“Livers from animals injured for 10-14 weeks show a HPC response around most portal 
tracts without portal-portal HPC bridging; this is associated with a sparse, mixed, 
neutrophil-rich inflammatory infiltrate. Pigment-laden macrophages are present in some 




larger portal tracts. At 14 weeks occasional large portal tracts are oedematous. There is no 
biliary epithelial or hepatocellular dysplasia or malignancy. After 16-18 weeks of injury the 
HPC response is more extensive, with widespread HPC portal-portal bridging and 
permeation into periportal sinusoids. In addition there are isolated (<4) and small (<5mm 
maximum diameter) foci of well-moderately differentiated adenocarcinoma in keeping with 
cholangiocarcinoma, focally showing mucin production; separate small foci of biliary 
dysplasia not definitely amounting to adenocarcinoma are also present. After 20 weeks, foci 
of cholangiocarcinoma are numerous, large and frequently coalescent.”(Figure 6.10) 








Figure 6.10  H&E staining of rat liver sections during the 26 week TAA timecourse.  Representative photomicrographs from H&E stained 
timecourse of rat livers following treatment with TAA for up to 26 weeks with uninjured control.  Scalebars represent 100µm.   




This model therefore offers a suitable platform for studying how the Notch pathway 
behaves during disease progression in ICC.  I firstly used Notch PCR arrays as used 
to look at pathway transcription in human ICC, to take a broad look at how the 
entire pathway is regulated during the course of disease development compared to 
uninjured controls.  As tumours were multifocal and not always macroscopically 
visible, samples of whole fresh frozen liver were cut at random from TAA and 
vehicle treated rats.  I pooled samples and categorised them according to 
histological diagnosis as follows:  Inflamed 8 to 10 weeks TAA; Fibrotic 12 to 14 
weeks ; Early malignant 16 to 20 weeks; Late malignant 22 to 26 weeks (n=3 at each 
timepoint).  Each group was then compared to uninjured controls (RNA pooled 
from n=6).  I observed a progressive up-regulation of the Notch pathway over time 
in response to injury with TAA.  As seen in human ICC, the Notch3 receptor was 
the most up-regulated paralog (2.3 fold during the fibrotic stage; 5.7 fold in late 
malignancy) (See Appendix Table 2 for full list of genes and fold regulation).  In 
advanced malignancy, Jag1 was the most highly up-regulated ligand (4.1 fold) and 
HeyL the most up-regulated target effector (6.6 fold) (Figure 6.11).   




Figure 6.11  PCR Array of rat Notch pathway transcription during inflammation and invasive adenocarcinoma in the TAA model of ICC.   
 
Figure 6.11  PCR Array of rat Notch pathway transcription during inflammation and invasive adenocarcinoma in the TAA model of ICC.  Graphs 
showing progressive up-regulation of Notch pathway transcription in rat livers during fibrosis (12 to 14 weeks TAA) and advanced 
malignancy (22 to 26 weeks TAA) compared to uninjured control.   Notch3 was the most highly up-regulated receptor (2.3 fold during 




fibrosis; 5.7 fold in invasive adenocarcinoma).  Jag1 was the most highly up-
regulated ligand (1.42 fold in fibrosis; 4.08 fold in adenocarcinoma) and HeyL the 
most up-regulated effector (1.46 fold in fibrosis; 6.58 fold in adenocarcinoma).  A 
significant fold change in transcription was set at +/- 4 fold change in expression.  
Up-regulated genes are noted in red; down-regulated genes notated in green.   
 
I then verified these data using rt-qPCR for key Notch pathway components using 
the same samples (Figure 6.12).  Of the Notch receptors, Notch3 was seen to be the 
most highly up-regulated paralog (52.0 fold ±30.2 p=0.0022) and Jag1 the most up-
regulated ligand (19.2 fold ±5.2 p=0.0022). Notch1 was up-regulated 5.32 fold ±1.69 
p=0.0411; Notch2 4.75 fold ±0.38 p=0.0022; Notch 4 9.67 fold ±3.78 p=0.0022 and Jag2 
2.36 fold ±0.45 p=0.312).  Interestingly in these samples from this model there was 
little change in transcription of the classical Notch effectors Hes1 (1.0 fold ±0.20), 
Hey1 (0.74 fold ±0.11), Hey2 (0.88 fold ±0.18) or HeyL (1.61 fold ±0.38). 




Figure 6.12  Notch3 and Jag1 transcription are most highly up-regulated during ICC 
progression in the TAA model in rat.   
 
Figure 6.12  Notch3 and Jag1 transcription are most highly up-regulated during ICC 
progression in the TAA model in rat.  qPCR data of the TAA timecourse in rat 
demonstrating Notch3 is the most highly up-regulated Notch receptor during early 
and late stage ICC (52.0 fold ±30.2 p=0.0022) and Jag1 the most up-regulated ligand 
(19.2 fold ±5.2 p=0.022).  Data are represented as means ±S.E.M.  As the animals 
receiving vehicle control in this experiment were not matched to the corresponding 
time points, I have used a Mann-Whitney U test to directly compare gene 
expression between rats receiving 26 weeks TAA and ‘control’ rats receiving 26 
weeks normal drinking water.  
 
To verify that these observed transcriptional changes were also recapitulated at the 
protein level within the tissue, I performed immunohistochemistry for the Notch3 
receptor and Jagged 1 ligand on the TAA timecourse (Figure 6.13).  As hyperplastic 
and ultimately malignant ducts appear (as demonstrated with CK19 staining), both 
Notch3 and Jagged1 are increasingly expressed.  In the homeostatic adult rat liver 
Notch3 is expressed solely by smooth muscle surrounding the hepatic vasculature.  
During inflammation and then fibrosis fibroblasts infiltrating the parenchyma 
become positive for Notch3, as do proliferating biliary ductules.  By early and late 




malignancy Notch3 positivity is observed throughout regions of adenocarcinoma in 
both the cancerous epithelium and the surrounding desmoplastic stroma.  Jagged1 
is not expressed in the adult rat liver in homeostasis.  As with Notch3, Jagged1 is 
up-regulated by infiltrating myofibroblasts in response to TAA damage, however its 
expression remains restricted to the mesenchymal compartment of the liver.  In 
early and advanced adenocarcinoma Jagged1 is widely expressed throughout the 
tumour stroma on cancer associated fibroblasts investing the malignant ducts.   




Figure 6.13  NOTCH3 and JAGGED1 proteins are increasingly expressed during the course of  ICC development in a TAA rat model 
 
 




Figure 6.13  NOTCH3 and JAGGED1 proteins are increasingly expressed during the course of  
ICC development in a TAA rat model.  In uninjured rat liver NOTCH3 is expressed in 
the smooth muscle surrounding the hepatic vasculature (middle panel).  As 
inflammation and fibrosis develop NOTCH3 is up-regulated in the mesenchymal 
compartment of the liver as well as the biliary epithelium.  By early and late 
malignancy, NOTCH3 can be observed on the malignant ductules as well as the 
surrounding desmoplastic stroma within areas of adenocarcinoma.  JAGGED1 is not 
expressed in the healthy adult rat liver.  It is progressively up-regulated by 
fibroblasts with increasing TAA damage, becoming florid in late malignancy.  I 
observe no JAGGED1 expression within the epithelial compartment.  Scalebars 
represent 100µm.   
 
Notch3 is up-regulated in a mouse model of ICC 
Finally I examined Notch pathway transcription in the murine model of ICC in 
which CK19CreYFPp53flox/flox mice underwent chronic liver injury with TAA for 26 
weeks.  I performed rt-qPCR on whole liver from CK19CreYFPp53flox/flox mice that 
developed tumours, CK19CreYFPp53flox/flox mice with no tumours, as well as 
CK19CreYFPp53flox/wt, CK19CreYFPp53wt/wt mice and uninjured controls (Figure 
6.14).   In this model both Notch3 and Notch1 were up-regulated in 
CK19CreYFPp53flox/flox mice without tumours and further up-regulated in 
CK19CreYFPp53flox/flox mice with ICC (Notch3 85.92 fold ±67.66 p=0.0286; Notch1 17.09 
fold ±9.04 p=0.0381).  Neither the up-regulation of Jag1 observed in 
CK19CreYFPp53flox/flox mice without tumours, nor that of Jag2 in 
CK19CreYFPp53flox/flox mice with ICC reached statistical significance but this may be 
a result of the experiment being insufficiently powered .  Of the Notch target genes, 
Hey2 was the only gene that up-regulated (45.48 fold ±21.46 p=0.0286), and this was 
only observed in the mice with tumours.   




Figure 6.14 Notch3 transcription is up-regulated in the CK19CreYFPp53f/f + TAA mouse model of ICC.   
 
Figure 6.14 Notch3 transcription is up-regulated in the CK19CreYFPp53f/f + TAA mouse model of ICC.   Rt-qPCR analysis of whole liver from 
CK19CreYFPp53 mice following 26 weeks of injury with TAA.  When normalised to CK19CreYFPp53fwt/wt mice undergoing 26 weeks of 
TAA, Notch3 is up-regulated 85.92 fold ±67.66 (p=0.0286) in CK19CreYFPp53flox/flox mice that developed ICC and 41.35 fold (p=0.0286) in 
CK19CreYFPp53flox/flox mice that did not.  Similarly Notch1exhibited a 24.28 fold (p=0.0286) up-regulation in CK19CreYFPp53flox/flox mice 
with ICC and a 14.94 fold (p=0.0381) up-




regulation in CK19CreYFPp53flox/flox mice without tumours.   The Notch target gene 
Hey2 was also up-regulated 45.47 fold (p=0.0286) in CK19CreYFPp53flox/flox mice with 
tumours. Data are represented as mean ±S.E.M.  
I confirmed with immunohistochemistry the tissue expression of Notch3 protein in 
this model and observed frequent co-localisation of Notch3 with the fluorescent 
reporter eYFP within tumours, indicating expression of Notch3 by CK19+ malignant 
ductules (Figure 6.15).   
 
Figure 6.15 Notch3 protein is expressed by CK19+ epithelia in the CK19CreYFPp53f/f + 
TAA  mouse model of ICC.   
 
Figure 6.15 Notch3 protein is expressed by CK19+ epithelia in the CK19CreYFPp53f/f + 
TAA  mouse model of ICC.  Notch3 (red) is expressed on malignant ductules arising in 
CK19CreYFPp53flox/flox mice that have undergone 26 weeks of injury with TAA.  In 
this lineage traced model Notch3 expression co-localises with the fluorescent 
reporter eYFP (green) driven by the CK19 promoter.  CV: Central vein.  Dashed line 
denotes tumour boundary.  Scalebars represent 100µm.   
Gamma secretase inhibition restricts tumour cell growth in vitro and in vivo 
DAPT reduces cell viability and sphere formation in vitro  
Before interrogating the effects of blocking signalling through the Notch pathway 
with γ-secretase inhibitors, I firstly confirmed that Notch pathway components are 
expressed in three intrahepatic cholangiocarcinoma cell lines (CC-SW-1; CC-LP-1; 




SNU-1079) (Figure 6.16 (A)).   Transcription of Notch receptors was detectable in all 
3 lines, although CC-LP-1 expressed significantly higher levels than SNU-1079 and 
CC-SW-1.  This pattern was recapitulated at the protein level (all photographs taken 
at same exposure) (Figure 6.15 (B)).  Interestingly all 3 clonal lines also expressed 
Jagged1, suggesting signalling may be activated in these cells through autocrine 
provision of ligand.   




Figure 6.16  Notch is expressed by human ICC cells   
 




Figure 6.16  Notch is expressed by human ICC cells  (A)  rt-qPCR of Notch receptor 
transcription in human ICC lines CC-SW-1, CC-LP-1 and SNU-1079 (two way 
ANOVA p=<0.0001)  (B)  Immunocytochemistry for Notch 1, 2, 3, 4 and Jagged1 in 
the ICC lines CC-SW-1, CC-LP-1 and SNU-1079 with isotype controls.  All 
photomicrographs were taken at the same exposure.  Scalebars represent 50µm.  
 
To determine an appropriate cell number for use in an assay of cell viability using 
the NADPH-dependent tetrazolium dye MTT, I plated cells at increasing densities 
in 96 well plates and cultured them for 48 hours before adding MTT and reading on 
a spectrophotometer.  An absorbance of 1.0 was deemed to be an appropriate 
baseline for assessment of changes in viability, and therefore the following cell 
densities were subsequently used for all in vitro viability assays: SNU-1079 3x103 
cells/well; CC-LP-1 1.4x104 cells/well; CC-SW-1 1.75x104 cells/well (Figure 6.17).  Cell 
lines were then cultured in the presence of increasing concentrations of the γ-
secretase inhibitor DAPT (3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl 
ester) or DMSO and viability measured after 48 hours.  Cells were plated in 
triplicate and the experiment repeated three times.  Cell viability decreases in a 
concentration dependent manner: at 50µM DAPT viability of the cell line SNU-1079 
is reduced by 66.6%; CC-SW-1 by 42.6% and CC-LP-1 by 39.6% (Figure 6.17).  To 
ensure treatment with DAPT had resulted in a reduction in Notch activity I 
measured Hes/Hey transcription in the 3 cell lines in response to 10µM DAPT.  I 
observed a non-significant trend to reduction in transcription of Hes1, Hey1 and 
HeyL in SNU-1079 (Hes1 39.12% p=0.1; Hey1 17.62% p=0.4; HeyL 31.99% p=0.4); 
Hey1, Hey2 and HeyL in CC-LP-1 (Hey1 59.14% p=0.1; Hey2 54.74% p=0.1; HeyL 
43.20% p=0.1) and Hes1 and Hey2 in CC-SW-1 (29.28% p=0.1; Hey2 51.66% p=0.1) 
(Figure 6.17). 




Figure 6.17  The γ-secretase inhibitor DAPT reduces cell viability in vitro    




Figure 6.17  The γ-secretase inhibitor DAPT reduces cell viability in vitro   (A)  
Determination of cell number for use in the MTT viability assay (using an 
absorbance of 1.0).  (B)  Concentration dependent reduction in cell viability in 
response to culture in 0 to 50µM DAPT.  Data are represented as means ±S.E.M from 
3 independent experiments.  At 50µM DAPT cell viability was reduced in SNU-1079 
by 66.6% (1.04 ±0.14 in control group; 0.33 ±0.04 in DAPT group), CC-SW-1 by 38.6% 
(1.02 ±0.08 in control group; 0.61 ± 0.08 in DAPT group) and CC-LP-1 by 42.6% (0.82 
±0.12 in control group; 0.57 ±0.09 in DAPT group).  (C)  rt-qPCR analysis of Hes/Hey 
gene transcription in ICC cells treated with 10µM DAPT.  A non-significant trend to 
reduction was observed in transcription of Hes1, Hey1 and HeyL in SNU-1079 
(Hes1 39.12% p=0.1; Hey1 17.62% p=0.4; HeyL 31.99% p=0.4); Hey1, Hey2 and HeyL 
in CC-LP-1 (Hey1 59.14% p=0.1; Hey2 54.74% p=0.1; HeyL 43.20% p=0.1) and Hes1 
and Hey2 in CC-SW-1 (29.28% p=0.1; Hey2 51.66% p=0.1).  
 




Tumour sphere culture is recognised to offer a more realistic representation of the 3-
dimensional growth and organisation of in vivo tumours compared to traditional 
monolayer culture of cancer cell lines (235).  The cell line CC-LP-1 was cultured on 
low adhesion plates in the presence of the same supplemented media used for 
culture in monolayer (see materials & methods).  Tumour spheres were observed to 
form after 6 hours of culture and could be maintained and passaged (following cell 
dissociation) indefinitely.  I found that the addition of the γ-secretase inhibitor 
DAPT to the culture media at the time of plating resulted in a significant reduction 
in the number of spheres (≥50µm diameter) formed after 48 hours of culture 
compared with DMSO control (Figure 6.18).   
 
Figure 6.18  The γ-secretase inhibitor DAPT reduces in vitro tumour sphere formation.   
 
Figure 6.18 The γ-secretase inhibitor DAPT reduces in vitro tumour sphere formation.  The 
addition of DAPT reduced the formation of tumour spheres after 48 hours of culture 
by 47.6% at 10µM DAPT (98 ±12 spheres/well with DMSO; 51 ±2 spheres/well with 
10µM DAPT; one way ANOVA p=0.0238).  Data are represented as means ±S.E.M.  
A significant difference between groups was demonstrated with the one-way 
analysis of variance test (n=3; p=0.0238).  Scalebars represent 10µm.   
 




DAPT enhances chemosensitivity of ICC cells in vitro 
To examine whether Notch inhibition sensitises ICC cells to the cytotoxic effects of 
chemotherapeutic drugs, I cultured the 3 ICC cell lines in the presence of increasing 
concentrations of one of three chemotherapeutic agents: 5-fluorouracil, gemcitabine 
or cisplatin, either alone or in combination with 50µM DAPT.  Cell viability was 
assessed after 72 hours of culture using MTT (Figure 6.19). I normalised data to the 
mean absorbance of no drug control wells and performed non-linear regression 
analyses on dose response curves of chemotherapy and chemotherapy in 
combination with DAPT.  I then compared the differences in IC50 values using the 
Mann-Whitney U test.  I observed a significant reduction in IC50 between 5-FU and 
5-FU in combination with DAPT in the ICC cell line SNU-1079 (i.e. a 
chemosensitisation) (IC50 5-FU alone 101.9µM ±31.3; IC50 5-FU + DAPT 15.6µM ±1.5) 
(p=0.012).  SNU-1079 also exhibited a trend to reduction in IC50 in response to the 
addition of DAPT with cisplatin but this was non-significant (IC50 Cisplatin alone 
6.94µM ±4.98; IC50 Cisplatin + DAPT 0.67 ±0.52) (p=0.114), as did the cell line CC-
SW-1 (IC50 Cisplatin alone 1.96µM ±0.54; IC50 Cisplatin + DAPT 0.32µM ±0.11) 
(p=0.10) (Figure 6.18).  No chemosensitisation to gemcitabine was exhibited by any 
cell line in response to DAPT.   




Figure 6.19  The γ-secretase inhibitor DAPT sensitises the ICC cell line SNU-1079 to treatment with 5-Fluorouracil. 
 




Figure 6.19  The γ-secretase inhibitor DAPT sensitises the ICC cell line SNU-1079 to 
treatment with 5-Fluorouracil. The ICC line SNU-1079 exhibited a significant reduction 
in IC50 in response to DAPT treatment in combination with 5-FU (IC50 5-FU 101.9µM 
±31.3; IC50 5-FU + DAPT 15.6µM ±1.5 (p=0.012).  SNU-1079 also exhibited a non-
significant trend to reduction in IC50 (i.e. a chemosensitisation) in response to the 
addition of DAPT with cisplatin (IC50 Cisplatin alone 6.94µM ±4.98; IC50 Cisplatin + 
DAPT 0.67 ±0.52) (p=0.114), as did the cell line CC-SW-1 (IC50 Cisplatin alone 
1.96µM ±0.54; IC50 Cisplatin + DAPT 0.32µM ±0.11) (p=0.10) (Figure 6.16).  No 
chemosensitisation to gemcitabine was exhibited by any ICC line in response to 
Notch inhibition with DAPT.  IC50s are represented as means ±S.E.M. 
 
DAPT reduces tumour growth in a xenograft model of ICC 
To determine whether γ-secretase inhibitors have potential to restrict the 
progression of ICC in vivo, I established a xenograft model in which CC-LP-1 cells 
(were subcutaneously injected bilaterally into the flanks of immunocompromised 
mice and tumours allowed to engraft over a 28 day period.  At 28 days all mice had 
palpable tumours bilaterally.  Animals were then treated systemically with 40mg/kg 
DAPT i.p. or olive oil vehicle control 3 times a week for 3 weeks (Figure 6.20 (A)).  
Tumour mass was reduced by 47.7% in response to DAPT treatment (mean mass 
115.96 ±10.6 mg vehicle group; 60.7 ±8.5 mg DAPT group), and tumour volume by 
72.0% (mean volume 230.7±40.3 mm3 vehicle group; 64.6 ±15.6 mm3 DAPT group) 
(Figure 6.20 (B-C)).  This reduction was associated with a non- significant trend to 
reduction in expression of the Notch target genes HES1, HEY1 and HEYL (fold 
change HES1 0.60 ±0.18 p=0.29; HEY1 0.87 ±0.22 p=0.56; HEYL 0.70 ±0.24 p=0.29) as 
well as genes involved in regulation of cell cycle; CYCLIN D1, CYCLIN D2 and 
CYCLIN E (fold change CYCLIN D1 0.66 ±0.25 p=0.41; CYCLIN D2 0.46 ±0.12 
p=0.19; CYCLIN E  0.64 ±0.20 p=0.56) (Figure 6.20(D-E)). 




Figure 6.20 The γ-secretase inhibitor DAPT reduces tumour growth in a xenograft model 
of ICC.   
 
Figure 6.20  The γ-secretase inhibitor DAPT reduces tumour growth in a xenograft model of 
ICC.  (A) Experimental schematic of xenograft model and treatment regime with 
DAPT.  (B) Tumour mass is reduced by 47.7% in response to 40mg/kg DAPT (mean 
mass 115.96 ±10.6 mg vehicle group; 60.7 ±8.5 mg DAPT group).  (C) Tumour 
volume is reduced by 72.0% in response to DAPT (mean volume 230.7±40.3 mm3 
vehicle group; 64.6 ±15.6 mm3 DAPT group).  (D) A non-significant trend to 
reduction in expression of Notch target genes HES1, HEY1 and HEYL was observed 
in response to DAPT.  (E) A non-significant trend to reduction in expression of the 
cell cycle regulators CYCLIN D1, CYCLIN D2 and CYCLIN E was observed in 
response to DAPT treatment (fold change CYCLIN D1 0.66 ±0.25 p=0.41; CYCLIN 
D2 0.46 ±0.12 p=0.19; CYCLIN E  0.64 ±0.20 p=0.56).  In both groups n=5 and all data 
were analysed using the Mann-Whitney U test.  Data are represented as means 
±S.E.M; *p≤0.05; **p≤0.01.    
 




To determine whether this observed effect was a direct result on epithelial cell 
proliferation or rather secondary to an inhibition in neoangiogenesis, I performed 
immunohistochemistry for the endothelial marker CD31+ on frozen sections from 
DAPT and vehicle treated xenografts.  The ratio of mean rodamine to dapi pixels 
was quantified for the total area of each xenograft section using Adobe Photoshop.    
The mean ratio of rodamine to dapi pixels in DAPT treated tumours was 0.047 
±0.023 compared to 0.109 ±0.088 in vehicle treated i.e. there was no significant 
difference between the groups.   




Figure 6.21  DAPT does not inhibit tumour growth through a reduction in 
neoangiogenesis.   
 
Figure 6.21  DAPT does not inhibit tumour growth through a reduction in neoangiogenesis.  
Representative immunofluorescent staining and quantification with pixel analysis 
showing no difference in expression of the endothelial marker CD31+ in human ICC 
xenografts treated with 40mg/kg DAPT or olive oil control.  The mean ratio of 
rodamine (CD31+) to dapi pixels in DAPT treated tumours was 0.047 ±0.023 
compared to 0.109 ±0.088 in vehicle treated.  Data are represented as means ±S.E.M 
normalised to vehicle and the difference between groups was analysed using the 
Mann-Whitney U test.   
 
DAPT reduces tumour growth in a chemically induced model of ICC in rat 
To investigate how γ-secretase inhibition might affect in situ tumour growth in an in 
vivo model of ICC, I used the TAA model in rat.  Sprague-Dawley rats were 
administered 0.06% TAA for a 26 week period with 10mg/kg DAPT (n=8) or olive oil 
control (n=10) i.p. 3 times a week between weeks 21 and 26.  Tumours are 
reproducibly observed in 100% of animals by 20 weeks of TAA administration and 
therefore this experiment aimed to establish whether inhibition of the Notch 
pathway using γ-secretase inhibition would restrict the progression of an already 




established tumour.  Sera were taken from rats at the time of sacrifice to determine 
whether TAA induced injury was equivalent between the two groups (Figure 6.22). 
 




Figure 6.22 Serum biochemical markers of liver function are equivalent in rats treated with TAA and DAPT vs. TAA and vehicle.   
 
Figure 6.22 Serum biochemical markers of liver function are equivalent in rats treated with TAA and DAPT vs. TAA and vehicle.  There is no difference 
in biochemical liver function tests between rats treated with TAA and DAPT and rats treated with TAA and vehicle.  Data are represented 
as means ±S.E.M and analysed using the Mann-Whitney U test.   




Figure 6.23 The γ-secretase inhibitor DAPT significantly reduces tumour growth in a TAA model of ICC.   




Figure 6.23 The γ-secretase inhibitor DAPT significantly reduces tumour growth in a TAA 
model of ICC.  (A) 10mg/kg DAPT or vehicle was administered to rats undergoing 26 
weeks of injury with 0.06% TAA (n=10 Vehicle group; n=8 DAPT group).  (B)  
Representative photographs of rat livers from animals treated with TAA and 
Vehicle and animals treated with TAA and DAPT.  (C)  Tiled low-power 
photomicrographs of representative sections of livers from rats treated with TAA + 
vehicle or TAA + DAPT.  Dashed white line represents tumour boundary.  Scalebar 
represents 10mm.  (D)  There is a 78.2% reduction in % tumour area in response to 
treatment with DAPT p=0.0148 (mean % tumour area in TAA + Vehicle group 7.66% 
±1.8; TAA + DAPT group 1.67% ±0.5).  There is a no difference in the mean number 
of tumours per liver in response to treatment with DAPT (21 ±6 in TAA + Vehicle 
group; 12 ±3 in TAA + DAPT group).  Data are represented as means ±S.E.M and 
passed the D’Agostino & Pearson omnibus test of normality of distribution.  
Differences between means were analysed using a two-tailed t test.   





During the course of this study two publications have described the capacity of 
transgenically activated Notch1 to induce development of biliary tumours in 
albumin-expressing cells (92, 230).  In this thesis I aimed to characterise the activity 
of endogenous wild type Notch in ICC in human disease and rodent models in 
which Notch has not been genetically altered.  These data demonstrate that in 
human disease, a chemically-induced model in rat and a transgenic murine model, 
the Notch pathway is indeed up-regulated in ICC.  In particular I have observed 
specifically that transcription of the Notch3 receptor is induced most strongly in all 
three species and have demonstrated functionality through this receptor as 
evidenced by western blotting for its intracellular domain (Figure 6.8) and nuclear 
positivity within malignant epithelia with immunohistochemistry (Figure 6.7).  
Whilst Notch1 is very lowly expressed in the healthy adult liver, strong Notch3 
positivity is consistently observed on the vascular smooth muscle, making the 
magnitude of the observed up-regulation of Notch3 transcription in cancer more 
remarkable.  Immunostaining for Notch1 reveals weak positivity when compared 
with isotype control, but little difference in expression between healthy liver and 
cancer (Figure 6.6).   
The TAA model of ICC in rat has enabled me to observe Notch activity during 
disease progression from healthy liver to inflammation, fibrosis and finally 
malignancy and I see that up-regulation of pathway transcription is a late event; 
occurring after initiation, during the process of tumour expansion.  In both human 
disease and rodent models, Jagged1 ligand appears to be provided by the 
surrounding desmoplastic stroma with little epithelial expression; whereas Notch3 
is observed both on myofibroblasts and malignant ductules (Figure 6.7).  Further 
analyses using laser-capture microdissection of the epithelial and stromal 
compartments of tumours would be informative to confirm with a second technique 
that Jagged expression is confined to the desmoplastic stroma compared to Notch3 
which appears to be up-regulated by both cancerous epithelia and myofibroblasts.  




Quantification of stromal reaction in these animals would also clarify whether 
activity through this axis correlates to myofibroblast intensity.     
The CK19YFPp53 + TAA murine model has enabled me to examine the differences 
in Notch expression between cancer and chronically injured liver.  Up-regulation of 
Notch1 and more strikingly Notch3 occurs in CK19YFPp53flox/flox mice with and 
without ICC formation, with levels higher in animals with tumours (Figure 6.13).  
This finding is in contrast to reports in the literature where Notch2 is described as 
the dominant paralog in driving biliary differentiation of hepatoblasts during 
development and HPCs during biliary regeneration in the adult (135, 169).  
Furthermore there does appear to be activity through the canonical Notch pathway 
in this model, as a significant increase in transcription of the target effector Hey2 is 
also observed in mice with ICC.   
Activity through the Notch signalling pathway is dependent on the generation of N-
ICD; that is cleavage of the intracellular fragment of the receptor to translocate to 
the nucleus and drive transcription.  This cleavage event and hence pathway 
functionality is mediated by the protease complex γ-secretase: introduction of a 
single point mutation into Notch1 at the γ-secretase cleavage site leads to total loss 
of Notch signal and embryonic lethality (236).  Due to the role of γ-secretase in the 
generation of Aβ peptide associated with Alzheimer’s disease, a number of 
pharmacological agents have been developed that inhibit this interaction, blocking 
activity via all four receptors (237).  Despite little success in clinical trials for 
Alzheimer’s disease, many of these compounds have been tested for their anti-
tumour efficacy; for example dibenzazepine (DBZ) has been shown to reduce 
epithelial proliferation and induce goblet cell transdifferentiation in the Apc(min) 
model of intestinal tumorigenesis (238).  In the above experiments I aimed to 
establish whether pharmacological inhibition of γ-secretase with DAPT would 
reduce tumour cell growth of ICC in vitro and in vivo.   




The anatomical complexity of resected BTC in man and vital importance of 
establishing the presence or absence of tumour at resection margins means that ICC 
specimens must be intact at the time of post-operative pathological examination.  
Furthermore at the time of pathological staging the clinical specimen is fixed in 
formalin and these issues have made it difficult to obtain fresh tissue for primary 
cell culture of human ICC in our department.  It has therefore been necessary to use 
ICC cell lines in this work and I have selected three that have been derived from 
typical examples of moderately differentiated biliary adenocarcinoma  with 
published characterisation of their cytogenetic and mutational profiles (239, 240).   
All three lines exhibited modest but dose-dependent reductions in viability in 
response to DAPT treatment (Figure 6.16).  The non-significant trend to reduction in 
Hes/Hey gene transcription observed in these cells following treatment with a high 
dose (10µM) of DAPT suggests that these in vitro cell lines are not sensitive to the 
effects of GSIs.  Although I have demonstrated presence of the Jagged1 protein on 
these cells with the implication of an autonomous signalling loop, it is possible that 
in the absence of an excess of ligand, these cells may not respond maximally to these 
agents.  I therefore went on to test the effects of GSIs in vivo, where provision of 
ligand from surrounding stromal cells would be more abundant.  Variation in the 
responsiveness of ICC lines to DAPT may also conceivably due to differences in 
gamma secretase activity at the membrane.  Assays developed to quantitate this 
have so far principally relied on N-ICD generation, making it challenging to 
discriminate between gamma-secretase activity and Notch responsiveness. 
My results similarly suggest that Notch inhibition reduces the sphere forming 
capacity of ICC cells.  These data should be interpreted with caution however.  Very 
few studies have been previously undertaken using tumour sphere culture as a 
model of cell behaviour in ICC, and hence little is known about the markers that 
define the sphere-forming population and how these might relate to self-renewal 
capacity.  Furthermore the potential to form spheres is frequently used as a marker 
of a chemoresistant population in many cancer types and this hypothesis has not 




been tested in ICC.  Ideally it would be informative to perform an unbiased gene 
expression analysis on the sphere forming population of these cells to determine 
whether they represent a subpopulation enriched for markers of stemness or 
chemoresistance as a response to cell adhesion, along with experiments to test 
tumorigenicity in vivo.  It must be considered that despite performing experiments 
at a low passage number, these cells do represent an immortalised cell line and are 
not primary cells newly derived from a patient.   
In light of these sphere data, I decided to evaluate the potential for the γ-secretase 
inhibitor DAPT to sensitise ICC cells to chemotherapeutic agents in vitro.  A 
significant chemosensitisation to 5-FU was observed in response to treatment with 
DAPT by the ICC line SNU-1079, although this was not replicated across the other 
lines or with other chemotherapies (a non-significant trend to sensitisation was 
exhibited by all three lines to cisplatin).  All three cell lines tested were relatively 
chemoresistant; requiring micromolar (and in the case of 5-FU millimolar) 
concentrations for maximal response.   
These in vitro data were used however to inform subsequent in vivo experiments as 
discussed above.  In comparison to orthotopic cell transplantation, xenograft models 
of cancer are limited by differences in the subcutaneous microenvironment, an 
altered immune response to tumorigenesis (due to the immunocompromised host), 
and differences arising due to species mismatch (232).  They do however offer 
advantages over other models; in particular a rapid and effective platform for 
testing therapeutic response to drugs (genetically engineered murine models of 
cancer frequently have long tumour latencies).  In response to systemic treatment 
with DAPT a significant reduction in the mass and volume of xenografted ICC was 
observed.   
Gamma secretase is a high molecular weight multiprotein complex which cleaves 
not only Notch, but a number of other proteins including E-cadherin, CD44+ and 
erbB-4 which are known modulators of new blood vessel formation (241).  This is 




likely to explain the non-significant reduction in Hes/Hey expression in DAPT-
treated xenografts and it is likely that GSIs are reducing tumour size through 
blockade of other signalling pathways in addition to Notch.  Mice lacking 
components of the γ-secretase complex including presenilin1 exhibit abnormal 
blood vessel development (242).  I therefore sought to determine whether the 
observed reduction in tumour growth was a direct consequence of a change in 
cancer cell proliferation, apoptosis or death, or secondary to an inhibition of 
neoangiogenesis: no difference in CD31+ positivity was observed between the two 
groups.   
These xenograft experiments provided evidence that a longer, more expensive 
protocol to investigate the anti-tumour potential of GSIs to inhibit the development 
of ICC in the TAA rat model was worthwhile.  A striking difference was seen in the 
macroscopic appearance of livers in rats following treatment with TAA and DAPT 
compared to rats treated with TAA and vehicle (Figure 6.22).  Given the known role 
of Notch in progenitor mediated biliary regeneration after chronic injury, it would 
be anticipated that the observed reduction in macroscopic nodules is due to an 
attenuation of the regenerating parenchyma in addition to inhibition of tumour 
growth.  This said, I observed no difference in serum biochemical markers of liver 
function, although these have poor correlation with tumour stage and therefore are 
difficult to interpret in this context.  The observed 78% reduction in % tumour area 
in response to DAPT treatment suggests that γ-secretase inhibitors might offer a 
potential therapeutic role in the treatment of advanced ICC.  No difference was 
observed in the number of tumours per liver, suggesting that Notch signalling plays 
a more prominent role in the promotion of tumour expansion and progression 
rather than its initiating molecular events.   
It is important to recognise that despite the similarities in histological appearance 
and backgrounds of chronic liver disease, it is as yet uncertain as to whether the 
genetic alterations of TAA-induced ICC in the rat are truly representative of human 
disease.  I have however demonstrated that the observed changes in Notch 




signalling in this model do closely mimic those seen in human tumours. Further 
work is necessary to elucidate the mechanism of Notch up-regulation in ICC. 
Since the commencement of this work, two publications have described anti-
tumoural effects of GSIs in similar in vitro systems and human xenograft models of 
ICC (230, 243).  These add further weight to the observations made here.  Notch is 
however only one of a number of substrates for the γ-secretase complex which 
include amyloid precursor protein, CD44+, E-cadherin and N-cadherin (244).  This 
may contribute to the significant side effects that have been reported with these 
inhibitors (245).  In particular cytotoxicity in the intestinal tract and 
transdifferentiation of enterocytes to a secretory, goblet cell phenotype secondary to 
loss of crypt-derived Notch, has led to scepticism about their clinical application 
(246).  Despite this, combination of GSIs with glucocorticoids in T cell acute 
lymphoblastic leukaemia has not only reduced gut toxicity but also improved anti-
tumoral efficacy (247).  Phase I clinical trials in many other cancer types have now 
reported (248-251) and phase II studies are now well underway in tumours 
including melanoma, glioblastoma, non-small cell lung cancer, renal cell carcinoma 
and ovarian cancer 
(http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=8608408). In 
light of the lack of available therapeutic agents offering superior specificity profiles 
to GSIs, at the current time it is likely that this strategy holds the most translational 
potential for anti-Notch therapies in ICC.  
The next key step in evaluating the utility of GSIs for down-staging ICC to increase 
the proportion of patients with surgically resectable disease will be to evaluate their 
in vivo efficacy both as a single agent in reducing tumour size, but also in sensitising 
tumours to existing chemotherapies.  The CK19CreYFPp53f/f +TAA model in mouse 
and TAA model in rat would be ideal platforms for these pre-clinical studies.  If the 
Notch positive population of cells within the tumour do represent a more naïve, 
stem-like phenotype, it may be that treating tumours with GSIs might eliminate this 
more chemoresistant population, thus sensitising tumours to conventional 




therapies.  Currently the mechanism or mechanisms through which Notch might 
drive chemoresistance (e.g. enhance drug efflux, defective apoptotic pathways, 
increased ability for DNA repair) are unknown and in fact given the mixed response 
of these three human ICC cell lines to GSI treatment, these in vivo animal studies are 
vital to establish whether GSIs can indeed chemosensitise tumours growing in situ.   




Chapter 7:  Investigating Notch3 as a non-redundant driver of ICC 
Introduction 
Given the up-regulation of Notch3 observed across three species in ICC (human, rat, 
mouse) using different modalities of cancer induction, I next sought to investigate 
whether Notch3 might represent a non-redundant driver of tumorigenesis.      
Notch3 exhibits a number of structural differences to Notch1 and 2 in all three of its 
domains.  In the extracellular region, Notch3 lacks EGF-like repeat 21 as well as a 
region corresponding to part of EGF-like repeats 2 and 3 in Notch1 and 2 (100) .  
Both the transmembrane domain (TMD) and RBPJκ-associated domain (RAM) have 
a much lower amino acid identity to Notch1 than that between Notch1 and 2 (99, 
252).  Most significantly Notch3 displays a significantly shorter region within the 
transactivation domain (TAD), which has been hypothesised to explain the weaker 
transactivational activity exhibited by N3-ICD compared to N1-ICD or N2-ICD (99). 
The tissue distribution of Notch3 is more restricted than that of Notch1 or 2; 
expression being strong in arterial smooth muscle, the CNS, thymocytes and T-
regulatory cells (100, 253-255).  Arguably for this reason Notch3 null mutant mice 
are embryologically viable (unlike Notch1 knock outs), but do display structural 
arterial defects and altered arterial myogenic responses (256, 257).  Interestingly 
embryos carrying double homozygous target mutations for both Notch1 and Notch3 
exhibit defects ordinarily observed in Notch1-deficient embryos, but no synergistic 
effects compared to Notch1 only mutants suggesting Notch3 does not have a 
redundant function with Notch1 during embryogenesis (257). 
Spontaneous activating mutations of Notch3 results in CADASIL (cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy); a late onset clinical syndrome of stroke and dementia 
characterised by recurrent subcortical ischaemic events (258).  Here mutation results 
in an odd number of cysteine residues within the Notch3-ECD and accumulation of 




ECD at the cell membrane leading to a lack of cerebrovascular reactivity (259, 260).  
Targeted transgenic overexpression of Notch3 in the developing lung results in a 
disruption of morphology with failure of type II pneumocyte differentiation and 
maturation (261).   
Notch3 has been studied as a non-redundant driver of tumorigenesis in other cancer 
types.  Overexpression of Notch3 has been observed in colorectal (262), ovarian 
(263, 264), cervical cancer (265), acute T-cell lymphoblastic leukaemia(266) and 
NSCLC (184) and mice carrying a thymocyte-specific activation of Notch3 exhibit 
increased number of thymocytes, particularly late CD4-CD8- cells and develop an 
aggressive multicentric T cell lymphoma (181).  Suppression of cancer cell growth in 
response to γ-secretase inhibition and specific Notch3 blockade have both been 
described in NSCLC, and indeed in the lung cancer cell line HCC2429 (which 
expresses both the Notch1 and Notch3 receptors), deletion of Notch3 by siRNA 
abrogates the response to GSI treatment, suggesting that Notch3 but not Notch1 
contributes to tumorigenesis (184, 267).  More recently data also suggest Notch3 
may play a particular role in cancer stem cell self-renewal (CSCs).  Specific Notch3 
inhibition with shRNA results in a decrease of aldehyde dehydrogenase positive 
lung CSCs (268) and NSCLC cell populations enriched for the three markers CD24+, 
ITGB4 and Notch3 appear to represent a rare population capable of serial 
transplantation and resistance to chemotherapy (191).  Furthermore enforced 
expression of N3-ICD in the T cell lineage is a potent inducer of T-cell lymphoma 
(181).   
 




Notch3 drives cell survival and clonogenicity  
To determine whether a unique role exists for Notch3 in driving cell survival in ICC, 
I took advantage of a spread of Notch3 positivity I had observed on flow cytometric 
analysis of the human ICC line CC-LP-1.  Approximately 5% of the total cell 
population analysed stain positively for Notch3 compared to isotype control and 
therefore cells were gated at the upper and lower 5% limits of positivity and FACS 
sorted to establish whether these populations exhibited differences in phenotype or 
behaviour.  Notch3 high, low and total CC-LP-1 populations were compared (Figure 
7.2A).  Although I observed no difference in cell cycle between the three populations 
after analysis with DAPT at the time of sorting (Figure 7.2B), after 48 hours in 
culture Notch3 high cells exhibited a mean absorbance 2.7 times greater than Notch3 
low cells by MTT (Notch3 high population 1.00 ±0.01; Notch3 low population 0.37 
±0.01  p=0.002; n=3), and after 3 weeks in culture, a 57.1% increase in colony forming 
efficiency; although this did not reach significance (Notch3 high population mean 
colony forming efficiency 30.00% ±0.94; Notch3 low population 9.33% ±1.44 n=3; 
p=0.10) (Figure 7.2C-D).  




Figure 7.2  Notch3 expressing ICC cells exhibit greater viability and clonogenicity.   
 




Figure 7.2  Notch3 expressing ICC cells exhibit greater viability and clonogenicity.  (A) The 
ICC line CC-LP-1 was stained for Notch3 or isotype control and analysed with flow 
cytometry.  (B)  No difference in cell cycle was observed between Notch3 high, low 
or total CC-LP-1 populations.  (C)  The Notch3 high population exhibited 63.45% 
greater viability than the low population following 48 hours in culture (MTT) 
(p=0.0022) (n=3).  (D)  The Notch3 high population exhibited a 68.89% better 
efficiency for forming colonies when plated at clonal density compared to the 
Notch3 low population although this was not statistically significant (p=0.1000).  
Data are represented as means ±S.E.M and differences analysed using the Mann-
Whitney U test.  * p≤0.05; ** p≤0.01; ***p≤0.001.   




The stability of the Notch3 protein is regulated by a balance of acetylation and 
deacetylation at the 1692Lys and 1731Lysresidues in the RAM domain of the protein.  
Acetylation at this site reduces protein stability through ubiquitination, targeting its 
degradation by the proteosome and reducing N3-ICD mediated transcription (182).  
This balance is mediated by histone acetyltransferases (HAT) and histone 
deacetylases (HDAC) and as a consequence Notch3 stability can be disrupted by the 
use of histone deacetylase inhibitors (HDACi) including an inhibitor of HDAC1, 
Trichostatin A (TSA).  TSA induces acetylation and proteosomal degradation of 
Notch3 in N3IC transgenic mice, thus inhibiting the development and progression of 
T-ALL ordinarily exhibited by these animals (182).  Furthermore it has been shown 
that this compound does not alter signalling through the Notch1, 2 or 4 receptors 
and therefore I selected this small molecule as a second, corroborative approach to 
study the effects of selective Notch3 inhibition of the malignant phenotype of ICC in 
vitro.   
I first established that signalling via N3-ICD was inhibited by Trichostatin A in this 
system by plating the ICC cell line CC-LP-1 in the presence of 500nM TSA or vehicle 
for 48 hours before performing western blotting for total Notch3 and N3-ICD 
(Figure 7.3(A)).  Signal from N3-ICD was significantly reduced following treatment 
even with this low dose of TSA.  I then went on to plate cells in increasing 
concentrations of TSA (0 to 10µM) and assessed viability with MTT.  I observed a 
dose-dependent reduction in viability in all 3 ICC lines tested (Figure 7.3(B)); 
strongly suggesting Notch3 may itself be an independent driver of cell survival in 
ICC.  The shape of the dose response curve suggests however that the effects of TSA 
on cell survival rapidly saturated in all three cell lines above a concentration of 1µM.   
On this basis I went on to test the effects of TSA in vivo in the xenograft model of 
ICC.  Tumours were established subcutaneously using the ICC cell line CC-LP-1 in 
immunocompromised mice as previously described.  Mice were then treated 
systemically with 1mg/kg TSA or vehicle daily for 14 days.  Tumour mass was 
reduced by 38.8% in TSA treated mice (Vehicle mean mass 138.83mg ±9.03 (n=12); 




TSA mean mass 84.90 ±13.49 (n=10); p=0.004) (Figure 7.3 (C)).  Tumour volume was 
reduced by 33.7% in TSA treated mice (Vehicle mean volume 169.56mm3 ±15.17 
(n=12); TSA mean volume 112.50mm3 ±17.36 (n=10) p=0.0296 (Figure 7.3(D)).   
 




Figure 7.3  The HDAC1 inhibitor Trichostatin A (TSA) disrupts N3-ICD mediated signalling 
in ICC and reduces tumour growth in vitro and in vivo.   
 
Figure 7.3  The HDAC1 inhibitor Trichostatin A (TSA) disrupts N3-ICD mediated signalling in 
ICC and reduces tumour growth in vitro and in vivo.  (A) A reduction in expression of 
both total Notch3 and N3-ICD protein is observed on western blotting in the ICC 
line CC-LP-1 following 48 hours of treatment with 500nM TSA.  GAPDH is used as 
a loading control.  (B) A dose-dependent reduction in cell viability (MTT 
absorbance) is observed following 72 hours of treatment with TSA or vehicle in 3 
ICC cell lines (CC-LP-1; SNU-1079; CC-SW-1).  (C) A 38.8% reduction in tumour 
mass was observed following 14 days systemic treatment with 1mg/kg TSA 
(p=0.004) (Vehicle group n=12; TSA group n=9).  (D)  A 33.7% reduction in tumour 
volume was observed following 14 days systemic treatment with 1mg/kg TSA 
(p=0.0296) (Vehicle group n=12; TSA group n=9.  Data are represented as means 
±S.E.M.  * p≤0.05; ** p≤0.01; ***p≤0.001.   
 




Stable Notch3 silencing:  Notch3 shRNA in vitro and in vivo 
HDAC inhibitors bind a large number of substrates in addition to Notch3; in 
particular core histone proteins instrumental to the regulation of chromatin 
topology and hence gene transcription (269).  I therefore sought a more targeted 
strategy to specifically and permanently silence Notch3 in vitro using shRNA.  Three 
commercially available plasmids were obtained containing individual NOTCH3 (or 
scrambled control) shRNA sequences and puromycin resistance cassettes for stable 
selection and generation of cell lines with stable gene silencing (see Materials & 
Methods Figure 2.2).  Briefly, E.coli were transformed with pDNA and colonies 
grown under ampicillin selection.  Minipreparations were made for each shRNA 
sequence and plasmid DNA isolated with a yield of 0.5 to 2.5µg pDNA.  To ensure 
purified plasmids contained the shRNA inset, a Pst1 restriction digestion was 
performed (Figure 7.4(A)).  The ICC cell line CC-LP-1 was transfected with 0.5µg 
pDNA and grown under stable selection with puromycin until colonies appeared.  
These were picked, transferred to new culture plates for culture before rt-qPCR and 
western blotting performed to ensure silencing of NOTCH3 had occurred (Figure 
7.4(B-C)).   
 




Figure 7.4  Generation of a stably silenced NOTCH3 ICC cell line using shRNA. 
 
Figure 7.4  Generation of a stably silenced NOTCH3 ICC cell line using shRNA.  (A) Pst-1 
restriction digestion of isolated pDNA showing DNA fragments at 3209 and 1402bp.  
(Lane 1: 100kb ladder; Lane 2: N3_2 (Clone1); Lane 3: N3_3 (Clone2); Lane 4: N3_4 
(Clone3); Lane 5: N3_OE (Note there is no uncut control on this gel)).  (B) rt-PCR 
analysis of NOTCH3 in CC-LP-1 clones transfected with pDNA containing 
NOTCH3 shRNA insert.  (C) Western blot analysis of NOTCH3 expression in CC-
LP-1 clones transfected with pDNA containing NOTCH3 shRNA insert.  Clone 1 
was selected for use in further studies.    
 
I firstly assessed the effect of Notch3 gene silencing on cell growth in vitro.  
Untransfected, scrambled control and N3 knock down (KD) cells were plated in 
standard conditions in 96 well plates and viability assessed after 48 hours.  I 
observed a modest and non-significant reduction in viability (19.4%) was observed 
as measured by MTT assay (n=3; p=0.07) (Figure 7.5 (A)).  In spite of this, I went on 
to evaluate whether silencing of Notch3 would have any effect of cell growth in vivo 
using the xenograft model of ICC.  Notch3 KD or scrambled control cells were 
subcutaneously injected into the flanks of immunocompromised mice as previously 
described.  Tumours were allowed to establish over 28 days at which time mice 
were culled and tumour mass and volume assessed.  Tumours from Notch3 KD 
cells exhibited 76% less mass than scrambled controls (N3 KD: 138.12mg ±35.04 
(n=10); Scrambled: 33.03mg ±8.23 (n=6)) and were 78% smaller in volume (N3 KD: 
187.63mm3 ±39.32; Scrambled: 40.54 ±9.83).  To strengthen the likelihood that this 




observed reduction was a consequence of loss of Notch activity, I performed rt-
qPCR analysis for Hes/Hey Notch target gene transcription on the harvested 
tumours.  A non-significant trend to reduction was observed in transcription of 
Hey1, Hey2 and HeyL (Hey1 fold change 0.936 p=0.1775; Hey2 0.869 p=0.0667; HeyL 
fold change 0.701 p=0.1775) and a significant reduction in Hes 4 (p=0.03) (Figure 7.5 
(E)). 
 




Figure 7.5  Stable silencing of NOTCH3 with shRNA reduces tumour growth in vivo. 
 
Figure 7.5  Stable silencing of NOTCH3 with shRNA reduces tumour growth in vivo.  (A) A 
non-significant reduction in cell viability (MTT assay)  was observed following re-
plating and 48 hours of culture of Notch3 KD cells compared to scrambled controls 
(n=3; p=0.07).  (B)  Notch3 KD cells have significantly less tumour mass (76%; N3 KD 
138.12mg ±35.04 (n=10)) compared to scrambled controls (33.03mg ±8.23 (n=6) 
p=0.0237).  (C)  Xenografted tumours from Notch3 KD cells exhibited 78% smaller 
volume tumours compared to scrambled control (N3 KD 187.63mm3 ±39.32; 
Scrambled 40.54 ±9.83 p=0.0057).  (D)  Transcription of the Notch target genes 
Hes/Hey are significantly reduced in xenografted tumours with Notch3 KD 
compared to scrambled controls (Hes 1 fold change 1.42 p=0.792; Hes4 fold change 
5.10  p=0.0303; Hey1 fold change 15.58 p=0.1775; Hey2 9.16 fold change p=0.0043; 
HeyL fold change 6.03 p=0.082).  Data are represented as means ±S.E.M and 
differences calculated using the Mann-Whitney U test of significance.   * p≤0.05; ** 
p≤0.01; ***p≤0.001. 
 




To ensure that the observed effect was not due to a reduction in neoangiogenesis I 
performed immunohistochemistry for the endothelial marker CD31+ in these 
xenografts and found no difference between positivity in xenografts from scrambled 
sequence transfected cells and those from cell transfected with Notch3 shRNA 
(Figure 7.6). 
 
Figure 7.6  Loss of Notch3 has no effect on neoangiogenesis in a xenograft model of ICC 
 
 
Figure 7.6  Loss of Notch3 has no effect on neoangiogenesis in a xenograft model of ICC 
No significant difference in CD31 positivity was observed in tumours from 
xenografted ICC cells transfected with scrambled control (mean red/blue compared 
to those with Notch3 shRNA.  The mean ratio of rodamine (CD31+) to dapi pixels in 
scrambled tumours was 0.051 ±0.007 compared to 0.036 ±0.007 in Notch3 knock 
down tumours.  Data are represented as means ±S.E.M normalised to vehicle and 








Investigating the downstream mediators of Notch3 in ICC 
To investigate the downstream mechanisms that might be mediating Notch3-driven 
cell survival in ICC, I sought to characterise the activity through signalling 
pathways already known to be dysregulated in primary hepatic carcinogenesis.  
Rather than analyse Notch3 KD cells maintained in culture for a number of weeks 
with the possibility of established adaptations in intracellular signalling activity; I 
sought to examine the consequent downstream effects of acute Notch3 silencing.  
Wild type CC-LP-1 cells were therefore transfected with siRNA targeted against 
either Notch3 or the downstream effector of canonical Notch, RBPJκ.  Three 
independent siRNA sequences were used for each gene and expression levels 
compared to scrambled and untransfected controls.  Knockdown efficiency was 
evaluated with rt-qPCR and western blotting for NOTCH3 and RBPJκ 36 hours after 
transfection.  Cells with effective gene silencing from each sequence were taken 
forward for further analysis.  In addition rt-qPCR of the Notch target genes Hes and 
Hey were performed to assess the functional effects of gene knock down (Figure 
7.7). 
 




Figure 7.7  Transfection with siRNA down-regulates transcription and protein expression 
of NOTCH3 and RBPJκ.   
 
Figure 7.7  Transfection with siRNA down-regulates transcription and protein expression of 
NOTCH3 and RBPJκ.  (A) rt-qPCR analysis showing inhibition of NOTCH3 expression 
in CC-LP-1 cells 36 hours following transfection with NOTCH3 siRNA compared 
with scrambled and untransfected controls.  18S was used as a housekeeping gene.  
Data are represented as means ±S.E.M. and normalised to scrambled control 
p=0.0175 (Kruskall Wallis test) (B) rt-qPCR analysis showing down-regulation of 
RBPJκ expression in CC-LP-1 cells 36 hours following transfection with RBPJκ 
siRNA compared with scrambled or untransfected controls. 18S was used as a 
housekeeping gene.  Data are represented as means ±S.E.M. and normalised to 
scrambled control p=0.0008 (Kruskall Wallis test)  (C) Western blots demonstrating 
down-regulation of NOTCH3 and RBPJκ protein in CC-LP-1 cells treated with 




siRNA or scrambled control.  β-actin is used as a loading control.  (D) rt-qPCR 
analysis of Hes/Hey gene expression in CC-LP-1 cells 36 hours following 
transfection with siRNA targeted against NOTCH3.  (E) rt-qPCR analysis of 
Hes/Hey gene expression in CC-LP-1 cells 36 hours following transfection with 
siRNA targeted against RBPJκ. 
 
Gene expression analysis was carried out using the SA Biosciences Liver Cancer 
Quantitative RT2 Profiler PCR array targeting 84 genes known to be dysregulated 
during progression of primary hepatocarcinogenesis (HCC and ICC).  Results from 
samples transfected with siRNA sequences were compared to scrambled controls 
for analysis of changes in gene expression (using the delta delta Ct method).  
Changes in gene expression was defined as a change ≤ or ≥ 4 fold.  In response to 
siRNA inhibition of NOTCH3, a number of genes were down-regulated across the 
different sequences: MET, PTEN, FAS, FADD, IRS1, RAC1, RUNX3, and XIAP 
(Figure 7.8 (A)) (see Appendix Table 3 for full list of gene changes in response to 
NOTCH3 inhibition across different sequences).  In contrast however, no changes in 
gene expression were observed in response to inhibition of the effector of canonical 
Notch, RBPJκ (see Appendix Table 4 for full list of gene changes) (Figure 7.8 (B)).    




Figure 7.8  Inhibition of NOTCH3 but not RBPJκ in ICC down-regulates transcription of components of the PI3K-AKT signalling cascade.   
 




Figure 7.8  Inhibition of NOTCH3 but not RBPJκ in ICC down-regulates transcription of 
components of the PI3K-AKT signalling cascade.  (A) NOTCH3 inhibition with 3 
independent siRNA  sequences results in down-regulation of a number genes 
implicated in the PI3K/AKT signalling cascade including MET, PTEN, FAS, FADD, 
IRS1, RAC1, RUNX3, and XIAP.  Genes represented in colour are down-regulated ≥ 
4 fold.  (B)  Inhibition of the effector of canonical Notch, RBPJκ does not result in a 
significant change in gene expression.   




Notch3 drives activity through the PI3K/AKT cascade in ICC in vitro 
The genes in this system observed to down-regulate in response to Notch3 
inhibition are linked via their participation in the PI3K/AKT signalling cascade.  
Highlighted genes are either key components of the pathway (PTEN), upstream 
drivers of AKT signalling (MET, IRS1, RUNX3) or downstream targets (XIAP, IRS1, 
FAS, FADD).  I therefore sought to verify in vitro whether functional signalling 
through the PI3K/AKT cascade was indeed attenuated in response to Notch3 
inhibition.   
The FOXO transcription factors are a subfamily of the Forkhead box transcription 
factors and are direct targets of PI3K/AKT signalling.  FOXO is directly 
phosphorylated and hence negatively regulated by AKT and therefore can be used 
as a surrogate marker of AKT activity: i.e. as activity through the AKT pathway 
increases, there is a reduction in FOXO activity (270).  I consequently used a FOXO-
responsive luciferase lentiviral vector to monitor the activity of FOXO in ICC cells in 
response to inhibition of NOTCH3.   
CC-LP-1 cells previously transfected with shRNA against NOTCH3 and selected for 
puromycin resistance (N3 KD cells) and control cells (scrambled sequence) were 
transfected with FOXO-responsive lentiviral particles or positive or negative 
luciferase controls (see Materials & Methods).  After 72 hours in culture, 
luminescence from both FOXO driven firefly and renilla luciferase were measured 
using a dual luciferase reporter assay and luminometer.  An 88.9% increase in 
FOXO-driven luciferase activity was measured in N3 KD cells compared to 
scrambled controls (luminescence N3 shRNA cells 8.46 A.U. ±5.53 vs. scrambled 
control 0.93 A.U. ±0.04; p=0.10; n=3) 




Figure 7.9  FOXO-responsive luciferase activity increases in response to stable inhibition of 
NOTCH3 with shRNA.   
 
Figure 7.9   FOXO-responsive luciferase activity increases in response to stable inhibition of 
NOTCH3 with shRNA.  (A) Schematic depicting the negative regulation of FOXO 
transcription factors by AKT.  (B) A 9.10 fold increase in FOXO-driven luciferase 
activity was observed in response to inhibition of Notch3 activity in CC-LP-1 cells 
transfected with NOTCH3 shRNA compared to scrambled controls (mean 
luminescence N3 shRNA cells 8.46 A.U. ±5.53 vs. scrambled control 0.93 A.U. ±0.04; 
p=0.10).  Cells were plated in triplicate and the assay was repeated three times.  
Positive controls not shown (luminescence off scale).  Data are represented as means 
±S.E.M. and differences analysed using the Mann-Whitney U test.   




Notch3 drives activity through the PI3K/AKT cascade in vivo 
I next sought to verify whether Notch3 was acting to promote PI3K/AKT-driven cell 
survival in vivo.  Firstly I analysed the expression of genes previously highlighted by 
the Liver Cancer PCR array in the tumours that had been xenografted using N3 KD 
cells (NOTCH3 shRNA) and scrambled controls (Figure 7.5).  I performed rt-qPCR 
for the genes (PTEN, MET, IRS1, RAC1, and FAS) and verified that expression of 
these genes was similarly decreased in tumours xenografted from N3 KD cells 
compared to scrambled controls (relative expression normalised to scrambled 
controls: MET scrambled 1.0 ±0.36, N3 KD 0.14 ±0.03; IRS1 scrambled 1.0 ±0.41, N3 
KD 0.46 ±0.20; FAS1 scrambled 1.0 ±0.43, N3 KD 0.12 ±0.03; RAC1 scrambled 1.0 
±0.48, N3 KD 0.02; PTEN scrambled 1.0 ±0.30, N3 KD 0.22 ±0.05) (Figure 7.9 (A)).   
To determine whether this translated into a reduction in expression of AKT protein 
and its targets, I performed immunohistochemistry of phosphorylated AKT 
(pAKT473 and pAKT308) and its downstream targets pmTor and pS6.  
Quantification of these revealed that AKT phosphorylated at the threonine 308 
residue, but not the serine 473 residue was reduced in response to inhibition of 
Notch3 in in vivo tumours.  Similarly I observed a reduction in protein expression of 
the downstream targets of AKT; pmTor and pS6 in xenografted tumours originating 
from N3 KD cells (Figure 7.10 (B)). 




Figure 7.10  Notch3 drives activity through the PI3K/AKT cascade in ICC in vivo.   
 




Figure 7.10  Notch3 drives activity through the PI3K/AKT cascade in ICC in vivo.  (A)  rt-
qPCR analysis of the expression of genes previously identified on liver cancer PCR 
array, in xenografted tumours of N3 KD cells and scrambled controls.  A significant 
reduction in gene expression was observed for MET and RAC1 (MET scrambled 1.0 
±0.36, N3 KD 0.14 ±0.03 (p=0.009); RAC1 scrambled 1.0 ±0.48, N3 KD 0.02 (p=0.009)), 
and a non-significant trend to reduction in the transcription of IRS1, FAS1 and 
PTEN (IRS1 scrambled 1.0 ±0.41, N3 KD 0.46 ±0.20 (p0.329); FAS1 scrambled 1.0 
±0.43, N3 KD 0.12 ±0.03 (p=0.519); PTEN scrambled 1.0 ±0.30, N3 KD 0.22 ±0.05 
(p=0.519)).  Data are expressed as means normalised to scrambled controls ±S.E.M. 
and differences were calculated using the Mann-Whitney U test.  * p≤0.05; ** p≤0.01; 
***p≤0.001.   





It is difficult to know whether correlations between mRNA levels of a gene of 
interest and tumour size and stage represent valid analyses.  This cohort of tumours 
by definition represents end-stage disease and it is unclear how actively Notch3 is 
acting to drive tumour expansion in this context.  In particular examining tumoural 
levels of Notch3 would seem unlikely to predict nodal status of resected tumours.  If 
Notch3 is indeed acting as a driver of self-renewal in a limited population of cancer 
cells during tumour propagation, absolute levels of Notch3 would not be expected 
to correlate necessarily to tumour size.   
The biggest challenge in elucidating a non-redundant role for Notch3 in ICC 
tumorigenesis is a paucity of specific molecular agonists or inhibitors to test this 
hypothesis.  Soluble agonists of the Notch pathway not only act as receptor 
antagonists unless polymerised or fixed to plates, but also lack specificity for 
individual receptors (271).  Efforts have been made to engineer agents including 
fusion proteins and neutralising antibodies to differentially inhibit Notch3 without 
disrupting signalling via the other Notch receptors (272, 273).  Acquisition of these 
antibodies however has proven difficult and therefore I have endeavoured to design 
experiments that assess whether observed differences in Notch3 expression result in 
differences in phenotype or that use a more selective approach using RNA 
interference.   
The principal limitation of these studies is their reliance on one ICC cell line that is 
known to be highly expressive of Notch3 (CC-LP-1).  Although it is unknown how 
representative this system is of the spectrum of ICC, I have established that a 
measurable difference in cell survival and clonogenicity is demonstrable in cells 
with high and low levels of Notch3 protein.  I have used an independent technique 
of inhibiting signalling via Notch3 using the HDAC1 inhibitor Trichostatin A (TSA) 
to corroborate this evidence both in vitro and a xenograft model; demonstrating that 
functional activity via Notch3 is reduced as evidenced by reduced expression of the 




N3-ICD.  Despite the potential therapeutic advantages of this experimental 
approach, HDAC inhibitors clearly will exert effects on many histone and non-
histone proteins undergoing deacetylation and indeed HDACs are aberrantly 
expressed in many cancer types (274).  Therefore I have substantiated these data 
using an independent approach to specifically target Notch3 using RNAi.   
To this end I have generated a stably knocked-down human ICC cell line using 
shRNA against NOTCH3.  When compared to cells carrying a scrambled sequence 
control insert, these cells demonstrated only a modest reduction in cell viability 
during culture in monolayer on plastic.  Interestingly this mirrors similar 
observations made in the lung cancer cell line HCC2429 (275).  When xenografted 
into immunodeficient mice however, a clear difference in tumour growth is seen 
between N3 KD cells and scrambled controls.  Although I have demonstrated 
Jagged1 ligand to be expressed by wild type CC-LP-1 cells in vitro, the threshold 
levels required for activation of signalling through Notch3 and indeed requirement 
of ICC cells for other microenvironment or stromal derived factors for Notch3-
driven cell survival are unknown and factors determining ligand availability may 
account for this observed difference of effect in vivo.  Further investigation of this 
relationship should include experiments to co-culture Jagged1 expressing 
myofibroblasts with Notch3 deficient ICC cells within this xenograft system to 
assess whether excess of Notch ligand results in an exaggeration of these observed 
differences in phenotype.   
To assess the effects of Notch3 inhibition on downstream signalling pathways I used 
a siRNA approach to examine acute Notch3 silencing, rather than screening cells 
with stable Notch3 knockdown that might have undergone adaptive transcriptional 
changes.  In light of the limitations of using a single cell line for analysis in this 
screen, I selected as unbiased approach as was practicable, using a PCR array 
covering 84 known modulators of liver carcinogenesis.   The same transcriptional 
changes were observed across independent siRNA sequences and were broadly 
grouped into members of the PI3K/AKT signalling cascade.  This is not the first 




description of such an interaction between Notch3 and the AKT cascade.  Notch3 is 
overexpressed in the paediatric soft tissue tumour rhabdomyosarcoma and 
inhibition of Notch3 in this context results in induction of hyper-phosphorylation of 
p38 and AKT, causing differentiation of cancer cells into myotubes expressing 
myosin heavy chain i.e. Notch3 inhibition results in reversion back to the 
differentiated state (276).  A larger body of evidence exists for Notch1 exerting its 
anti-apoptotic effects through PI3K/AKT signalling.  In T cells for example, PI3K 
and the tyrosine kinase p56 are both required for the induction of IAP proteins 
(inhibitors of apoptosis) by Notch1(277).  Furthermore Notch1 has been 
demonstrated to directly regulate transcription of PTEN and mutational loss of 
PTEN results in induction of resistance to Notch inhibition (278). 
Experiments in the developing tracheal system of Drosophila where invasive growth 
and branching morphogenesis is Met dependent, have demonstrated that Hes1 is 
able to bind to the transcriptional promoter of Met and suppress its transcription.  In 
this system the authors found that Notch-driven down-regulation of Met can also be 
induced by Met itself: i.e. Met activation results in transcriptional induction of the 
Notch ligand Delta, and that Delta acts to activate Notch, which in turn further 
down-regulates Met.  In this way, the outcome of Notch activation here is an 
inhibition of HGF-dependent Ras activation (279).  Although there are a number of 
core components of the Notch pathway that are conserved between Drosophila and 
vertebrates, in particular the DNA-binding protein Suppressor of Hairless (SuH) 
(known in mammals as RBPJκ), it is apparent that functionally Notch interactions 
have diverged and diversified across species with the result that this one pathway 
can regulate multicellular development through local cell interactions in pleiotropic 
contexts and species.  Although I have used this example to illustrate that the 
Met/Hes1 interaction has been previously described, the functions observed in the 
Drosophila trachea are in contrast to my results, where I observe a down-regulation 
of Met transcription to Notch3 inhibition, and what adds further complexity to the 
relationship is that the transcriptional changes in AKT effectors in response to 




Notch3 silencing are not observed in response to inhibition of the transcriptional 
effector of canonical Notch RBPJκ, suggesting that in this particular context, Notch3 
may be driving AKT activity via a non-canonical mechanism.  Certainly in the 
chemically-induced rat model, no increase in transcription of Notch target effectors 
was seen with tumour progression, suggesting either that the observed response to 
GSI therapy may be a result of non-Notch mediated effects of gamma secretase 
inhibition, or that the Hes/Hey gene family is not regulating this effect.   
The first evidence for the existence of a non-canonical (CSL-independent) Notch 
pathway came from studies of the developing muscle in Drosophila mesoderm, 
where Notch mutants exhibit twice the number of muscle precursor cells, but 
mutants lacking Notch ligands or downstream effectors do not (280, 281).  
Subsequently such CSL-independent functions have been described in a range of 
systems and species, can be ligand-dependent or independent, but principally are 
observed in stem or embryonic cells with capacity for differentiation and expansion; 
it has therefore been suggested that this indicates an interaction between this 
pathway and known cell regulators, in particular the Wnt pathway (282).  Canonical 
Notch and Wnt signalling frequently co-operate throughout development, for 
example in the imaginal wing disc of Drosophila, or in the developing and 
regenerating mammalian intestinal crypt (151, 283).  In contrast however non-
canonical Notch appears more frequently to antagonise Wnt, in particular through 
regulation of β-catenin activity (284).  Recently it has been demonstrated that 
uncleaved, membrane-bound Notch and not just N-ICD, is able to exert functional 
activity within the cell, and that this form of receptor is able to physically interact 
and negatively regulate β-catenin in Drosophila, acting as a membrane-tethered 
transcription factor (285).  It has also been shown that Notch is able to act post-
translationally to phosphorylate and hence de-activate β-catenin (286).  Furthermore 
other components of the β-catenin destruction complex, Axin and Apc, participate 
in this process by regulating endocytosis and trafficking of Notch receptor (287).  It 
is unclear in this system and further work is required to determine how Notch3 




might be acting in this non-canonical manner to drive ICC growth.  Given such 
frequently described effects of membrane-tethered Notch on activated β-catenin in 
other contexts, it would be desirable to examine the consequence of Notch3 
silencing on phosphorylated β-catenin here.  In light of the observed down-
regulation in transcription in PI3K/AKT signalling components, it would similarly 
be interesting to investigate whether any physical interaction is able to occur 
between these targets and Notch3.   
Should this paradigm of Notch acting in a non-canonical fashion prove to also hold 
true in ICC in vivo, there may be important implications for Notch-targeted 
therapies in ICC as RBPJκ-directed inhibitors may prove to be inefficacious.  The 
murine model I have described in this study offers an appropriate tool for 
addressing this question.  Mice carrying targeted deletion of the Notch3 gene (N3-/-) 
(257) have been bred with CK19YFPp53f/f mice.  The tumour burden from ICC in 
these mice following 26 weeks of injury with TAA will be compared to that 
occurring in CK19YFPp53f/f mice bred with those carrying tamoxifen inducible 
floxed alleles of RBPJκ (RBPJκf/f).  These experiments will not only determine 
definitively whether Notch3 is a critical and non-redundant driver of ICC 
tumorigenesis, but will assess the requirement for integrity of the canonical Notch 
pathway in this process.   
This apparent divergence of the role of Notch3 in ICC away from that of Notch1 or 
the canonical Notch cascade presents an exciting opportunity for therapy.  The 
ubiquitous requirement for Notch in such a plethora of fundamental developmental 
and adult systems has made targeting this pathway in disease states particularly 
challenging, and an approach that bypasses such key components of the canonical 
system is highly desirable.  Notch3 as a target however presents particular 
challenges to the development of both therapeutic neutralising antibodies and small 
molecule inhibitors.  The structural differences that distinguish Notch3 from the 
other receptors are principally found within the transmembrane and intracellular 
portions of the protein and as such are inaccessible to the local environment (99, 




252).  Consequently neutralising antibodies have been targeted against EGF-like 
repeats 7-10 and 21-22, or the NRR region of the protein (272, 273), but this process 
has proven to be highly complex: Li and colleagues found that antibodies exhibiting 
the most potent activating and inhibitory activity actually shared overlapping 
epitopes within the NRR; a region that protects the receptor from proteolysis and 
autoactivation in its resting autoinhibited state (273).  A further obstacle to the 
development of Notch3 specific inhibitors is the lack of a paralog-specific read out 
of receptor blockade: RBPJκ-driven reporter activity would screen compounds 
affecting canonical activity through all four receptors; N-ICD-RBPJκ reporters 
would be more specific, but the mechanisms of downstream target activation are 
very similar between receptors and so to date these have not been developed.  Much 
work is currently focussed on characterising individual receptor-ligand interactions 
using structural studies, as the development of receptor-specific Notch inhibitors 
continues to be highly desirable.   
Individualised neutralising monoclonal antibodies targeted against Notch ligands 
are under development although currently are not active against Jagged1 and 2 
(288).  The overexpression of stromal ligand makes this an alternative attractive 
strategy for therapeutic development; although it is not known to what degree 
established invasive tumours remain ligand-dependent and further work would be 
required.  Equally enticing is the prospect of the application of Notch components 
as disease biomarkers.  Although the majority of ICC arises sporadically and is in 
general detected at a late, often inoperable stage, there exists a discrete cohort of 
patients, particularly those with PSC undergoing liver transplantation, who are at 
an especially high risk of tumour development, and in whom graft surveillance is 
highly challenging.   The temporal increase in Notch expression with progression of 
disease observed in the TAA rat model timecourse suggests that Notch3 and to a 
lesser extent Jagged1 may represent potential biomarkers of ICC development.  
Further analysis in premalignant models is required to assess its discriminatory 
potential from PSC as well as its sensitivity. 




CONCLUSIONS AND FUTURE PERSPECTIVES 
ICC is a highly aggressive malignancy that is diagnosed late and currently has few 
effective treatment options.  If we are to increase the proportion of patients who 
might be potential candidates for curative resectional surgery, new strategies to 
improve early detection diagnosis are urgently required.  This project aimed to 
determine whether targeting Notch signalling represents a new therapeutic strategy 
in ICC. 
I have described how the Notch pathway is up-regulated across three species in ICC 
(human, rat and mouse) and how the Notch3 paralog in particular is strikingly up-
regulated during the process of tumour expansion.  I have demonstrated functional 
activity through the Notch cascade and how Notch transcription is activated during 
the natural history of disease progression.  I have characterised the spatial and 
cellular expression of Notch components within the tumour-stromal 
microenvironment and observed that stromal derived ligands, in particular Jagged1 
and Jagged2, appear to activate epithelial Notch3 receptor. 
I have used γ-secretase inhibitors to demonstrate significant reductions in tumour 
burden in response to pharmacological pan-Notch blockade both in a human 
xenograft model and a chemically induced model in rat, and have preliminary in 
vitro  data to suggest these agents warrant further investigation as to their potential 
for chemosensitisation in ICC.  Finally, I have used multiple independent methods 
to specifically inhibit the Notch3 receptor and demonstrate a significant attenuation 
in tumour burden in xenografted immunodeficient mice. 
The data presented in this study regarding the potential for γ-secretase inhibitors to 
sensitise ICC cells to chemotherapeutic agents are preliminary.  Further work using 
a broader range of human cell lines as well as in vivo testing using animal models is 
required.  My data have suggested, although not proven, that Notch3 may represent 
a more naïve, stem-like population of cells within ICC.  If these cells can be targeted 
with anti-Notch therapies, it is tempting to speculate that a consequence might be 




sensitisation of the residual tumour mass to conventional agents allowing 
neoadjuvant shrinkage of tumours to permit resection or even transplantation.  The 
pre-clinical models are now available to determine this and this will be a crucial step 
if anti-Notch treatments are to be translated to the clinical setting.   
A further aim of this thesis was to establish a novel murine model of ICC to permit 
inducible, tumour-specific genetic alterations and hence enable interrogation of 
specific signalling pathways during disease pathogenesis.  I have described a model 
that combines transgenesis with chronic injury using the hepatotoxin TAA, to 
induce ICC that closely mimics human disease histologically and has an acceptable 
tumour latency and penetrance.  In particular, and in contrast to other published 
models, no concomitant occurrence of HCC or extra-hepatic tumours were 
observed. Tamoxifen induction of Cre will enable concomitant deletion or activation 
of floxed alleles in conjunction with p53 deletion at the start of injury with TAA, 
allowing future assessment of genetic contributions to disease development. 
The next phase of this work will involve cross-breeding of this model with a N3 null 
mouse to establish genetically the extent to which Notch3 drives progression of in 
situ developing tumours.  This will be essential for determining whether the 
potential benefits warrant the investment to overcome the challenges of developing 
a drug with anti-Notch3 efficacy.   To further elucidate whether Notch3 does indeed 
act to stimulate AKT via a non-canonical mechanism in vivo, models will be 
similarly engineered to carry floxed alleles for Notch1 and the effector of canonical 
Notch, RBPJκ.  It will be interesting to evaluate these data in light of the results from 
the current trials of GSIs in other solid organ tumours as this class of agents may 
still represent an alternative therapeutic strategy in ICC, particularly if issues with 
toxicity can be overcome.   
The development of a Notch3 specific small molecule antagonist will be challenging.  
In the absence of a stereotypical Hes/Hey transcriptional response following activity 
through Notch3, an in vitro assay would be required to reproducibly detect the 




presence of N3-ICD, in order to assess Notch3 signalling during for example 
screening of small molecule libraries for anti-tumoral efficacy.   
Many unanswered questions still remain regarding the role of Notch in driving the 
malignant phenotype in ICC.  The mechanisms through which Notch is up-
regulated are yet to be determined.   One compelling hypothesis is that the 
infiltrating stroma might act to induce epithelial Notch, acting as a bridge between 
chronic inflammation and cancer.   My data in the rat do demonstrate that Jagged1 
up-regulates during the late inflammatory/early malignancy stage of disease 
progression, in contrast to Notch3 which appears to be a late event occurring in line 
with tumour expansion.  In order to test this, stromally-driven Cre-loxP systems 
such as the PDGFRβ-Cre (289)could be used to delete Notch ligand and assess the 
subsequent effects on tumour formation.  It is also unknown how Notch activity 
changes according to epithelial mutation in ICC and whether certain oncogenic 
events may act as drivers for Notch up-regulation.  This will be able to be addressed 
as more disease models are developed employing different genetic aberrations.  In 
light of the data presented here it would be of interest to assess the role played by 
Notch in PTEN deleted models of ICC in particular.   
Finally, the data in this study have demonstrated that the cell of origin of ICC can be 
the CK19+ cholangiocyte or progenitor cell and that this cell population in the liver 
should not be ruled out as a target for future drug development.  These lineage 
tracing data combined with recently published hepatocyte tracing experiments 
make it desirable to concomitantly trace both liver cell types during different injury 
models to assess the contributions of both populations in vivo.  Our lab has currently 
replicated data demonstrating that during chronic biliary injury, hepatocytes are 
able to contribute both to ductule formation during regeneration and malignancy 
during carcinogenesis.  It would seem likely therefore that during the progression 
from chronic inflammation to cancer both cell types may make contributions to the 
same tumour.  The transgenic technology necessary for concomitant dual labelling 
does not currently exist and viral labelling of cell types can be flawed.  These data 




do suggest however that in contrast to the traditional paradigm of a mutated 
epithelial clone expanding to form a tumour, niche-derived signals may possess 
potential to recruit multiple cell types and induce de-differentiation as part of the 
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Appendix 2:  Normal liver development 
Transplantation studies have determined that hepatoblasts develop from the 
definitive endoderm lining the putative ventral foregut near the developing heart.  
At embryonic day 9 in the mouse (7-8 somite stage) foregut endoderm is in contact 
with cardiac mesoderm (and therefore receptive to FGF signalling (290)) and begins 
to proliferate more rapidly before firstly α-fetoprotein (αFP) and then albumin 
mRNA become detectable. By day 9.5 the hepatic endoderm migrates into the 
posterior mesenchyme of the septum transversum and begins to form the liver bud 
in response to BMP signalling (291).  Endothelial cells are critical in this process in 
delimiting the mesenchymal domain into which the bud grows (292).  At this point 
haemopoietic cells migrate into the liver bud and proliferate whilst concomitantly 
providing growth factors including Oncostatin M to the developing liver (293).  
Specification of endoderm into a hepatic fate occurs in response to a number of cues 
including expression of FoxA and GATA4, which are able to bind to the albumin 
enhancer before the onset of albumin expression, and HNF1β (294-296).   
Once the hepatic endoderm has been specified and the liver bud is growing, 
epithelia within the bud become known as hepatoblasts.  It is important to note that 
at this stage, even before commitment into hepatocyte and cholangiocyte lineages 
has occurred, these bipotential hepatoblasts will activate transcription of genes 
which will later be thought of as stereotypical hepatocyte genes including albumin, 
transthyretin, α-fetoprotein (αFP) and retinal binding protein (RBP) (297).  It is at 
this point that a subpopulation of hepatoblasts will initiate transcription of biliary-
specific genes including Sox9 and some cytokeratins, whereas the remaining 
hepatoblasts remain cytokeratin-negative and will go on to become hepatocytes 
(145).  The cytokeratin-positive population become known as biliary progenitor cells 
before differentiating further into biliary epithelial cells (BECs).  Once specified, 
these will organise into a single-layered sheet surrounding the portal vein, known 
as the ductal plate (E15.5-16.5).  Polarisation of the liver bud occurs to create 





After E16.5 a second ductal plate layer begins to form from hepatoblasts on the 
parenchymal side of the plate, in which in situ asymmetrical dilatations begin to 
appear; precursors of mature, lumenised intrahepatic bile ducts.  This process 
continues into the post-natal period until the second postnatal week, by which time 
all unincorporated biliary precursor cells have disappeared.  Following the 
commencement of duct formation, asymmetric expression of biliary and hepatocyte 
genes can be observed to occur along the tubule; CK19 gets expressed along the 
portal side of the plate, whereas HNF4α appears only on the parenchymal side 
(145).  Hepatocyte maturation is regulated through expression and cross-regulation 
of a set of transcription factors which include HNF1α HNF1β, FoxA2, HNF4α1, 
HNF6 and LRH-1 (298).  Hepatic zonation and the positioning of hepatocytes within 
the liver lobule is controlled at least in part via Wnt/β-catenin signalling(299).   
The large extrahepatic bile ducts arise through branching of a gut-derived 
diverticulum containing pancreatobiliary precursors coexpressing PDX1 and SOX17 
(300).  Expression of SOX17 is regulated by Hes1 and mutant studies have shown 
that the absence of Hes1 results in accelerated development of pancreatic endocrine 













Appendix Table 1 (relating to Table 6.1):  Full list of Notch pathway genes and their 
fold transcriptional change in human ICC vs. patient-matched, non-cancerous distal 

















Appendix Table 2 (relating to Figure 6.10):  Full list of Notch pathway genes and their 
fold transcriptional change during a timecourse of ICC development in rat using the 
chemical carcinogen TAA, as measured by a Notch pathway RT2 Profiler™ PCR 
array (SABiosciences).  Comparison was made between pooled RNA from whole rat 
liver exposed to 8 to 10 weeks (inflamed) (n=3), 12 to 14 weeks (fibrotic) (n=3), 16 to 
20 weeks (early malignant) (n=3) and 22 to 26weeks (late malignant) (n=3) to 












Appendix Table 3 (Relating to Figure 7.7):  Complete table of gene changes following 
silencing of NOTCH3 with siRNA in ICC cells.  CC-LP-1 cells transfected with siRNA 
against NOTCH3 down-regulated a number of genes in response to transfection 
with 3 independent siRNA sequences.  Down-regulation is defined as ≥4 fold 












Appendix Table 4 (Relating to Figure 7.7): Complete table of gene changes following 
silencing of NOTCH3 with siRNA in ICC cells.  CC-LP-1 cells transfected with siRNA 
against RBPJκ down-regulated a number of genes in response to transfection with 3 
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